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CHAPTER I 
 
 
INTRODUCTION 
 
1.1 Background 
            Urinary tract infections (UTIs) are the most frequently acquired bacterial 
infections by humans (Drekonja & Johnson, 2008).  Women are more prone to UTIs than 
men.  About 40-50 % of women in all age groups are estimated to acquire UTIs during 
their lifetime (Brown et al, 2005, Foxman et al, 2003, Franco, 2005, Zhang & Foxman, 
2003).  Despite successful and effective antimicrobial treatment, UTIs remain a 
significant clinical problem accounting for more than 6 billion dollars annually in 
healthcare (Drekonja & Johnson, 2008, Foxman, 2003).  Development of drug resistant 
bacterial strains has added to the complications and has increased the frequency of 
recurrent UTIs (Blango & Mulvey, 2010, Drekonja & Johnson, 2008, Mazzulli, 2002).  
Thus, a critical need exists for alternative therapeutic strategies to complement antibiotic 
treatment against UTIs. 
 
      Incidence of UTIs in females seems to vary with age and stages of menstrual cycle 
suggesting hormonal regulation of susceptibility to UTIs (Stamm & Raz, 1999, 
Valiquette, 2001).  Post-menopausal women have high prevalence of UTIs and estrogen 
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deficiency is considered an important contributing factor (Altoparlak et al, 2004, Foxman 
et al, 2001, Franco, 2005, Hu et al, 2004, Pabich et al, 2003).  Exogenous estrogen 
replacement therapy in postmenopausal women is effective in preventing UTIs and 
ameliorating symptoms associated with infection and inflammation (Devillard et al, 
2004, Heinemann & Reid, 2005, Maloney, 2002, Rozenberg et al, 2004, Stern et al, 
2004).  Beneficial effects of estrogen-treatment in postmenopausal females may include 
restoration of the periurethral and vaginal microflora and reduction in the risk of vaginal 
atrophy; however molecular mechanisms associated with the therapeutic effects of 
estrogen against UTIs are poorly understood (Cardozo et al, 1998, Cardozo et al, 2001, 
Rozenberg et al, 2004). 
 
      Estrogen is considered to be an anti-oxidant and anti-inflammatory agent that acts via 
the estrogen receptor (ER) subtypes, ER alpha (ERα) and ER beta (ERβ), to mediate 
regulation of gene transcription (Nilsson et al, 2001, Nilsson & Gustafsson, 2002).  
Expression of ERα and ERβ varies with circulating estrogen levels in humans and in 
animals (Ben-Hur et al, 1995, Esqueda et al, 2007, Rogers et al, 2007).  Furthermore, 
reduced ER subtype expression in rat and mouse urogenital tissues following 
ovariectomy is found to be restored upon β-estradiol (E2) replacement (Carley et al, 
2003, Esqueda et al, 2007, Rogers et al, 2007).  Moreover, in kidney ERα is the 
predominant subtype expressed and is reported to be the primary mediator of estrogen 
regulated gene expression in the renal cells (Jelinsky et al, 2003).  However, the effects 
of estrogen/ERα action in the kidney during uropathogenic infections are not completely 
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understood.  Thus, a complete understanding of the molecular mechanisms underlying 
the estrogen related etiology of UTIs pathogenesis is warranted. 
 
      Uropathogenic Escherichia coli (UPEC) are the primary etiological agents (80%) of 
acute and chronic UTIs, including cystitis and pyelonephritis (Czaja et al, 2007, Marrs et 
al, 2005, Ronald, 2002, Zhang & Foxman, 2003).  Colonization of the urinary tract by 
virulent UPEC strains occurs via various adhesins, including type I fimbriae, P pili, and 
Dr adhesins (Hagberg et al, 1983b, Johnson & Russo, 2005, Svanborg & Godaly, 1997). 
Dr adhesion expressing E. coli (Dr+ E. coli) are associated with cystitis, recurrent UTIs, 
and pyelonephritis in humans (Goluszko et al, 1997, Nowicki et al, 2001, Servin, 2005).  
Dr+ E. coli colonize the uroepithelium via Dr adhesin specific tissue receptors, decay 
accelerating factor (DAF, also known as CD55) and type IV collagen  (Nowicki et al, 
2001, Selvarangan et al, 2000, Selvarangan et al, 2004).  Dr adhesin of Dr+ E. coli has 
been found to be critical for the development of chronic pyelonephritis in an 
experimental UTI C3H/HeJ mouse model (Goluszko et al, 1997, Nowicki et al, 2001).  
Binding of Dr adhesin to DAF allows attachment and colonization of Dr+ E. coli to the 
uroepithelium; while attachment of Dr adhesins to type IV collagen allows persistence of 
Dr+ E. coli within the tissue (Nowicki et al, 2001, Selvarangan et al, 2000, Selvarangan 
et al, 2004).  Following infection, engagement of Dr+ E. coli with DAF on the host 
uroepithelium induces recruitment of additional DAF around the bacteria, leading to 
internalization into the epithelial cells (Das et al, 2005, Goluszko et al, 1999, Guignot et 
al, 2001, Kansau et al, 2004, Plancon et al, 2003, Selvarangan et al, 2000).  
Internalization of UPEC including Dr+ E. coli by the uroepithelial cells has been found to 
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be associated with tyrosine phosphorylation of specific host proteins (Guignot et al, 2001, 
Palmer et al, 1997, Peiffer et al, 1998).  Moreover, tyrosine kinase pathway is activated 
following engagement of DAF with its ligands (Abedi & Zachary, 1997, Burridge et al, 
1988, Shenoy-Scaria et al, 1992, Stefanova et al, 1991, Zachary & Rozengurt, 1992).  
Expression of DAF and type IV collagen is reported to be hormonally regulated (Potier et 
al, 2001, Potier et al, 2002, Seliger et al, 2001, Silbiger et al, 1998, Song et al, 1996).  
Estrogen has also been shown to modulate tyrosine kinase activity (Gao & Yamaguchi, 
2000, Li & Yu, 2003, Liu & Howard, 1991, Pascoe & Oursler, 2001, Yoneda et al, 
1993).  Nonetheless, modulation of DAF and type IV collagen expression, and regulation 
of tyrosine kinase activation by estrogen during Dr+ E. coli uropathogenesis have not yet 
been investigated. 
 
      Pathology during UTIs is caused by UPEC colonization and inflammation induced 
tissue damage (Brogden et al, 2005, Svanborg et al, 1999, Svanborg et al, 2001a, Zasloff, 
2006, Zasloff, 2007).  Renal pyelonephritis is caused by ascent of UPEC from the bladder 
to the kidney followed by inflammation induced damage to the pelvic and renal tubules 
(Svanborg et al, 2001a, Vandewalle, 2008).  Animal and clinical studies have shown that 
the uroepithelial toll like receptors (TLRs) including TLR2, TLR4, TLR5, and TLR11, 
play a central role in UPEC recognition to initiate host innate inflammatory responses 
against invading pathogen, and these responses further lead to specific activation of 
adaptive immunity (Chowdhury et al, 2006, Hawn et al, 2009a, Hawn et al, 2009b, 
Svanborg et al, 2001b, Tseng et al, 2007, Vandewalle, 2008, Wullt et al, 2001).  For 
instance, TLR4 binds to lipopolysacharide (LPS) of gram negative UPEC.  Upon ligand 
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binding, TLR4 is activated to stimulate transcription and secretion of pro-inflammatory 
cytokines (TNFα, IL6, Il-1β) and chemokines (IL8/MIP2, RANTES, MCP1), as well as 
up-regulation of TLR2 activation (Chassin et al, 2006, Chowdhury et al, 2006, 
Samuelsson et al, 2004, Schroppel & He, 2006, Vandewalle, 2008).  TLR4 signaling 
defects cause LPS unresponsiveness, thus increases susceptibility to gram negative 
bacterial infections and UTIs in animals and humans (Agnese et al, 2002, Hawn et al, 
2009a, Karoly et al, 2007, Poltorak et al, 1998, Ragnarsdottir et al, 2007).  
Immunomodulatory roles of estrogen are well documented; however, to our knowledge 
the regulatory effects of estrogen on immune response associated with uropathogenic 
infection have not been investigated.  
 
      Estrogen appears to be an effective modulator of UPEC colonization in the female 
urinary tract; however the benefits of estrogen treatment in postmenopausal UTI 
susceptibility are poorly understood (Cardozo et al, 1998, Cardozo et al, 2001, Elloso et 
al, 2005, Rozenberg et al, 2004).  In this study, we aim to investigate the role of 
estrogen in host/pathogen interactions and inflammatory responses during Dr+ E. 
coli induced UTIs by utilizing an in vivo experimental UTI murine model and an in 
vitro, kidney cell culture model.  The long term goals of this study are to understand 
the cellular and molecular regulatory mechanisms involved in estrogen mediated 
modulation of host susceptibility to Dr+ E. coli induced UTIs.  This information will 
contribute toward the understanding of UTI pathogenesis, help in identification of 
novel biomarkers, and guide in the development of novel therapeutic strategies 
other than antibiotics for effective treatment of UTIs.  
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1.2 Preliminary Studies 
            Our preliminary in vivo and in vitro studies indicate an increase in susceptibility 
to Dr+ E. coli infection under estrogen-deficient conditions and support the protective 
role of physiological doses of E2 against Dr+ E. coli infection.  We have determined the 
impact of ovariectomy induced menopause on susceptibility towards Dr+ E. coli induced 
experimental UTI using the C3H/HeJ mouse model at 21 days post-infection.  The 
ovariectomized (OVX) mice treated with a physiological dose of E2 and the estrogen 
sufficient-ovary intact (Non-OVX) mice show reduced bacterial colonization and 
infection related tissue inflammation in the kidneys, compared to the colonization in the 
kidneys of estrogen-deficient-vehicle-treated OVX mice (Figures 1 and 2).  Pretreatment 
of Non-OVX with ER-antagonist ICI 182780 led to a significant increase in bacterial 
colonization of the kidneys, compared to that in the kidneys of vehicle-treated Non-OVX 
mice (Figure 3).  These observations suggest an ER mediated protective role of E2 at a 
physiological dose against UTI in C3H/HeJ mice.  
 
      Quantitative real-time RT-PCR analysis revealed that ERα is more abundantly 
expressed than ERβ in the kidneys of C3H/HeJ mice and that ovariectomy decreased ERα 
mRNA levels in the kidneys of these mice, with no change in ERβ expression (Figure 
4A).  Notably, the vehicle-treated OVX mice showed increase in ERα mRNA levels in 
the kidney following infection, compared to the uninfected OVX mice but the infected 
Non-OVX mice showed decrease in ERα mRNA levels, compared to the uninfected Non-
OVX mice (Figure 4A and 4B). 
 
23 
 
 
 
 
Figure 1 
 
 
 
Figure 2 
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Figure 1:  Bacterial counts in the kidneys of C3H/HeJ mice at 21 days post-UTI induction.  
OVX mice were treated with vehicle (Veh) or E2.  The number of viable bacteria (CFU) from 
Non-OVX mice (n = 14) are depicted by filled circles while bacterial counts from vehicle (n = 
28) and E2 (n = 27) treated OVX mice are indicated by closed triangles and open circles, 
respectively.  Each symbol represents the number of viable bacteria from a single mouse.  
Bacterial counts are presented as mean CFU ± SEM and the error bars represent data from two 
independent experiments.  Data were analyzed by One-way ANOVA, followed by Tukey’s post 
hoc test for multiple comparisons where P < 0.05 was considered significant (*** indicate P < 
0.0001).  (Unpublished data) 
 
 
 
Figure 2:  Representative renal pathology in C3H/HeJ mice at 21 days post-UTI induction.  
A) Histopathological analysis of the kidney tissues from vehicle- (1, 2) or E2- (3, 4) treated 
groups of OVX mice, 21 days post-UTI induction.  Images represent hematoxylin-eosin staining 
of kidney tissue sections.  Arrows are pointing at the lymphocytes and neutrophils infiltration.  B) 
The inflammatory scores taken from the pelvis, medulla and cortex of vehicle and E2 treated 
tissues are based on cellular infiltrate and fibrosis in the kidney tissues and are presented as mean 
score ± SEM.  The error bars represent scores from 8 mice for each treatment group.  Scores 
represent a scale of 0 to 4, where 0 represents normal or no inflammation and 4 represents end 
stage disease with chronic inflammation.  Data were analyzed by Student’s t test for each region 
in the kidney tissue section (pelvis, medulla and cortex) where P < 0.05 was considered 
significant (*).  (Unpublished data) 
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Figure 3 
 
 
 
Figure 4 
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Figure 3:  Bacterial counts in the kidneys of ICI 182, 780-treated C3H/HeJ mice at 21 days 
post-UTI induction.  Non-OVX mice were treated with vehicle (Veh) or an ER-antagonist ICI 
182, 780, prior to UTI induction.  Viable bacterial counts from vehicle treated mice (n = 14) are 
depicted by filled circles, and bacterial counts from ICI 182,780 treated mice (n = 9) are indicated 
by closed squares.  Bacterial counts from two independent experiments are presented as mean 
CFU ± SEM.  The error bars represent data from n=9 and n=14 animals for vehicle and ICI 182, 
780-treated group of animals, respectively.  Data were analyzed by Student’s t-test where P < 
0.05 was considered significant (** indicate P < 0.001). (Unpublished lab data). 
 
 
Figure 4:  ER subtype mRNA levels in the kidneys of C3H/HeJ mice.  A) The Kidney ERα 
and ERβ mRNA levels of uninfected, OVX and Non-OVX C3H/HeJ mice.  B) The kidney ERα 
mRNA levels of Non-OVX C3H/HeJ mice and vehicle-(veh) or E2-treated OVX mice at 21days 
post-UTI induction.  The mRNA levels were analyzed by SYBR green quantitative real-time RT-
PCR. The expression levels of ER subtypes are normalized to PPIA expression.  Expression 
values are presented as mean relative expression ± SEM. and the error bars represent data from 
10-11 mice per group for Figure 4A and 4-6 mice per group for Figure 4B.  Data were analyzed 
by One-way ANOVA followed by Tukey’s post hoc test for multiple comparisons.  P< 0.05 was 
considered significant (*** indicate P < 0.000).  The character ## (P < 0.001) indicate significant 
difference compared to E2-OVX and xxx (P < 0.0001) indicate significant difference compared to 
Veh-OVX. 
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Following infection, the ERα mRNA levels in the estrogen-sufficient Non-OVX, and the 
E2-treated OVX mice were found to be markedly reduced compared to those in the 
estrogen-deficient- vehicle- treated OVX mice.  Reduction in ER transcription level 
following activation with estrogen has been previously reported (Ihionkhan et al, 2002, 
Lee & Gorski, 1998).  Reduced levels of ERα in estrogen-sufficient mice and increased 
levels of ERα in estrogen deficient mice following infection suggests that ERα activation 
may have an important functional role during Dr+ E. coli induced UTI pathogenesis 
(Figure 4B). 
 
      E2-mediated protection at physiological doses was also observed in our in vitro 
invasion studies using Huh7 hepatoma cells and in primary human hepatocytes.  Primary 
human hepatocytes were obtained from University of Minnesota, NIH Liver Tissue 
Procurement and Distribution System (LTPADS) (PI collaboration).  Human 
hepatocytes, as well as Huh7 cells, expressed DAF and both the ER subtypes.  
Pretreatment of cells with physiological doses of E2 (0.126ng/ml-1.26ng/ml) 
significantly reduced bacterial invasion in the Huh7 cells, as well as in the human 
hepatocytes (Figure 5).  E2-mediated protection was significantly reversed in Huh7 cells 
when treated with ER- antagonists ICI 182,780 and 4-hydroxytamoxifen (OHT), 
suggesting involvement of ERs (data not shown). 
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Figure 5:  Relative invasion of Dr+ E. coli in the E2-treated Huh7 cells and the primary 
human hepatocytes.  Relative bacterial invasion in cells treated with various doses of E2, where 
1.26 ng/ml E2 corresponds to 5nM E2.  The E2 doses ranging from 0.126-1.26 ng/ml are 
considered physiological.  Invasion values are mean bacterial CFU ± SEM expressed as 
percentage of the bacteria internalized, relative to that in the untreated cells (invasion in control 
untreated cells was considered as 100 %). The error bars represent mean % bacterial CFU ± SEM 
from at least three independent experiments performed in triplicate, for each cell type.  Data were 
analyzed by One-Way ANOVA for Huh7 and primary human hepatocytes followed by Tukey’s 
post hoc test for multiple comparisons.  P< 0.05 was considered significant.  The character * 
indicate significant difference compared to the control in each cell type, where * indicate P < 
0.05, **indicates P < 0.005, and *** indicates P < 0.0005.  (Unpublished lab data). 
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1.3 Hypothesis 
            Based on the observations from our preliminary studies, we hypothesize that host 
endogenous estrogen levels, as well as ER subtypes expression, may play an important 
role in determining the host susceptibility to Dr+ E. coli mediated UTIs and associated 
inflammatory responses.  We further hypothesize that estrogen via ERα activation may 
regulate the expression of host bacterial colonization receptors, DAF and type IV 
collagen, as well as activation of tyrosine kinase signaling pathway following Dr+ E. coli 
infection.  In addition, we propose that estrogen regulates the inflammatory responses 
following Dr+ E. coli infection by modulating the expression of inflammatory markers, 
TLRs and pro-inflammatory cytokines. 
 
 
1.4 Specific Aims 
            We tested our hypothesis using both, in vivo and in vitro studies as outlined in the 
following two specific aims. 
 
AIM-1:  Elucidate the role of estrogen and ERα in regulation of Dr+ E. coli colonization 
and subsequent inflammation in the urinary tract of OVX C3H/HeJ mice during 
ascending UTI. 
 
      The experimental UTI murine model established in OVX C3H/HeJ mice was used in 
the present in vivo experiments.  C3H/HeJ mice carry a mutation in TLR4 that results in 
TLR4 signaling defect and LPS unresponsiveness in these mice (Poltorak et al, 1998).  
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Increased susceptibility to UTIs is reported in C3H/HeJ mouse and thus it serves as an 
appropriate model for inducing experimental UTIs (Hoshino et al, 1999, Poltorak et al, 
1998).  
 
  Aim 1A:  Determine the effects of estrogen and ERs activation on UTI 
susceptibility by studying bacterial colonization in mouse kidney following Dr+ 
E. coli infection. 
      The impact of estrogen deficiency and physiological E2 doses on UTI 
susceptibility was evaluated in vehicle- or E2-treated OVX C3H/HeJ mice induced 
with Dr+ E.coli -mediated experimental UTI.  We evaluated the changes in bacterial 
colonization in the bladders and kidneys of these mice at 2 and 6 days post-infection.  
Impact of pure ER antagonist, ICI 182,780 or vehicle-treatment on UTI susceptibility 
in Non-OVX mice was determined to confirm the role of ERs in estrogen protective 
effects.  Furthermore, UTI was induced in female ERα gene knock-out (ERα-/-) and 
ERα gene intact (ERα+/+) mice to confirm the role of ERα in mediating protective 
effects of estrogen against UTI susceptibility.  
 
Aim 1B:  Determine the effects of estrogen and ERs action in regulating 
expression of Dr+ E. coli host colonization receptors and inflammatory markers 
in mouse kidney following infection. 
       Expression of Dr+ E. coli colonization receptors, DAF and type IV collagen, 
inflammation inducers, TLR2 and TLR4, and pro-inflammatory cytokines, TNFα, 
IL6, and MIP2 was determined in the kidneys of mice at 2 and 6 days following 
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experimental UTI induction as described in Aim 1A.  Expression analysis of target 
genes at the mRNA level was performed by quantitative SYBR green real time RT-
PCR.  
 
AIM2:  Establish an in vitro model of Dr+ E. coli infection in mouse kidney cell line, 
mIMCD3 cells to study E2/ER mediated modulation of Dr+ E. coli infection at the 
cellular level. 
 
      The most distal renal tubule segment, the medullary collecting ducts are the first to 
come in contact with the ascending UPEC.  They serve as the primary site for bacterial 
adherence and early inflammatory responses against UPEC (Chassin et al, 2006, 
Vandewalle, 2008).  Therefore, we used a mouse kidney inner medullary collecting duct 
cell line (mIMCD3) for establishing our in vitro cell model for studying Dr+ E. coli 
induced uropathogenesis (Rauchman et al, 1993).  
 
Aim 2A: Determine the impact of E2 and ERs on Dr+ E. coli invasion and 
expression of Dr+ E. coli adhesin receptors and inflammatory markers in 
mIMCD3 cells following infection. 
      Effects of pretreatment with E2, ER antagonist (ICI 182,780), an ERα selective 
agonist ( propyl pyrazole triol: PPT), an ERα selective antagonist (methyl piperidino 
pyrozole: MPP), an ERβ selective agonist ( diaryl propio nitrile: DPN) and an ERβ 
selective antagonist (R, R-tetrahydrochrysene: R,R-THC), on Dr+ E. coli invasion in 
mIMCD3 cells were determined.  Changes in bacterial invasion and mRNA levels of 
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DAF, type IV collagen, TLR2, TLR4, TNFα, IL6, and MIP2 mRNA were analyzed 
following drug treatments in Dr+ E. coli infected, as well as uninfected mIMCD3 
cells.  Bacterial invasion was assessed by the standard gentamicin protection assay 
and mRNA levels were determined by quantitative SYBR green real-time RT- PCR.  
 
Aim 2B:  Determine the impact of E2 on regulation of tyrosine kinase signaling 
pathway in the mIMCD3 following Dr+ E. coli infection.  
      The impact of tyrosine kinase inhibitor, genistein and phosphoinostide 3-kinase 
(PI3K) inhibitor, LY294002 on bacterial invasion in mIMCD3 cells was determined 
to study the role of tyrosine kinase activation during Dr+ E. coli internalization in 
these cells.  We also determined, the effect of E2 on activation status of tyrosine 
kinase in these cells was determined by detecting the levels of cellular signaling 
proteins, phosphorylated PI3K (pPI3K) and Akt (pAkt) (Protein kinase B) using 
western blots. 
 
      These specific aims, comprising of in vivo as well as in vitro studies showed that the 
molecular mechanisms associated with estrogen mediated attenuation of Dr+ E. coli 
mediated kidney infection involve ER mediated regulation of bacterial adherence 
receptors expression and host inflammatory responses.  Furthermore, the in vitro 
mIMCD3 cell model of Dr+ E. coli uropathogenesis allowed us to demonstrate that Dr+ 
E. coli internalization in mIMCD3 cells require activation of tyrosine kinase involving 
PI3k/Akt signaling pathways and that estrogen differentially regulates the activation of 
these pathways, thus influencing bacterial invasion.
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CHAPTER II 
 
 
LITERATURE REVIEW 
 
2.1 UTI and UPEC 
 
            UTIs are the most frequently acquired bacterial infections, are considered to be 
the most common hospital acquired infections and are the second most common 
community acquired infections (Valiquette, 2001).  UTIs cause significant morbidity and 
mortality in humans accounting for substantial healthcare costs (Foxman & Brown, 2003, 
Foxman et al, 2003, Foxman, 2003, Johnson & Russo, 2005).  Females are significantly 
more likely to experience UTIs than men, and about 40-50 % of women are estimated to 
suffer from UTIs in their life time (Brown et al, 2005, Foxman et al, 2003, Franco, 2005, 
Zhang & Foxman, 2003).  UTIs affect the upper as well as the lower urinary tract 
(Diagram 1) and include urethritis, cystitis, pyelonephritis, recurrent UTI, and 
asymptomatic bacteriuria.  Pyelonephritis is the most severe form of UTIs, occurring in 
all age groups and gender with prevalence observed in females; about 10-30% of all 
patients with acute pyelonephritis are hospitalized for treatment (Brown et al, 2005).  
Incidence of UTI seems to vary with age and menstrual cycle, suggesting hormonal 
regulation of susceptibility to UTIs (Franco, 2005, Hooton, 2000, Ribeiro et al, 2002, 
Sonnex, 1998).   Post-menopausal women have a high prevalence of UTI and estrogen
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 deficiency is considered to be an important contributing factor (Altoparlak et al, 2004, 
Foxman et al, 2001, Franco, 2005, Pabich et al, 2003). 
 
 
 
Diagram 1:  Sites of infection in the urinary tract.  Image adapted and modified from Nat 
Rev.Microbiology, 2, 2004 (Kaper et al, 2004) 
 
      UPEC are the most prevalent etiological agent of all UTIs including recurrent UTI, 
cystitis, and pyelonephritis (Johnson & Russo, 2002, Johnson, 2003, Ronald, 2002, Russo 
& Johnson, 2003, Zhang & Foxman, 2003).  They are the primary cause of community 
acquired UTIs (70-95%) and many nosocomial UTIs (50%) (Foxman, 2003). 
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      The urinary tract is considered to be a sterile site and entry of microbes into the 
urinary tract is mostly associated with physical introduction of organisms that colonize 
the perianal and periurethral areas.  The gastrointestinal tract is thought to be the main 
reservoir for these uropathogens (Wiles et al, 2008).  Commensal bacteria colonizing the 
gastrointestinal tract include several strains of E. coli that may inhabit this site for all of 
the individual’s life, or only be present transiently.  Several of these strains may colonize 
the periurethral areas and gain entry into the bladder via ascending route but may or may 
not cause any infection in the urinary tract.  The E. coli strains which do persist and 
colonize the urinary tract but do not invade the uroepithelium or initiate any UTI 
symptoms show characteristics similar to the spectrum of gut colonizing E. coli.  
However, those bacteria who enter and elicit symptoms or cause asymptomatic UTI are 
not random samples of fecal E. coli; rather, they are a subset of E. coli strains known as 
the uropathogenic E. coli commonly referred as UPEC (Johnson & Russo, 2002, Johnson, 
2003, Johnson & Russo, 2005, Marrs et al, 2005).  These strains differ from fecal strains 
by possessing virulence factors unique to enable invasion and infection in the urinary 
tract and most of these virulence factors are coded by a stretch of chromosomal DNA 
called Pathogenicity Associated Islands (PAIs) (Bergsten et al, 2005, Bower et al, 2005, 
Brzuszkiewicz et al, 2006, Ronald, 2002, Yamamoto, 2007).  In some cases the 
dissemination of a single clone group of a UPEC isolate may occur within a community 
via contaminated food or consumables (Manges et al, 2001, Manges et al, 2006, Manges 
et al, 2008).  Aditionally, UPEC isolated from sexually active patients often matches with 
bacteria in the fecal isolates from their partners, indicating that UTI can be sexually 
transmitted (Foxman et al, 2002, Manges et al, 2004).  UPEC strains act as opportunistic 
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intracellular pathogens taking advantage of host behavior and susceptibility by employing 
a diverse repertoire of virulence factors to colonize the urinary tract.  The virulence 
factors include but are not limited to polysaccharide capsule (to evade phagocytosis), 
adhesion factors (to attach to the uroepithelium to prevent being washed away by urine 
flow), siderophores (to acquire iron), and cytotoxins (for invasion); these virulence 
factors facilitate the UPEC’s ability to colonize and invade the uroepithelium (Johnson, 
2003, Yamamoto, 2007).   
 
      UPEC adhesins are very crucial virulence factors as they allow the uropathogens to 
firmly adhere to the uroepithelium and initiate bacterial colonization in otherwise hostile 
environment (Antao et al, 2009, Wright & Hultgren, 2006).  Adhesins of UPEC 
determine the bacterial affinity for and persistence in the urinary tract (Mulvey, 2002, 
Schilling et al, 2001a).  Urinary tract colonization by virulent UPEC strains is mediated 
via various fimbrial and afimbrial adhesins including type I fimbriae, P pili, or Dr 
adhesins which determine the tissue specificity of UPEC.  The uropathogens use these 
adhesive factors to firmly adhere to the receptors on the uroepithelium in the urethra and 
further ascend to the lower urinary tract (bladder) and upper urinary tract (kidney) 
establishing UTIs (Goluszko et al, 1997, Hagberg et al, 1983b, Hagberg et al, 1983b, 
Johnson & Russo, 2005, Nowicki et al, 2001, Svanborg & Godaly, 1997).  In an 
experiment studying the ascent of bacteria from the bladders to the kidneys following 
bladder catheterization in mice, it was found that <0.01% of the inoculum reaches the 
kidneys (Hagberg et al, 1983a).  In the urinary tract a thin film of fluid around the 
luminal surface of the epithelium represents the 'battlefield' where uropathogen interact 
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with the epithelial cells and the innate immune system, resulting in bacterial invasion and 
inflammation that finally contribute to uropathogenesis and cellular damage (Diagram 2) 
following UPEC infection (Brogden et al, 2005, Zasloff, 2006, Zasloff, 2007). 
 
      UPEC strains may ascend to the lower and the upper urinary tract via uroepithelial 
binding sites.  Like enteric E. coli pathogens, UPEC isolates are genetically 
heterogeneous and vary significantly in their abilities to colonize and persist within either 
the bladder or the kidney (Mulvey, 2002).  For example, the pyelonephritogenic P 
fimbriated E. coli colonize the apical surface of the renal tubules via attaching to the α D-
Gal-(1,4)-β-D-Gal containing surface glycolipid receptors present abundantly in the 
kidney.  In contrast, the Type 1 pili bearing UPEC that bind to the mannosylated 
glycoproteins are significantly associated with the bladder infection.  Less well 
characterized S pili bearing UPEC are associated with cystitis, pyelonephritis and may 
cause disseminated infection including sepsis and meningitis.  The S pilus has been found 
to attach to the sialic acid residues of the receptors expressed on kidney, bladder and 
endothelial cells.  The F1C pili can bind to β-GalNac-1, 4β-Gal residues on glycolipids 
expressed by epithelial cells of the distal tubules, collecting ducts of the kidney, bladder 
and kidney endothelial cells, and may contribute significantly to the pathogenesis of a 
number of UTI cases.  Furthermore, the Dr adhesin bearing UPEC that attach via 
complement regulatory receptor DAF/CD55 (expressed on the erythrocytes, 
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Diagram 2:  Uropathogen and host interaction during establishment of infection in the 
urinary tract by ascending UPEC.  1, Uroepithelium constitutively express and secrete 
antibacterial peptides in the lumen of urinary tract ; 2, UPEC ascend and approach the epithelial 
surface anticipating attachment; 3, antibacterial peptides levels rapidly rise, translation is 
activated, and peptide secreted rapidly, killing nearby bacteria, some UPEC survive and continue 
to ascend; 4, neutrophils begin to migrate toward the lumen; 5, neutrophils secrete antibacterial 
peptides, complementing epithelial sources, but viable microbes persist; 6 neutrophils continue to 
invade the epithelium and so does the uropathogen, resulting in cellular damage.  Image adapted 
and modified from Nature Medicine, 12, 2006 (Zasloff, 2006). 
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endothelial, and epithelial cells) are associated with recurrent UTI, 30-50% of cystitis 
cases and about 30% of pregnancy associated pyelonephritis cases (Servin, 2005)  
 
 
2.2 Uropathogenic Dr+ E. coli 
           Dr+ adhesin bearing E. coli belong to the family of Afa/ Dr adhesin bearing E. coli 
broadly classified as diffusely adhering E. coli (DAEC).  Afa/ Dr DAEC strains exhibit 
identical genetic organization, they bind to human DAF/CD55 and cause intestinal 
(diarrhea) as well as extraintestinal (uropathogenic) infections (Servin, 2005).  
Uropathogenic Dr+ E. coli, strain IH11128 is associated with recurrent UTI, cystitis, and 
pyelonephritis in humans (Goluszko et al, 1997, Goluszko et al, 2001, Nowicki et al, 
2001, Servin, 2005).  It has been suggested that first UTI infection with Dr+ E. coli 
increases the risk for second UTI in patients by 2-fold (Foxman et al, 1995, Zhang & 
Foxman, 2003).  Adherence to host epithelium by UPEC is crucial for establishing 
infection.  Dr adhesin provides attachment of the Dr+ E. coli to the luminal apical surface 
within the urinary tract.  An isogenic Dr negative mutant (Dr14/ Dr- E. coli) of IH11128 
was developed by insertional inactivation of draC gene of Dr+ E. coli (Goluszko et al, 
1997).  The draC gene product is essential for the assembly of functional Dr adhesin, 
thus Dr14 E. coli do not assemble functional Dr adhesins and show reduced adherence 
and virulence towards the host cells (Goluszko et al, 1997, Kaul et al, 1999).  This 
confirms that Dr adhesin of Dr+ E. coli mediates bacterial adherence to host epithelial 
cells and is important for host colonization.  Dr+ E. coli has been successfully used for 
developing experimental chronic pyelonephritis in C3H/HeJ mouse model where Dr 
adhesin was found to be critical for development of chronic pyelonephritis (Goluszko et 
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al, 1997, Nowicki et al, 2001).  Dr adhesin was found to recognize a tyrosine containing 
molecule in the Dr blood group antigen that was further identified as the complement 
regulatory protein CD55 most commonly known as DAF.  DAF is a membrane 
associated phosphatidyl-inositol anchored glycoprotein (GPI) expressed on all the blood 
cells, endothelial and epithelial cell surfaces.  Dr adhesins bind at short consensus repeat 
(SCR)-3 and SCR-4 domain of DAF (Hasan et al, 2002, Nowicki et al, 1990, Nowicki et 
al, 1993, Nowicki et al, 2001, Pham et al, 1995, Selvarangan et al, 2000).  Within the 
urinary tract, the epithelial surfaces of urethra, bladder, ureter, and renal pelvis are rich in 
DAF expression and bind to Dr fimbria (Nowicki et al, 1988).  Dr adhesins of Dr+ E. coli 
also recognize type IV collagen as its colonization receptor in the host urinary tract 
(Selvarangan et al, 2004, Westerlund et al, 1989).  Type IV collagen is an important 
component of the specialized extracellular matrix (ECM) that underlies all the epithelial 
membrane and functions to compartmentalize the tissue.  Dr adesins binds to the renal 
tubular basement membrane and the Bowman’s capsule in the renal glomerulus which 
have abundant type IV collagen (Nowicki et al, 1988).  Dr+ E. coli recognizes 
DAF/CD55 to adhere, invade, and colonize the kidney epithelium (Nowicki et al, 2001, 
Selvarangan et al, 2000, Selvarangan et al, 2004, Servin, 2005) and further binds to type 
IV collagen in the epithelial basement membrane which allows it to localize in the 
interstitial compartment of the renal tissues (Diagram 3) that may further contribute to 
pyelonephritis (Selvarangan et al, 2004, Mulvey, 2002).   
 
      Interaction of Dr+ E. coli with DAF and type IV collagen in the kidney leads to 
bacterial infection and persistence inducing inflammation in renal tubules and  
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Diagram 3:  Mechanism of Dr+ E. coli uropathogenesis.  I, Bacterial  colonization and 
attachment  to DAF on the apical surface of the host renal epithelium; II, clustering of DAF 
following bacterial attachment; III, Initiation of bacterial internalization by phagocytic pathway 
and introduction of lesion at the tight junction on the epithelial surface; IV, Bacterial 
internalization into a vacuole within the host cell, loss of epithelial polarization, invasion of 
bacteria via paracellular route and attachment of bacteria to type IV collagen in the basement 
membrane of the epithelium facilitating renal persistence of Dr+ E. coli and development of 
pyelonephritis.  Image based on information published in Cell Microbiology, 4, 2002 (Mulvey, 
2002) 
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interstitium.  In an in vitro cell monolayer model, Dr+ E. coli were shown to increase 
DAF expression and IL-8 production leading to increased transepithelial neutrophil 
migration, suggesting possible mechanism of increased adherence and inflammatory 
activation during Dr+ E. coli pathogenesis (Betis et al, 2003a, Betis et al, 2003b).  Dr+ E. 
coli are invasive bacteria that bind to GPI-DAF on epithelial cell surface subsequently 
leading to their internalization by the cells (Diagram 3) (Goluszko et al, 1997, Kansau et 
al, 2004, Selvarangan et al, 2000, Mulvey, 2002).  Recruitment of DAF and α5β1integrins 
around Dr+ E. coli, following the bacterial engagement is crucial for bacterial 
internalization (Das et al, 2005, Goluszko et al, 1999, Guignot et al, 2001, Kansau et al, 
2004, Plancon et al, 2003, Selvarangan et al, 2000).  The cellular invasion by Dr+ E. coli 
has been shown to occur via a zipper like mechanism (Diagram 4) employing 
accumulation of polymerized actin around the adherent bacteria followed by microtubule 
mediated internalization of the bacteria containing vacuole into the cell (Das et al, 2005, 
Goluszko et al, 1999, Guignot et al, 2001, Kansau et al, 2004). 
 
      Internalization of E. coli by renal epithelial cells is associated with tyrosine kinase 
mediated tyrosine phosphorylation of specific host proteins (Guignot et al, 2001, Palmer 
et al, 1997, Peiffer et al, 1998) (Diagram 5).  DAF and integrins are known to activate 
tyrosine kinase following engagement with their ligands (Abedi & Zachary, 1997, 
Burridge et al, 1988, Shenoy-Scaria et al, 1992, Stefanova et al, 1991, Zachary & 
Rozengurt, 1992).  PI3K has been identified as a downstream effector of both receptor 
and non-receptor tyrosine kinases (Wymann & Pirola, 1998).  PI3K is a heterodimeric 
protein consisting of a regulatory subunit (p85) and a catalytic subunit (p110).   
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Diagram 4:  Dr+ E. coli internalization in the host epithelial cells.  Scanning electron 
microscopic examination of the zipper like internalization of Dr+ IH11128 E. coli into HeLa cells 
(A-C). (A) Microvillus-like extensions (arrow) extend from the cell surface and are associated 
with bacteria, (B) Fused extensions (arrow) forming a zipper-like structure, (C) Enlarged 
extensions (arrows) form a zipper-like structure. Image adapted from Infection And Immunity, 72, 
2004 (Kansau et al, 2004).  D) Dual immunofluorescence labeling of IH11128 bacteria in 
infected Caco-2/TC7 cells and visualization of extracellular and internalized bacteria with FITC 
or tetramethyl rhodamine isothiocyanate immunolabeling, respectively. Green extracellular 
bacteria and red intracellular bacteria (arrows) were seen at the periphery of the cell clusterin 
which proliferative cells were localized.  Image adapted from: Infection And Immunity, 69, 2001 
(Guignot et al, 2001). 
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The regulatory subunit of PI3K interacts with several intracellular signaling molecules.   
Interaction of p85 with phosphotyrosine residues on tyrosine kinase results in PI3K 
activation causing the catalytic subunit to phosphorylate the inositide ring of 
phosphotidylinositol to form phosphotidylinositol 3, 4, 5 tripohosphate (PIP3).  PIP3 can 
then causes downstream activation of Akt (also known as protein kinase B-PKB).  PI3K 
signaling has been implicated in a variety of cellular processes, including survival, 
proliferation, migration, metabolic changes and bacterial invasion (Diagram 5) into the 
cell (Brumell & Grinstein, 2003, Wymann & Pirola, 1998).  PI3K has been shown to be 
necessary for the invasion of epithelial cells by several bacteria, including Listeria 
monocytogenes (Ireton et al, 1996), Helicobacter pylori (Kwok et al, 2002), Neisseria 
gonorrhoeae (Booth et al, 2003), Pseudomonas aeruginosa (Kierbel et al, 2005), Group 
B streptococci (Goluszko et al, 2008) and Escherichia coli K1 (Reddy et al, 2000).  Dr 
adhesin expressing recombinant bacteria have been shown to require PI3K activity for 
internalization into primary human bladder epithelial cells which express DAF and 
carcinoembryonic antigen (CEA)-related cell adhesion molecules (CEACAMs) as 
receptors for Dr adhesins (Korotkova et al, 2008). 
 
 
2.3 UTI and Inflammation 
      Pathology associated with UTI is caused due to UPEC mediated and inflammation 
related tissue damage. Pyelonephritis is associated with inflammatory damage of the 
pelvic and kidney tubules (Scherberich & Hartinger, 2007). UPEC attach to specific 
receptors through their adhesisn on host mucosa and trigger innate immune responses via 
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Diagram 5:  Mechanism of UPEC invasion in the host epithelial cells. Cellular signaling 
molecules and host components involved in the internalization of UPEC studied in different cell 
types are outlined: A) Dr adhesin mediated entry into host epithelial cells and B) Type 1 pilus 
mediated entry into bladder epithelial cells.  Following bacterial interaction with the cellular 
receptor for UPEC adhesisns, signal transduction cascades are activated leading to internalization 
of the bacteria.   CD55/ DAF (Dr adhesisn receptor) PTK, protein tyrosine kinase; PI3-K, 
phosphoinositide-3-kinase; FAK, focal adhesion kinase; PKC, protein kinase C; PLC 
phospholopase Cγ and MT, microtubule.  Image adapted and modified from Cellular 
Microbiology, 4, 2002 (Mulvey, 2002) 
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interactions with co-receptors including TLRs.  Tissue damage during UTI is associated 
with UPEC mediated apoptosis in urothelium and activation of macrophages and 
neutrophils which contributes to renal cell apoptosis directly as well as indirectly (Billips 
et al, 2008, Kipari & Hughes, 2002, Klumpp et al, 2006, Lange-Sperandio et al, 2003).  
Epithelial cells are known to be the early producers of pro-inflammatory cytokines and 
chemokines (TNF-α, IL-6, IL-1β, IL-8, RANTES, MCP-1) that are found to be increased 
in UTI patients and in experimental UTI mouse models (Agace et al, 1993, Betis et al, 
2003a, Connell et al, 1997, Godaly et al, 2000, Hedges et al, 1994, Samuelsson et al, 
2004, Scherberich & Hartinger, 2007, Svanborg et al, 1994, Svanborg et al, 1996, 
Svanborg et al, 1999, Wullt et al, 2002).  During bacterial infection virulence factors are 
released and the immune system is activated to secrete pro-inflammatory cytokines.  
Induction of the inflammatory immune response subsequent to infection determines the 
course of disease and extent of tissue damage.  An initial rapid inflammatory response is 
essential for clearing up the invading pathogen; however persistent chronic inflammation 
leads to tissue damage.  Less virulent strains have been suggested to cause asymptomatic 
bacteriuria, where the bacteria is able to colonize the urinary tract without activation of 
inflammatory response and thus no symptoms associated with UTI is observed (Zdziarski 
et al, 2008).  This suggests that inflammatory responses contribute to not only bacterial 
clearance, but also to tissue damage and associated symptoms during UTI, acting as a 
double edge sword. 
 
     Initial recognition of unique molecular patterns associated with pathogens by immune 
cells and epithelial cells via pattern recognition receptors like TLRs and other pattern 
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recognition receptors (PRRs) like -NOD like helicases and RIG like helicases- is the most 
crucial step in immune activation.  Members of the TLR family are located on the plasma 
membrane and membranes of endogenous vesicles in renal epithelial and immune cells; 
they bind to different signature ligands from a wide variety of pathogens (Anders & 
Schlondorff, 2007, Anders, 2007, Vandewalle, 2008).  Upon ligand binding and 
activation, these receptors interact with several adaptor proteins via their cytoplasmic 
domain leading to activation of cellular signaling pathways including NF-κB and MAP 
kinase (p38 and JNK).  This response leads to up-regulation of cytokines, chemokines 
and antimicrobial products synthesis that are crucial for inflammation and bacterial 
clearance (Akira et al, 2006, Kaisho & Akira, 2006, Kawai & Akira, 2005a, Kawai & 
Akira, 2005b, Kawai & Akira, 2007, Li & Cherayil, 2004).  For instance, secreations of 
CXC chemokines MIP2 (mouse) or IL-8 (humans) by renal epithelial cells upon TLR 
activation induce influx and activation of neutrophils in the renal interstitium, thus 
promoting interstitial inflammation (Samuelsson et al, 2004, Tang et al, 2003).  
Furthermore, reduced expression of IL8 receptors is associated with increased 
susceptibility to acute pyelonephritis (Lundstedt et al, 2007, Svensson et al, 2008).  IL-6 
production during UTI is associated with stimulation of IgA secretion by B cells 
contributing to protection against UTI (Hedges et al, 1991, Hedges et al, 1992).  MCP-1 
and RANTES are also reported to be secreted by renal tubular epithelial cells following 
TLR activation by bacterial components (Tsuboi et al, 2002).  IFN-gamma and TNF-
alpha released by activated renal tubule epithelium cells are responsible for regulating 
TLR2 and TLR4 expression in this tissue (Wolfs et al, 2002).  
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      The UPEC interact with urethral, bladder epithelium and renal tubule cells upon 
infection in the urinary tract.  The inner medullary collecting duct (IMDC) cells of the 
kidney are the first to come in contact with ascending UPEC strains, therefore they form 
the site for bacterial adherence and initiation of immune responses in the kidney (Chassin 
et al, 2006, Vandewalle, 2008).  In vivo experiments with pyelonephritis murine models 
have demonstrated that UPEC  adhered preferentially and constantly to the apical 
membranes of the medullary collecting duct  cells following transurethral inoculation and 
induce expression and bipolarized secretion of MIP-2 via TLR4 dependent and 
independent pathways (Chassin et al, 2006).  Renal tubular epithelial cells (Diagram 6) 
and interstitial myeloid dendritic cells are reported to constitutively express TLR1, 2, 3, 
4, 5, and 6, and show enhanced cytokine production following UPEC interaction (Anders, 
2007, Anders, 2007, Lech et al, 2007, Patole et al, 2005, Samuelsson et al, 2004, 
Scherberich & Hartinger, 2007, Svanborg et al, 2001b, Tsuboi et al, 2002, Vandewalle, 
2008).  TLR2 and TLR4 expressed on renal tubular cells have been shown to mediate 
direct inflammatory responses to bacterial products by activating secretion of cytokines 
and chemokines secretions (Chowdhury et al, 2006, Scherberich & Hartinger, 2007, 
Tsuboi et al, 2002, Wolfs et al, 2002).  In mouse, TLR11 expressed on kidney epithelial 
cells is reported to play an important role in protection from uropathogenic bacterial 
infection (Zhang et al, 2004).  LPS is the prominent gram negative E. coli product that 
activates TLR4 in immune and epithelial cells inducing proinflammatory immune 
responses.  Besides LPS, UPEC produce various fimbrial and afimbrial adhesins that 
trigger TLR mediated inflammatory immune responses in the urinary tract independently 
of LPS  
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Diagram 6:  Intrarenal distribution of TLRs along the kidney nephrons. Image adapted from 
Chang Gunj Med J , 31, 2008 (Vandewalle, 2008) 
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(Chassin et al, 2006, Fischer et al, 2006, Patole et al, 2005, Uhlen et al, 2000).  In studies 
utilizing human kidney biopsies and an experimental murine UTI model, UPEC adhesins- 
P pili and type 1 fimbriae have been shown to initiate a rapid inflammatory response via 
TLR4 activation independent of LPS (Bergsten et al, 2007, Fischer et al, 2006, Fischer et 
al, 2007, Frendeus et al, 2001, Godaly et al, 2007, Samuelsson et al, 2004).  Cirl et al 
have reported that UPEC strains promote bacterial survival and kidney damage by 
secreting products that interact and interfere with TLR activation (Cirl et al, 2008) 
suggesting importance of TLR signaling in the host defense against bacterial infection 
and is a possible virulence mechanism developed by pathogens to avoid TLR activation. 
 
      Reduction in TLR4 expression has been associated with asymptomatic bacteriuria 
(Ragnarsdottir et al, 2007).  C3H/HeJ mice carry a point mutation in the cytoplasmic 
region of TLR4, a replacement of proline with histidine, causing defective signaling 
leading to the LPS hyporesponsive phenotype and increase susceptibility to bacterial 
infections (Hoshino et al, 1999, Poltorak et al, 1998).  In C3H/HeJ mice this inactivating 
mutation also subdues the cytokine production in response to TLR2 mediated signaling 
(Li & Cherayil, 2004) suggesting that TLR4 activation is important for TLR 2 mediated 
inflammatory signaling.  The attenuation of bacterial defense due to TLR4 polymorphism 
might become crucial during severe infections.  In humans, Asp299Gly polymorphism of 
TLR4 is associated with defective LPS signaling (Agnese et al, 2002, Arbour et al, 2000, 
Lorenz et al, 2002), and the frequency of the Asp299Gly polymorphism of TLR4 ranges 
from 3% to 11% in the white human population (von Aulock et al, 2003).  Recent studies 
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have shown a higher prevalence of gram-negative infections and a more severe course of 
disease for carriers of the Asp299Gly allele (Agnese et al, 2002, Arbour et al, 2000, 
Lorenz et al, 2002).  Forthermore, studies in women with UTI have reported that adult 
susceptibility to UTI is associated with polymorphism in TLR2, TLR5 and TLR1gene 
(Hawn et al, 2009a, Hawn et al, 2009b).  TLR5 that recognizes bacterial flagellin is an 
important inducer of inflammation in experimental UTI in mice and TLR5 gene knock-
out mice were found to have increased susceptibility to UTI (Andersen-Nissen et al, 
2007).  In an experimental UTI murine model, presence of TLR 11 in the urinary tract 
was found to provide significant protection against uropathogen infection (Zhang et al, 
2004).  Thus, it is evident that TLR activation and cytokines secretion is critical for 
clearing UPEC from the host urinary tract.  Moreover, with the rising trends in antibiotic 
resistant UPEC strains contributing to more frequent, recurrent, and chronic UTIs, it 
seems important to explore the possible immunomodulatory mechanisms as effective 
prophylaxis and treatment options for UTI patients with normal as well as dysfunctional 
immune system. 
 
 
2.4 Estrogen and Estrogen receptors 
            Estrogen is a steroid hormone that acts via activation of its receptors ERα and 
ERβ.  ERα and ERβ belong to the superfamily of nuclear receptors and specifically to the 
family of steroid receptors that act as ligand-regulated transcription factors.  ERα and 
ERβ show high sequence homology and share affinity for the same ligands and DNA 
response elements.  Estrogen is the biological ligand to both the ER subtypes subtypes; 
however ERα and ERβ exhibit different affinities for some natural and synthetic 
52 
 
compounds.  They have distinct expression patterns in a variety of tissues and in different 
cell types, thus generating diverse effects following ligand induced activation (Barkhem 
et al, 2004, Barkhem et al, 2004, Nilsson et al, 2001, Nilsson & Gustafsson, 2002). 
 
      ERs consist of a C-terminal steroid ligand–binding domain (LBD), a centrally located 
DNA binding domain (DBD), and an N-terminal domain of less well-characterized 
function.  Additionally, the ERs contain two autonomous transcriptional activation 
domains (AF); the AF-1 domain, located in the N terminus, and AF-2, located within the 
LBD.  Transcriptional activation by ERα is mediated by two distinct activation functions: 
the constitutively active AF-1 and the ligand-dependent AF-2.  ERβ seems to have a 
weaker corresponding AF-1 function and thus depends more on the AF-2 for its 
transcriptional activation function.  ERs are latent transcriptional activators that require 
ligand binding for activation.  The estrogen binding induces a specific conformational 
change(s) in the ERs resulting in dissociation of the receptors from a protein chaperone 
complex, dimerization of the ERs, and binding of the receptor dimer to the specific 
estrogen response elements (EREs) located in the 5′ regulatory region of the primary 
steroid-responsive target genes.  Through interaction with AF-1 or AF-2, the activated, 
DNA-bound receptors recruit transcriptional co-activators that mediate assembly of 
productive transcription complexes at the promoter of target genes.  ERα and ERβ have 
shown different activities in certain ligand, cell-type, and promoter contexts (Barkhem et 
al, 2004, Nilsson et al, 2001, Nilsson & Gustafsson, 2002). 
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        Estrogen activated ERs regulate (enhance or repress) target gene expression either 
directly via the classical genomic pathway or indirectly via a rapid non-genomic 
signaling pathway (diagram 7).  In the classical genomic pathway, the ligand activated 
ERs directly bind to estrogen responsive elements (ERE) in the target gene promoter or 
interact with other transcription factors involved in transcription modulation.  In the non-
genomic pathway, the estrogen activated ERs interact with membrane bound or 
cytoplasmic signaling molecules to modulate gene expression and cellular function 
(Katzenellenbogen, 1996, Katzenellenbogen et al, 2000, Losel & Wehling, 2003, 
McKenna & O'Malley, 2002).  Although the classical pathway is considered  the major 
pathway for estrogen action in transcriptional regulation of specific gene networks, it is 
now well understood that integration of membrane-initiated non-genomic signaling along 
with genomic mechanisms represents in the complete cellular response to estrogen in the 
target cells (Cato et al, 2002, Edwards & Boonyaratanakornkit, 2003, Watson & 
Gametchu, 1999). 
 
 
2.5 Estrogen and Kidney 
       The kidney is considered to have the third largest number of estrogen regulated 
genes, and these genes are suggested to be regulated via ERα mediated mechanism 
(Jelinsky et al, 2003, Kuiper et al, 1997).  Female mice were found to show more ERα 
than ERβ expression in renal cortex cells; ovariectomy associated with decreased 
estrogen levels tends to decrease the ERα expression levels (Rogers et al, 2007). 
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Diagram 7: Genomic and non-genomic actions of the ERs. Estrogenic ligands (triangles) 
activate ERs as a transcription factor (1) by inducing conformational changes that leads to its 
nuclear translocation, dimerization, and binding to specific steroid receptor response elements 
(SRE) in promoters of primary target genes. Activated ER recruits coactivators that are essential 
for assembly of a productive transcription complex at the promoter. Alternatively, a 
subpopulation of ER associates in an estrogen-dependent manner (2) with cytoplasmic- and/or 
cell membrane–signaling molecules (shown here is the tyrosine kinase Src). This extranuclear 
interaction promotes the Shc-Src-Raf–MAPK kinase (MEK)–MAP kinase phosphorylation 
cascade. Because MAPK can directly (solid arrows) or indirectly (dashed arrows) activate other 
transcription factors (TF), the MAP kinase pathway can potentially regulate distinct or 
complementary sets of genes from those regulated by nuclear ER pathways. Estrogen-activated 
MAPK can also enhance the direct transcriptional activity of ER by an auto-feedback loop 
through phosphorylation of ER or ER-associated co-activators. The green hexagon indicates an 
adaptor protein.  Image adapted from Mol Interv., 3, 2003 (Edwards & Boonyaratanakornkit, 
2003) 
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      Estrogen is considered renoprotective.  Chronic renal disease development in 
menopausal females is suggested to be due to loss of ovarian estrogen.  It was shown in 
female Dahl salt-sensitive rats that ovariectomy increased renal diseases due to increased 
renal inflammation and the damage was reduced with E2 supplement (Maric et al, 2008).  
Decrease in ERα expression following ovariectomy contributed to renal damage and 
hypertension in female Dahl salt sensitive rats (Esqueda et al, 2007).  Estrogen is 
reported to regulate extracellular matrix (ECM) kinetics in kidney by increasing matrix 
metalloproteinase synthesis and decreasing type I and IV collagen synthesis, thus 
protecting kidney from damage and fibrosis (Dixon & Maric, 2007, Mankhey et al, 2005, 
Mankhey et al, 2007, Maric & Sullivan, 2008, Neugarten et al, 2000, Potier et al, 2001, 
Potier et al, 2002, Silbiger et al, 1998).  
 
 
2.6 Estrogen and Inflammation 
      The anti-inflammatory, as well as pro-inflammatory effects of estrogen, at various 
doses in different cell types and under different physiological conditions have been 
numerously demonstrated (Straub, 2007).  Recent studies have shown the presence of 
estrogen receptors on the cells involved in the immune response, namely thymocytes, 
macrophages, and endothelial cells (Straub, 2007).  Furthermore, cytokine production has 
also been shown to vary with changes in the circulating levels of estrogen in females 
during pregnancy and menopause (Diagram 8) (Straub, 2007).  Physiological estrogen 
levels have been reported to have positive protective effects on the kidney tissue.  For 
example, estrogen has been shown to inhibit the IL-6 production in Kupffer cells and thus 
reduce the risk of liver cancer in female mice (Naugler et al, 2007).  In a study IL6 
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Diagram 8:  Dichotomy of the effects of estrogen on inflammatory pathway during 
pregnancy and menopause.  Influence of estrogen on several pro and anti inflammatory 
pathways at different estrogen doses as determined by various studies on different cell types. 
Depending on the dose of estrogens, factors in green boxes are stimulated while factors in orange 
boxes are inhibited by estrogens.  Estrogen at doses found during pregnancy appears to be more 
anti-inflmmatory, while reduced estrogen levels during menopausal stages seems to promote pro-
inflammatory conditions.   DC, Dendritic cell; MØ, monocyte/macrophage; NK cell, natural killer 
cell; OPG, osteoprotegerin; PDGF, platelet-derived growth factor; VSMC, vascular smooth 
muscle cell.  Image adapted from Endocr. Rev., 28, 2007 (Straub, 2007) 
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expression in human retinal pigment epithelial cells was found to be down-regulated by 
estrogen treatment following TLR activation (Paimela et al, 2007).  ERα activation was 
also shown to inhibit the IL-1β gene induction in the mice livers (Evans et al, 2002).  In 
addition, IFN γ  production in the spleens was found to be increased by approximately 4-
fold in ERα-deficient mice over wild type mice, suggesting a suppressing role for ERα in 
IFNγ production during chronic bacterial infection (Curran et al, 2004).  Estrogen 
mediated regulation of endothelial nitric oxide synthase (NOS) expression is known to 
control renal inflammation (Maric et al, 2008, Satake et al, 2008).  Estrogen treatment of 
endometrial epithelial cells stimulated with TLR3 ligands showed repression of 
chemokines and cytokine expression via ERα activation pathway (Lesmeister et al, 
2005).  TLRs expressed on renal epithelial cells and macrophages are activated by 
bacterial components to induce chemokines and cytokine secretion.  Yao et al reported 
change in expression levels of TLRs in murine vaginal epithelium in different stages of 
estrous cycle (Yao et al, 2007).  Moreover, men with chronic renal failure experience 
more rapid decline in renal function than women (Straub, 2007).  
 
 
2.7 Estrogen and UTI 
      Incidence of UTI seems to vary with age and stages of menstrual cycle suggesting 
hormonal regulation of UTI susceptibility.  Postmenopausal women have high prevalence 
of UTI and estrogen deficiency appears to be an important contributing factor (Altoparlak 
et al, 2004, Foxman et al, 2001, Franco, 2005, Pabich et al, 2003).  Moreover, in canine 
studies, it has been reported that uterus infection in bitches occur during the first half of 
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the diestrous stage of estrous cycle, when the estrogen dose is the lowest (Sugiura et al, 
2004).  Estrogen treatment in postmenopausal women is reported to reduce the incidence 
of UTIs and extent of inflammation induced tissue damage following UPEC infection 
(Devillard et al, 2004, Heinemann & Reid, 2005, Maloney, 2002, Perrotta et al, 2008, 
Rozenberg et al, 2004, Stamm, 2007, Stern et al, 2004, Valiquette, 2001).  Estrogen 
treatment in postmenopausal women was found to be protective against UTI by 
contributing towards restoration of the periurethral and vaginal microflora and reduction 
of the risk of developing vaginal atrophy (Altoparlak et al, 2004, Devillard et al, 2004, 
Franco, 2005, Perrotta et al, 2008, Raz & Stamm, 1993, Rozenberg et al, 2004, Stamm, 
2007).  However, the exact mechanism of estrogen mediated protection is  not completely 
understood and appears to be more complex involving functions extending beyond 
restoration of commensal microflora and organ structure.  Studies until now have 
explored the effects of estrogen on UTI susceptibility in postmenopausal women and 
have shown contradictory outcomes (Curran et al, 2007, Hu et al, 2004).  In a study by 
Perrotta C. et al, it was found that estrogen treatment reduced the number of UTIs in 
postmenopausal women suffering with recurrent UTI.  However the protection varied 
according to the type of E2 used and the duration of the treatment given (Perrotta et al, 
2008).  Increased susceptibility for UTI in an experimental mouse model following high 
dose of estrogen treatment was recently reported (Curran et al, 2007).  The variation in 
estrogen doses used, the target organs studied and the age groups of the study populations 
may contribute to the conflicting results observed in different studies in this direction 
(Stamm, 2007).  The effects of estrogen may vary as there is variation in circulating 
estrogen doses in pubertal, menstruating, menopausal, and postmenopausal female.  In 
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the study by Curran et al, increased risk for UTI was found in the kidneys but not in the 
bladders suggesting differential effects on lower and upper urinary tract at that dose of 
estrogen used (Curran et al, 2007).  Despite numerous studies, the exact mechanism of 
estrogen mediated immunomodulation during UTIs remains an enigma. 
 
      Physiological levels of estrogen have an important role to play in modulating the risk 
factors for urinary tract infection. Increased (pregnancy) as well as decreased levels of 
estrogen (menopause, hysterectomy, and ovariectomy) are considered as factors 
contributing to UTI susceptibility.  In addition, long term hormone therapy with estrogen 
seems to have some non beneficial outcome in treatment groups (Ahmed et al, 2008, 
Franco, 2005, Hooton, 2000, Ribeiro et al, 2002, Sonnex, 1998).  Therefore, it seems 
necessary to explore the effects of estrogen on UTI susceptibility and immunomodulation 
at the physiological doses of estrogen in female urinary tract.  This will guide us to 
understand the mechanistic roles of estrogen in different anatomical parts of the female 
upper and lower urinary tract.  This information will help in determining more judicious 
use of estrogen in treatment prescription for females with differing physiological 
conditions and also to look for therapeutic alternatives including estrogen related drugs 
for UTI treatment.  
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CHAPTER III 
 
 
RESEARCH DESIGN AND METHODOLOGY 
 
3.1 Experimental Models for UTI induction 
3.1.1 Uropathogen for induction of experimental UTI  
            We have used Dr+ E. coli, strain-IH11128 (O75:K5: H-) for inducing 
experimental UTI in vivo and in vitro in the present study.  Pure culture of Dr+ E. coli 
was obtained from Dr Bogdan Nowicki (University of Medical Branch at Galveston, 
Texas) and maintained in our laboratory.  E. coli strain-IH11128 is a clinical isolate 
identified from a girl diagnosed with acute pyelonephritis and it has been further 
characterized as a UPEC bearing Dr adhesin (Nowicki et al, 1987, Vaisanen-Rhen et al, 
1984, Vaisanen-Rhen, 1984).  Dr+ E. coli is associated with cystitis, recurrent UTI and 
pyelonephritis in humans (Goluszko et al, 1997, Nowicki et al, 2001, Servin, 2005, 
Vaisanen-Rhen et al, 1984, Vaisanen-Rhen, 1984).  This E. coli strain has been 
previously used to develop experimental mouse model for ascending urinary tract 
infection using C3H/HeJ mice (Goluszko et al, 1997, Kaul et al, 1999, Nowicki et al, 
2001).  
61 
 
3.1.2  In vivo murine models for induction of experimental UTI 
            Mice are preferred in vivo model for studying pathogenesis of lower and upper 
urinary tract infections due to the predominance of glycolipids that form the attachment 
receptors for majority of UPEC in both human, as well as mouse kidney (Hagberg et al, 
1983a).  We have used TLR4 mutant female C3H/HeJ mice as well as ERα gene 
knockout (ERα-/-) and ERα gene intact (ERα+/+) female B6.129 mice for inducing 
experimental UTI in our study. 
 
A)  Menopausal C3H/HeJ murine model for in vivo experimental UTI induction 
      OVX TLR4 mutant-C3H/HeJ mice were used for the development of an experimental 
menopausal UTI murine model to study the effects of estrogen on the development of 
ascending UTI infection.  TLR4 expressed on renal tubular cells mediate direct 
inflammatory responses against bacterial products, especially LPS by activating secretion 
of cytokines and chemokines.  Mutations in TLR4 are associated with endotoxin 
hyporesponsiveness resulting in impaired inflammatory response and thus increased risk 
towards gram negative infections (Chowdhury et al, 2006, Scherberich & Hartinger, 
2007, Tsuboi et al, 2002, Wolfs et al, 2002).  Moreover, increased UTI infections in 
children with TLR4 mutation has also been reported (Karoly et al, 2007) and reduction in 
TLR4 expression has been observed to be associated with asymptomatic bacteriuria in 
children (Ragnarsdottir et al, 2007).  C3H/HeJ mice carry a point mutation in the tlr4 
gene that results in replacement of proline with histidine at position 712 in the 
cytoplasmic domain of TLR4 leading to defective signaling.  This causes the LPS 
hyporesponsive phenotype and increased susceptibility to bacterial infection (Poltorak et 
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al, 1998).  These mice show increased susceptibility for E. coli mediated urinary tract 
infection (Hagberg et al, 1983b, Hagberg et al, 1984) and have been successfully used for 
developing the experimental chronic pyelonephritis model with Dr+ E. coli (Goluszko et 
al, 1997) and other UPEC (Chassin et al, 2006).  We have therefore used OVX C3H/HeJ 
mice as an in vivo surgically induced menopausal mouse model for induction of 
experimental UTI to investigate the effects of estrogen on bacterial colonization and 
infection associated inflammation in the urinary tract.  We have confirmed the expression 
of ER subtypes and Dr+ E. coli colonization receptors DAF and type IV collagen in the 
kidney of C3H/HeJ mice at mRNA levels by quantitative SYBR green realtime PCR and 
at protein levels by immunohistochemistry. 
 
B)  ERα-/- murine model for in vivo experimental UTI induction 
      To discern the role of ERα in determining susceptibility to Dr+ E. coli colonization 
and infection associated inflammation in kidney, we have used female ERα-/- mice.  The 
ERα-/- B6.129-Estratm1N10 mice (Jackson Laboratory) carry disrupted ERα gene (ESR1) 
and completely lack functional ERα protein, however ERβ protein remains functional in 
these mice (Lubahn et al, 1993).  ERα+/+ B6.129 female mice (Jackson Laboratory) were 
used as experimental control.  We detected the expression of Dr+ E. coli colonization 
receptors DAF and type IV collagen in the kidney of ERα-/-  and ERα+/+ mice at mRNA 
levels by quantitative SYBR green real-time PCR 
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3.1.3  In vitro cell culture models for induction of experimental UTI 
            The most distal renal tubule segments, the medullary collecting ducts are the first 
to come in contact with ascending UPEC and thus are the primary site of bacterial 
adherence and early inflammatory responses against UPEC (Chassin et al, 2006, 
Vandewalle, 2008).  Immortalized kidney cells have been observed to induce cytokine 
and chemokines expression following interaction with UPEC (Chassin et al, 2006, 
Chassin et al, 2007).  We have used the following immortalized kidney inner medullary 
collecting duct (IMCD) cell lines of mouse and human origin for establishing in vitro 
UTI model for the present study : Mouse and human inner medullary collecting duct cells 
(mIMCD3 and hIMCD) 
      The kidney IMCD cell lines, mIMCD3 and hIMCD cell were generous gifts from Dr. 
Hari. Koul (University of Colorado at Denver and Health Science Center, Denver, CO).  
The mIMCD3 cell line (ATCC #CRL-2123™) was derived from the terminal one-third 
of the IMCD tubule obtained from the transgenic mouse carrying genes for the early 
region of SV40 [Tg(SV40E)bri/7].  This is a polarized epithelial cell line which retains 
many differentiated characteristics of the terminal IMCD (Rauchman et al, 1993).  The 
hIMCD cell line was developed from normal papillary tissues dissected from the surgical 
waste of consenting patients undergoing renal surgery  and was shown to retain 
expression of several epithelial cell markers and characteristics of IMCD cells 
(Khandrika et al, 2008).  We established an in vitro experimental UTI model using 
mIMCD3 and hIMCD cells to study the invasion of pyelonephritic Dr+ E. coli strain in 
the kidney IMCD cells and to further investigate the molecular mechanisms underlying 
uropathogenesis and estrogen mediated protection during infection with Dr+ E. coli.  In 
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the present study we have performed most of our in vitro experiments using mIMCD3 
cells.  We confirmed the expression ER subtypes and Dr+ E. coli colonization receptors 
DAF and type IV collagen in mIMCD3 and hIMCD at mRNA levels by quantitative 
SYBR green real-time RT-PCR using either SYBR green or TaqMan chemistry.  We 
detected the protein expression of DAF in mIMCD3 and hIMCD by western blot.  
Surface expression of DAF on mIMCD3 cells was determined by flow cytometry.  ER 
subtypes expression at protein level in mIMCD3 was detected by immunocytochemistry 
and western blot. 
 
 
3.2 In vivo Methods 
 
3.2.1  Animals and Animal care 
A) C3H/HeJ mice:  Six weeks old OVX (ovariectomy at 5 weeks), and Non-OVX 
C3H/HeJ mice were purchased from Jackson Laboratories.  Following arrival, 
mice were kept in microisolater cages and were housed in a room with controlled 
temperature and a 12 hrs light-dark cycle in the animal facility of the Oklahoma 
State University, Center for Health Sciences.  They had free access to filtered 
water and regular diet (Harlan Teklad Global diets #2018S).  The animals were 
rested for a week following arrival and categorized into different groups as per 
their treatments and infection scheme (Table 1). 
B) ERKO mice:  Female ERα-/- B6.129-Estratm1N10 mice and ERα+/+ mice were 
obtained as gifts from Dr Susan Kovats, Oklahoma Medical Research Foundation, 
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OK.  Mice were transported from the animal facility of OMRF to the animal 
facility of the Oklahoma State University, Center for Health Sciences in two 
batches at an interval of one month.  The first batch included five 20-32 weeks old 
ERα-/- mice and ten 20-32 weeks old ERα+/+ mice.  The second batch included 
five 8-10 weeks old ERα-/- mice and five 8-10 weeks old ERα+/+ mice.  
Following arrival, mice were kept in microisolater cages and were housed in a 
room with controlled temperature and a 12 hrs light-dark cycle, in the animal 
facility of the Oklahoma State University, Center for Health Sciences.  They had 
free access to filtered water and regular diet (Batch #1: Picolab mouse lab diet 20 
# 5058 and Batch #2: Harlan Teklad Global diets #20185).  The animals were 
rested for a week following arrival and categorized into different groups as per 
their infection scheme (Table 2). 
      Following housing the animals, the cage’s soiled bedding were routinely changed. 
The microisolater cages with infected bedding containing excretion of animals were 
treated as contaminated and were sprayed with 10% bleach and autoclaved in biohazard 
bags before disposal.  Cages were washed, acid rinsed and thoroughly decontaminated 
after beddings were removed.  All experiments were conducted in accordance with the 
principles and procedures of the NIH Guide for the Care and Use of Laboratory Animals 
approved by Oklahoma State University, Center for Health Sciences.  All animals were 
used for experiments within two weeks of delivery.  
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3.2.2  Animal Treatment 
           OVX C3H/HeJ mice were treated with a physiological dose of E2 (17, β-estradiol 
Sigma, E 4389) or vehicle (sterile PBS+corn oil).  Non-OVX mice were treated with ICI 
182, 780 (Tocris 1047) or vehicle (sterile PBS+corn oil).  E2 dissolved in PBS was mixed 
with corn oil (1:2 vol/vol) and 100 µL of this mixture was administered subcutaneously 
into each mouse before induction of experimental UTI.  Each mouse received either 6 µg 
of E2 /kg/day in corn oil or received corn oil with PBS per day, for five consecutive days 
prior to infection.  ER antagonist ICI 182, 780 dissolved in ethanol and diluted in PBS 
was administered along with corn oil at the rate of 5 mg/kg/day to Non-OVX mice in the 
a similar way as described for E2.  Treatment with ICI 182, 780 was given for 5 days 
prior to UTI induction and continued for 6 days post-UTI induction.  The dose of E2 
treatment (for treatment at physiological levels) and the dose for ICI 182, 780 used in this 
study have been described previously (Elloso et al, 2005, Sawada et al, 2000) 
 
3.2.3  Culture of Dr+ E. coli and Hemmaglutination of red blood cells 
            Dr+ E. coli was revived from frozen stock and was grown on Luria Bertani agar 
(LB) plates (Fisher Scientific) overnight to maintain the culture.  Pure cultures of Dr+ E. 
coli strain were routinely tested for hemagglutination using a 30% suspension (vol /vol) 
of human O erythrocytes in phosphate-buffer saline (PBS). 
 
3.2.4  Dr+ E. coli inoculum preparation for induction of experimental UTI 
      Bacterial suspension prepared with pure culture of Dr+ E. coli was used to induce 
experimental UTI in mice as described before (Kaul et al, 1999).  Dr+ E. coli was 
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cultured on LB plates at 37°C overnight.  Isolated colonies of Dr+ E. coli from overnight 
bacterial culture were used to prepare bacterial suspension in sterile PBS.  Bacterial 
suspension with an optical density of 1 at 600nm (corresponding to approximately 108 
bacterial cells) was used as inoculum for experimental UTI induction.  Bacterial counts in 
bacterial suspension were determined by plating 10-fold serial dilutions of bacterial 
suspension on LB plates and counting the viable colonies following 18 hrs of incubation 
at 37º C.  The hemagglutination property of the Dr+ E. coli pure culture was tested before 
inoculum preparation.  
 
3.2.5  Experimental UTI induction in mice 
            Induction of experimental UTI in mice was performed by bladder catheterization. 
The mice were anesthetized by isoflurane inhalation and 50µl of bacterial inoculum was 
instilled slowly into the bladder through a soft catheter with an outer diameter of 0.30 
mm (Norton Performance Plastics Soft Plastics, Akron, Ohio) adapted to a needle on a 
tuberculin syringe (0.4 by 20 mm).  After injection, the catheter was immediately 
withdrawn and no further manipulations were performed.  Controls were similarly 
injected with 50 µl of sterile PBS.  Following infection, mice were returned to their cages 
and monitored daily for any adverse symptoms or changes in body weight until 
euthenized.  Mice were euthanized by CO2 inhalation followed by cervical dislocation.  
Kidneys and bladders were aseptically harvested and snap frozen.  Summary of the 
infection scheme is represented in Table 1 for C3H/HeJ mice and Table 2 for ERα +/+ 
and ERα-/- mice.  The in vivo research design for C3H/HeJ mice is pictorially 
represented in Diagram 9. 
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Table 1:  Treatment groups for OVX and Non-OVX C3H/HeJ mice 
 Number of mice  
 Infected 
(Dr+ E. coli) Uninfected Total 
 
Days of infection 2 days  6 days 2 days  6 days  
Treatments 
     
OVX C3H/HeJ mice 
    
 
E2 (6 µg/kg mouse /day in PBS 
+ corn oil)* 6 6 4 4 20 
Vehicle (PBS + corn oil) 6 6 4 4 20 
Non-OVX C3H/HeJ mice 3 days 7 days 3 days 7days  
ICI 182,780 (5 mg/kg mouse/day 
in ethanol and PBS + corn oil)* 5 5 0 2** 12 
Vehicle  
(ethanol and PBS + corn oil) 5 5 0 2 12 
 
Total 22 22 8 12  64 
*E2 treatments were continued for 5 consecutive days pre-UTI induction.  ICI 182, 
780 treatment was given for 5 consecutive days pre-UTI induction and then 
continued for 6 consecutive days post-UTI induction; ** 1 mouse died during the 
treatment 
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Diagram 9:  In vivo research design using C3H/HeJ mice.  Diagramatic representation 
of research design for studying bacterial colonization, expression of colonization 
receptors and inflammatory responses following Dr+ E. coli infection using the in vivo 
C3H/HeJ murine model 
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Table 2:  Infection groups for ERα-/- and ERα+/+ mice 
 Number of mice Total 
 
Infected 
(Dr+ E. coli) Uninfected 
 
 
Days of Infection 3 days  7 days 3 days  7 days  
Experiment I       
ERα-/- 2 3 0 0 5 
ERα+/+ 4 4 0 2 10 
Experiment II      
ERα-/- 0 5 0 0 5 
ERα+/+ 0 5 0 0 5 
 
Total 6 17 0 2 25 
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3.2.6  Tissue homogenate culture 
            The aseptically removed kidney and bladder tissues were weighed and 
homogenized in sterile PBS using an Omini Tip homogenizer.  The number of viable Dr+ 
E. coli in the tissues was determined by plating tissue homogenates on LB plates in 
duplicates.  The plates were incubated overnight at 37ºC and the numbers of bacterial 
colonies obtained were counted manually on a colony counter grid.  The bacterial counts 
represented viable bacteria present in the bladder and kidney homogenates.  Counts of 
bacterial colonies obtained were expressed as the number of CFU per gram tissue weight. 
Summary of the infection scheme is represented in Table 1 for C3H/HeJ mice and Table 
2 for ERα +/+ and ERΑα-/- mice. 
 
3.2.7  Serum Preparation 
            Blood samples were collected from mice by tail bleeding and centrifuged for 20 
minutes at 16000 rpm at 4°C. Clear serum was collected from each sample transferred to 
fresh tubes and stored at80°C. 
 
3.2.8  Measurement of serum E2 levels 
            Serum E2 dose was measured in each group using a competitive EIA kit (Oxford 
Biomedical Research # EA70). 
 
3.2.9  Measurement of serum TNFα levels 
            Serum TNFα dose was measured in ERα-/- and ERα+/+ mice using mouse TNFα 
ELISA kit ( eBiosciences # 88-7324-22) 
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3.3 In vitro Methods 
3.3.1  Cell culture 
            The mIMCD3 cells were cultured and maintained in Dulbecco’s modified Eagle’s 
Medium (DMEM-F12), (Invitrogen/Gibco) and hIMCD cells were cultured and 
maintained in DMEM (Invitrogen/Gibco).  The cell culture medium was supplemented 
with 5% FBS (Atlanta Biologicals) and antibiotics: 100 U/ml penicillin and 100 µg/ml 
streptomycin (Invitrogen).  Cells were plated in T-25 or T-75 flasks and cultured in a 
humidified atmosphere (95%) containing 5% CO2 at 37°C   Cell cultures were maintained 
by subculturing and were passaged at a ratio of 1:4 once they became 80-90% confluent 
(every 3-4 days).  
 
3.3.2 Drug treatment 
            For all the drug treatment experiments, mIMCD3 cells were plated at a dose of 
0.5 million cells per well in 12 well plates and cultured in a medium supplemented with 
antibiotics and 5% heat-inactivated fetal bovine serum depleted of steroids by dextran-
charcoal treatment (charcoal stripped serum : VWR).  The cells were allowed to grow and 
attach overnight (18-24 hrs) followed by treatement with different drugs (Table 3).  For 
drug treatments, the cell monolayers grown in 12 well plates were washed twice with 
PBS gently and serum free culture medium containing various doses of drugs was added 
to each well.  For untreated control cells, no drug was added to the culture medium.  The 
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stock solutions of the compounds: E2 (Sigma-Aldrich), ICI 182, 780, PPT, DPN, MPP, 
R, R-THC, Genestein or LY294002 (Tocris Bioscience) were diluted up to the required 
working doses in serum free media.  The cells were incubated for desired period of time 
with the drugs prior to infection with Dr+ E. coli.  For mIMCD3 cells, the doses used and 
the duration of treatment for each drug is described in Table 3.  The hIMCD cells were 
treated with E2 at 1, 10 and 50 nM doses for 24 hrs prior to infection.  The in vivo 
research design for mIMCD3 cells is pictorially represented in Diagram 9. 
 
3.3.3  Gentamicin Protection Assay 
            Following infection with Dr+ E. coli for 2 hrs, non adherent bacterial cells were 
aspirated, and loosely adherent bacterial cells were removed by washing the infected cells 
monolayers with PBS atleast 2-3 times.  The cell monolayers were then incubated with 
50µg/ml gentamicin for 90 minutes to kill the extracellular adhering bacteria.  
Gentamicin was aspirated and cell monolayers were washed thrice with PBS to remove 
the residual gentamicin.  The cells were then permeabilized with lysis buffer (1% Triton 
X-100 in PBS), following which the cell lysates were spread on LB plates in duplicates 
and incubated at 37°C overnight.  Bacterial colonies that appeared after 18 hrs of 
incubation were counted and represented as colony forming unit (CFU). The percentage 
of bacteria invasion in drug treated cells was determined relative to the invasion in 
untreated control cells (Duncan et al, 2004).  Invasion in untreated control cells was 
considered 100%. 
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Table 3:  Drug treatment in mIMCD3 cells 
Drug Drug Action Doses  used for treatment 
Duration 
of 
treatment 
17, β-Estradiol (E2) ER-agonist 1 nM, 10 nM, 50 nM, and 100 nM 
24hrs 
ICI 182, 780 ER-antagonist 0.1 µM, 1 µM, and 10 µM 24hrs 
PPT ERα selective 
agonist 
0.01 µM, 0.1 µM, and1 µM 24hrs 
DPN ERβ selective 
agonist 
0.01 µM, 0.1 µM, and1 µM 24hrs 
MPP ERα selective 
antagonist 
0.01 µM, 0.1 µM, and1 µM 24hrs 
R,R-THC ERβ selective 
antagonist 
0.1 µM, 1 µM, and 10 µM 24hrs 
Genistein Tyrosine kinase 
inhibitor 
0.1 µM, 1 µM, and 10 µM 24hrs 
LY294002 PI3K inhibitor 10 µM, 50 µM, and 100 µM 15 min 
Co-treatment of cells with 10 nM E2 and various doses of ICI 182, 780, MPP or 
R,R-THC was performed for 24hrs. 
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Diagram 10:  In vitro research design using mIMCD3 cells.  Diagramatic 
representation of research design for studying the effects of estrogen and ER subtype 
specific ligands on bacterial invasion, expression of colonization receptors, and 
inflammatory responses, following Dr+ E. coli infection in vitro, using mIMCD3 cell 
culture model. 
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      For enumeration of total infection, (bacteria adhered and internalized), following 2 
hrs of infection, the cell monolayers were washed with PBS thrice after aspirating the 
bacterial suspension.  The cells were then lysed with the lysis buffer and the lysates were 
cultured on LB plates at 37°C for 18 hrs.  The bacterial colonies that appeared were 
counted and represented as CFU. 
 
3.3.4  MTT test for cell toxicity 
            Cell viability in response to treatment with different drugs was determined 
colorimetrically by measuring the reduction of tretrazolium salt MTT (3-(4,5-
dimethyldiazol-2-yl)-2,5 diphenyl Tetrazolium Bromid) to insoluble formazan by 
mitochondrial dehydrogenase.  Cells (mIMCD3 and hIMCD) were cultured in 96 well 
plates at a dose of 50,000 cells per well in 200 µl of culture media.  The confluently 
growing cells were then incubated with different drugs (Table 3) for desired period of 
time (Table 3).  Following incubation 10mg/ml MTT (Sigma) solution was added to the 
media in each well and incubated for 2hrs at 37°C.  The media was the aspirated and 100 
µl of dimethyl sulphoxide (DMSO) was added to each well to dissolve the developed 
formazan.  Absorbance was measured at 570 nm.  The absorbance values from wells 
containing drug treated cells were compared to the values from untreated control cells to 
determine the viability of cells in each treatment group. 
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3.4 Quantitative analysis of mRNA expression 
 
3.4.1  RNA isolation and cDNA synthesis 
            Total RNA was isolated from kidney tissues and mIMCD cells with Trizol 
reagent (Invitrogen) using manufacturer’s instructions.  Inner medullary and renal pelvis 
regions were dissected out from the kidney tissues and were used for RNA isolation.  
RNA samples were quantitated on ND-1000 (NanoDrop Technologies) and their integrity 
was determined by denaturing agarose gel electrophoresis.  RNA samples showing 
protein and chemical contamination as determined by 280/260 and 230/260 ratio were 
purified using RNeasy columns (Qiagen), using the manufacturer’s instructions.  Total 
RNA from each sample was given DNase treatment (Ambion) and then reverse-
transcribed to cDNA, using High capacity cDNA synthesis kit (Applied Biosystems), 
following the kit’s instructions.  
 
3.4.2  Quantitative real-time reverse transcriptase-polymerase chain reaction (real-
time RT-PCR) 
            Quantitative real-time RT-PCR was performed using TaqMan or SYBR green 
chemistry on an ABI StepOne Real-Time PCR System (Applied Biosystems).  PCR 
Reactions were performed using cDNA as template (approximately 10-100 ng), target 
gene and endogenous control specific primers and reaction master mix.  SYBR green 
PCR primers were purchased from realtimeprimers.com (Table 4), and TaqMan primers 
were purchased from Applied Biosystem (Table 5).  Power SYBR green master mix 
(Applied Biosystems) or GoTaq qPCR master mix (Promega) was used for SYBR green  
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Table 4:  Primer pairs for SYBR green real-time RT-PCR (realtimeprimers.com). 
Target 
Gene Name 
 
Forward and Reverse primer 
sequence(5'-3') 
Primer 
Tm 
Amplicon 
size 
Gene 
Accession 
Regognition 
region on 
genome 
ESR1(ERα) 
Fp: TTCTCCCTTTGCTACGTCAC 
Rp:  TCGCTTTGTCAACGACTTC 
 
58°C 212bp NM_007956 2208-2419 
ESR2 (ERβ) Fp: GGTCATCAAATCGACCTTT Rp:GGAACAAGGTCACATCCAAG 58°C 185bp NM_207707 2413-2597 
Collagen 
Type IVa1 
Primerset#3 
Fp: CCACTGTCCAGTGTTTCCAC 
Rp:CCACACAGGGCATAAGTTTG 59°C 132bp NM_009931 5654-5785 
DAF/CD55
Primerset#3 
Fp: AGCAAAGTGGCATACTCGTG 
Rp: CTGGGAGTGGAGGTTGTTTT 59°C 247bp NM_010016 246-492 
TLR2 
 
Fp: GACGACTGTACCCTCAATGG 
Rp: TAAATGCTGGGAGAACGAG 58°C 226bp NM_011905 1205-1430 
TLR4 
Primerset#2 
FP: AAGGTTGAGAAGTCCCTGCT 
Rp: TTGTTCTCCTCAGGTCCAAG 58°C 207bp NM-021297 2232-2538 
TNFα Fp: CCCACTCTGACCCCTTTACT Rp: TTTGAGTCCTTGATGGTGGT 58°C 201bp NM_013693 899-1099 
Mip 2 Fp: TCATGGAAGGAGTGTGCAT Rp: CACGAAAAGGCATGACAAA 59°C 216bp NM_009140 803-1018 
IL6 Fp: GGAGAGGAGACTTCACAGA Rp: CAGTTTGGTAGCATCCATC 58°C 218bp NM-_031168 122-339 
Mouse endogenous control for relative expression studies 
ACTB Fp: AGAGCTATGAGCTGCCTGA Rp: ACGGATGTCAACGTCACAC 58°C 160bp NM_007393.1 792-951 
B2M 
Fp:GGCCTGTATGCTATCCATAA 
Rp:GAAAGACCAGTCCTTGCTGA 
 
58°C 198bp NM_009735.2 103-300 
GAPDH 
Fp:CTGGAGAAACCTGCCAAGTA 
Rp:TGTTGCTGTAGCCGTATTCA 
 
58°C 223bp BC083080.1 796-1018 
GUSB Fp:GACTCAAAGGTGTCCCCAGA Rp: CTTCACTCCAGCCTCTCACC 58°C 227bp NM_010368.1 1981-2254 
HPRT1 
Fp: GCTGACCTGCTGGATTACAT 
Rp:TTGGGGCTGTACTGCTTAAC 
 
58°C 242bp NM_013556.1 313-554 
PGK 
Fp:GCAGATTGTTTGGAATGGTC 
Rp:TGCTCACATGGCTGACTTTA 
 
58°C 185bp NM_008828.2 1123-1307 
PPIA 
Fp:AGCTCTGAGCACTGGAGAGA 
Rp:GCCAGGACCTGTATGCTTTA 
 
58°C 178bp AK028210 155-332 
RPL13A Fp:ATGACAAGAAAAAGCGGATG Rp:CTTTTCTGCCTGTTTCCGTA 58°C 215bp Bbc086896 358-572 
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Table 5:  Primer pairs for TaqMan real-time RT-PCR (Applied Biosystems). 
Target 
Gene Name 
 
Assay ID Amplicon length Exon 
Interrogated 
sequence 
 
Mouse specific primers 
ESR1(ERα) Mm00433149_m1 56 4&5 NM_007956.4 
ESR2 
(ERβ) Mm00599819_m1 71 6&7 NM_010157.3 
PPIA Mm02342429_g1 112 3&4 NM_008907.1 
Human specific primers 
ESR1(ERα) Hs01046816_m1 65 6&7 NM_001122740 
ESR2 
(ERβ) Hs00230957_m1 63 4&5 NM_001040275 
PPIA Hs01893911_s1 90 1&1 AK123006.1 
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PCR reactions.  TaqMan Universal PCR Master Mix (Applied Biosystems) was used for 
TaqMan PCR reactions.  Standard TaqMan or SYBR green protocols were followed for 
PCR amplification on ABI StepOne Real-Time PCR System.  Melt curve analysis was 
performed for all the SYBR green real-time PCR reactions. Reaction products were 
checked on 2% agarose gel to confirm the correct amplicon size generated following 
PCR amplification of each target.  We evaluated expression of several target genes (Table 
4) as candidates for endogenous control for relative expression analysis.  Expression of 
PPIA (peptidylprolyl isomerase A also known as cyclophilin A) was determined to be the 
appropriate endogenous control for our gene expression studies in vitro as well as in vivo.  
Primer sequence information for target genes and endogenous controls is presented in 
Table 4.  RNA standard curve was prepared for all the targets to ensure 90-100% RT 
efficiency of the reaction for each target.  A validation experiment was also conducted for 
each set of primers using serial-fold dilutions of cDNA in comparison with the 
endogenous control to ensure that amplification efficiency falls between 95-100%.  All 
PCR experiments were performed with hot start and were run in duplicates.  Relative 
differences in gene expression between groups were expressed using cycle time values 
(CT).  The expression of target genes was normalized to the expression of PPIA 
(endogenous control) and delta CT was calculated where, ∆CT =CT target-CT endogenous 
control.  Relative expression using comparative ∆CT or ∆∆CT (∆∆CT= ∆CT of target of 
treatment group- ∆CT of target of the calibrator group) method was determined and 
relative gene expression (RQ) was calculated as 2-∆CT or 2-∆∆CT.  The results were 
expressed as relative expression of target genes in the kidney tissues for each group of 
mice and for each treatment group of mIMCD3 cells.  
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3.5  Analysis of protein expression 
3.5.1 Protein isolation 
            Cells were washed with PBS and incubated on ice for 20 minutes in RIPA buffer 
(cell lysis buffer- Cell Signaling,) supplemented with 2mM phenylmethanesulfonyl 
fluoride (PMSF).  Cells were then scraped and lysed by gently pipetting up and down.  
The lysates were briefly sonicated for 5 seconds followed by centrifugation at 16,000 x g 
for 30 minutes at 4ºC.  The supernatants were collected and stored at -80ºC until 
analyzed.  Protein dose of the extracts was determined with Pierce BCA (bicinchoninic 
acid) protein reagent kit (Pierce) using manufacturer’s instruction. 
 
3.5.2 Western Blotting 
            Twenty to 40 µg of cell lysate protein was subjected to gel electrophoresis on 
commercially available 4-12% pre-casted Bis–Tris Gel (Invitrogen).  The separated 
proteins were transferred electrophoretically onto a 0.2 µM nitrocellulose membrane. The 
membranes were blocked in blocking buffer (5% non fat dry milk in Tris Buffer Saline 
with 0.1% Tween 20-TBST) for 2 hrs and incubated overnight at 4°C with appropriate 
dilutions of antigen specific primary antibodies (Table 6).  Following washing with 
TBST, primary antibody binding was detected by incubating the membranes with 
appropriate dilutions of alkaline phosphatase (AP) labeled species specific secondary 
antibody (Sigma) for 2 hrs at room temperature.  The resultant complex was detected by 
chemiluminescence detection system (Lumi-Phos TM, WB, and Pierce).  The membranes 
were stripped and re-probed for detecting more than one antigen on the same membrane.  
Equivalent protein loading and transfer efficiency was verified by staining for β-actin.   
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Table 6:  List of primary and secondary antibodies 
 
 
Antigen Antibody Catalog # Isotype Source 
Amount of 
Antibody Application 
Mouse ERα  (Mc-20), #sc-542 
Rabbit 
polyclonal Santa Cruz 
1:1000 (WB) 
1: 50 (ICC) 
Western blot, 
Immunocytochemistry 
Mouse ERβ (PPG5/10)#M2792 Mouse Dako 1:50 
Western blot, 
Immunocytochemistry 
Mouse ERβ  (H-150) #Sc-8974 
Rabbit 
polyclonal Santa Cruz 1:1000 Western blot 
Mouse 
DAF/CD55  *(2C6)- Rat IgG2a 
*Dr. Claire 
Harris 10µg/ml 
Western blot, 
 
Human 
DAF/CD55 
(278803) 
#MAB2009 
Mouse 
IgG2b 
R&D 
Systems 2µg/ml 
Western blot, 
 
Mouse 
DAF/CD55 
558037 
(RIKO-5) 
Hamster 
monoclon-
al IgGλ3 
BD 
Pharmingen 1µg/ml Flow cytometry 
Isotype control 553980 Hamster IgGλ3 
BD 
Pharmingen 1µg/ml Flow cytometry 
Mouse 
Phosphorylated 
PI3-K 5(T458) 
4228 Rabbit polyclonal 
Cell 
signaling 1:1000 
Western blot, 
 
Mouse Total 
PI3-K 4292 
Rabbit 
polyclonal 
Cell 
Signaling 1:1000 
Western blot, 
 
Mouse Total 
Akt 9272 
Rabbit 
polyclonal 
Cell 
Signaling 1:1000 
Western blot, 
 
Mouse 
Phosphorylated 
Akt (S473) 
9271 Mouse IgG2b 
Cell 
Signaling 1:1000 
Western blot, 
 
β-Actin A5060 Rabbit polyclonal Sigma 1:2000 
Western blot, 
 
Anti-Rabbit A3687 IgG Sigma 1:30,000 Western blot 
Anti-Rat A3438 IgG Sigma 1:30,000 Western blot 
Anti-Mouse A3562 IgG Sigma 1:30,000 Western blot 
WB:Western blot; ICC Immunocytochemistry ; * 2C6 an anti Mouse DAF antibody was a generous gift 
from Dr Claire Harris at  Cardiff University School of Medicine, UK. 
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Images were digitally captured using Alpha Innotech Instrumentation (Alpha Innotech 
Corp).  Quantitative analysis was performed using Image J software program (NIH 
Image, Scion Corp, Frederick MD). 
 
3.5.3  Immunocytochemistry 
            Cells were plated at a dose of 1x105 cells per well in 8-well chambered slides (BD 
Falcon Culture Slides, BD Biosciences;VWR) and cultured in DMEM F-12 medium 
supplemented with 5% fetal bovine serum and antibiotics.  For staining, cell monolayer 
were washed gently with ice cold PBS and then fixed with methanol at 20ºC for 10 min 
(methanol fixation also causes delipidization and thus renders permeability to the cells).  
To block the endogenous peroxidase activity 1 drop of peroxidase block (Dako) was 
applied to each chamber such that the cells are completely covered and incubated for 6 
min at room temperature (RT).  The cells were washed twice with PBS.  Excess buffer 
from and around the chambers was gently wiped off without touching the cells.  For ERβ 
staining, Avidin /Biotin block was applied following peroxidase block.  Cells were then 
incubated with PBS containing 3% BSA for 15 min for nonspecific antigen blocking and 
washed twice with PBS.  Subsequently, the cells were incubated at 4°C overnight in a 
humidified chamber with ERα or ERβ specific antibody (Table 6).  For negative control 
staining, cells were incubated with PBS containing 3% BSA and 0.1% Nonidet P-40 
(buffer used for antibody dilution).  Cells were then washed and incubated with 
peroxidase–labeled polymer conjugate to specific secondary antibody (Dako Envision 
system kit) for 30 min at room temperature.  The cells were then washed and coveredwith 
DAB chromogen (3,3' Diaminobenzidine) substrate and incubated for 10 min at room 
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temperature.  Following washing, cells were counterstained with hematoxylin and 
mounted with Super Mount mounting medium (Biogenex). 
 
3.5.4  Flow cytometry 
           Cells growing in T-25 flasks were dissociated by incubating with 3 ml of cell 
dissociation buffer (Sigma) at 37º C for up to 20 minutes.  Cells were removed by 
pipetting up and down gently.  Cell suspension so obtained was centrifuged at 1100 rpm 
for 5 minutes at 4ºC and the cell pellet was suspended in cell suspension/wash buffer 
(PBS and 5% serum).  Cells were then incubated with fluorescent labeled (R-
phycoerythrin, also called PE) hamster anti-mouse DAF monoclonal antibody (RIKO 5) 
or an isotype-matched non-relevant control monoclonal antibody (Table 6) at a dose of 
1µg per 1 X 106 cells on ice for 60 min.  Following staining, cells were analyzed in the 
Accuri C6 flow cytometer (Accuri Cytometers). 
 
 
3.6 Statistical analysis 
            GraphPad Prism version 5 (Graph Pad Software Inc, San Deigo, CA) was used for 
statistical analysis.  Student t-test or non parametric Mann Whitney U-test was performed 
for comparing two experimental groups.  Data analysis for more than two experimental 
groups was conducted using either One-way or Two-way ANOVA followed by Tukey’s, 
Bonferroni or Dunnett post hoc tests for multiple comparisons.  Differences at P< 0.05 
were considered significant (The character * signifies P<0.05, ** signifies P<0.005 and 
*** signifies P<0.0005). 
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CHAPTER IV 
 
 
ESTROGEN MODULATES Dr+ESCHERICHIA COLI COLONIZATION IN THE 
THE MOUSE URINARY TRACT VIA ESTROGEN RECEPTOR ACTIVATION 
 
4.1 Introduction 
            Clinical and animal studies have indicated that changes in the circulating ovarian 
hormone levels influence UTI susceptibility in females (Franco, 2005, Hooton, 2000, 
Ribeiro et al, 2002, Sonnex, 1998).  Increased ovarian hormone levels during pregnancy 
and decreased ovarian hormone levels during menopause lead to increased incidence of 
UTI in women.  In premenopausal women, adherence of E. coli to the uroepithelium is 
reported to vary through the menstrual cycle, and use of oral contraceptives also 
contributes significantly to an increase in bacterial adherence on the uroepithelium 
(Schaeffer et al, 1979, Sharma et al, 1987, Sonnex, 1998).  The incidence of UTI in 
postmenopausal women is reported to be high; 20% incidence of recurrent UTI has been 
reported in community dwelling women, and over a 50% incidence has been reported in 
institutionalized women (Rozenberg et al, 2004).  UTIs in postmenopausal women are 
mostly severe and are associated with a high rate of impaired kidney function, morbidity, 
and mortality (Brown et al, 2005, Dulawa, 2004, Molander et al, 2000). 
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      Estrogen deficiency has been implicated as one of the contributing factors to 
postmenopausal UTIs, and supplementation of estrogen at low doses attenuate the 
progression of UTI in these women (Raz, 2001a, Stamm & Raz, 1999).  However, the 
therapeutic benefits of estrogen replacement in postmenopausal women are not 
completely understood.  Despite the beneficial effects observed, estrogen replacement 
therapy in postmenopausal women is associated with unwanted side effects.  In addition, 
there are conflicting reports on the effects of route, duration, and dose of the estrogen 
administration during the therapy (Hextall, 2000, Raz, 2001a).  Thus, it is important to 
understand the actions of estrogen in the female urinary tract and the possible molecular 
mechanisms associated with estrogen related etiology of UTI pathogenesis.  This 
information will help in determining and improving effective treatment strategies for 
estrogen replacement therapy in estrogen deficient women. 
 
      Uropathogenic Dr+ E. coli colonize the host uroepithelium by attaching to 
hormonally regulated DAF and type IV collagen (Goluszko et al, 1997, Kaul et al, 1995, 
Kaul et al, 1996, Nowicki et al, 2001, Selvarangan et al, 2000, Selvarangan et al, 2004, 
Servin, 2005, Virkola et al, 1988).   Folllowing 21 days post-experimental-UTI induction 
in the C3H/HeJ mice, we found increased Dr+ E. coli colonization in the kidneys of 
estrogen-deficient OVX mice compared to that in the kidneys of estrogen-sufficient Non-
OVX mice and OVX mice treated with a physiological dose of E2.  The present study 
was conducted to determine the protective role of estrogen on Dr+ E. coli colonization in 
the lower (bladders) as well as upper (kidneys) urinary tracts of C3H/HeJ mice at earlier 
time points during infection.  Bacterial colonization in bladders and kidneys of OVX 
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mice and Non-OVX mice was observed and compared at 2 and 6 days post-UTI 
induction.  We also tested the effects of E2 pretreatment at a physiological dose on the 
bacterial colonization in the OVX mice at these time points.  To further determine the 
involvement of ERs in estrogen mediated modulation of Dr+ E. coli uropathogenesis, 
Dr+ E. coli colonization was observed in the ER-antagonist(ICI 182, 780)-treated Non-
OVX mice, at 3 and 7 days post-infection.  Since we have found (Figure 4) and other 
studies have also reported the predominance of ERα in the mouse kidney (Carley et al, 
2003, Jelinsky et al, 2003, Sharma & Thakur, 2004), we employed ERα-/- and ERα+/+ 
female B6.129 mice to investigated the role of ERα in estrogen-mediated modulation of 
Dr+ E. coli colonization in the the mice urinary tractss. 
 
      We found that compared to the estrogen-sufficient Non-OVX mice, the estrogen-
deficient OVX mice and the ER-antagonized Non-OVX mice show increased 
susceptibility to Dr+ E. coli colonization in the bladders, as well as in the kidneys, at 
earlier time points following infection.  Furthermore, E2 replacement at a physiological 
dose led to a significant reduction in the bacterial colonization in the the mice urinary 
tracts.  We further observed that compared to the ERα+/+ mice, the ERα-/- mice have 
increased susceptibility to Dr+ E. coli colonization in the upper, as well as in the lower 
urinary tracts. 
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4.2 Statement of Hypothesis. 
           The host’s endogenous estrogen levels modulate Dr+ E. coli colonization in the 
urinary tract via ER activation pathway. 
 
 
4.3 Results 
4.3.1:  Estrogen deficiency increases Dr+ E. coli colonization in the bladders and 
kidneys of OVX C3H/HeJ mice 
      To investigate the effects of estrogen deficiency on Dr+ E. coli colonization in the 
urinary tract, age-matched OVX and Non-OVX mice were subjected to Dr+ E. coli 
induced experimental UTI.  Infected mice were euthenized at 2 and 6 days post-UTI 
induction and colonization in the urinary tracts was evaluated by determining the 
bacterial load (details in chapter III, sections 3.2.5 and 3.2.6).  
 
      Bacterial counts in the bladders of the OVX and the Non-OVX mice at 2 and 6 days 
post-infection are represented in figures 6A and 6B, respectively.  The bacterial 
colonization in the bladders of OVX mice was significantly higher than the colonization 
observed in the bladders of Non-OVX mice (Figure 6A and 6B).  Notably, the viable 
bacterial counts from the bladders of OVX mice at 2 and 6 days post-infection remained 
similar.  However, in the Non-OVX mice, bladder colonization at 6 day post-infection 
was 20-fold lower than the colonization observed at 2 days post-infection, though the 
difference was not found to be statistically significant (Figure 6C). 
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      Bacterial colonies were recovered from both of the kidneys of all the animals in each 
of the experimental groups.  The bacterial counts obtained from the left and the right 
kidney of each mouse in the study were found to be comparable for 2, as well as 6 days 
post-infection, indicating that each kidney was equally infected following UTI induction 
at both the time points (appendix supplementary Figures 1A-1D).  To be consistent, CFU 
from the left kidneys of mice were used for comparison of bacterial load among the study 
groups.  
 
      Bacterial counts in the kidneys of the infected OVX and Non-OVX mice at 2 and 6 
days post-infection are represented in Figures 6D and 6E respectively.  Following 2 days 
of infection, the bacterial colonization in the kidneys of OVX mice was lower compared 
to that in the kidneys of Non-OVX mice (Figure 6D).  In contrast, at 6 days post-
infection, colonization in the kidneys of OVX mice was found to be 13-fold higher 
compared to that in the kidneys of Non-OVX mice (Figure 6E).  Although the kidneys of 
all the mice remain infected at day 6 post-infection, bacterial colonization increased in 
the OVX mice, but decreased in the Non-OVX mice by 10-fold from 2 to 6 days post-
UTI induction (Figure 6F).  We have earlier observed that at 21 days post-infection, Dr+ 
E. coli colonization in the kidneys of OVX mice remained significantly higher compared 
to the Dr+ E. coli colonizationt in the kidneys of Non-OVX mice (Figure 6F and 
preliminary data, Figure 1). 
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Figure 6 
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Figure 6:  Bacterial counts in the bladders and kidneys of OVX and the Non-OVX C3H/HeJ 
mice.  Bacterial counts per gram bladder (A and B) and kidney (D and E) tissues in OVX and 
Non-OVX mice following 2 and 6 days post-UTI induction were enumerated and represented as 
CFU/gm tissue.  Bacterial counts from OVX mice are depicted by closed circles and those from 
Non-OVX mice are indicated by closed triangles.  Each symbol in the graphs represents values 
from a single mouse.  The horizontal black bars denote the mean CFU ± SEM from each study 
group and the error bars represent data from 4-6 mice in each study group.  C) The bacterial 
counts in the bladders of OVX mice remained similar at 2 and 6 days post-infection while the 
bacterial counts in the bladders of Non-OVX mice decreases.  F) The bacterial counts in the 
kidneys of OVX mice increased while those in the kidneys of Non-OVX mice decreased during 
the course of infection.  Data were analyzed by Student’s t-test where P<0.05 was considered 
significant (*). 
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4.3.2:  Estrogen pretreatment decreases Dr+ E. coli colonization in the bladders and 
kidneys of OVX C3H/HeJ mice 
      To further investigate the effects of a physiological dose of estrogen on colonization 
of Dr+ E. coli in the the mice urinary tracts, we pretreated the OVX mice with a 
physiological dose of E2 prior to UTI-induction.  E2-treated OVX mice attained 
physiological levels of serum E2 following the treatment, and maintained it at the 
physiological levels during the experiment (Table 7) (Tai et al, 2008).  Age matched 
vehicle- and E2-treated OVX C3H/HeJ mice were induced with Dr+ E. coli mediated 
experimental UTI and the bacterial counts in the bladder and kidney tissues were 
enumerated at 2 and 6 days post-infection. 
  
Table 7:  Serum E2 levels in OVX and E2 treated OVX C3H/HeJ mice 
Mice Serum E2 levels 
(mean ± SEM) 
Number of mice (n) 
OVX 15.40±0.092 pg/ml n=5 
OVX-E2 
(2 days post-infection) 
33±1.7 pg/ml ** n=6 
OVX-E2 
(6 days post-infection) 
34.17±4.8 pg/ml** n=6 
**E2-treated OVX mice attained physiological levels of E2 which are significantly 
higher than the E2 levels in untreated OVX mice.  
 
 
      Viable bacterial counts obtained from the bladders of vehicle-and E2-treated OVX 
mice at 2 and 6 days post-infection are represented in Figures 7A and 7B respectively.  
Pretreatment with a physiological dose of E2 markedly decreased bacterial colonization 
in the bladders of OVX mice.  The bacterial colonization in the bladders of vehicle-and 
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E2-treated mice was not significantly different at 2 days post-infection (Figure 7A), but at 
6 days post-infection the bladders of vehicle-treated OVX mice were significantly more 
colonized, showing 47-fold higher bacterial colonization compared to that in the bladders 
of E2-treated OVX mice (Figure 7B).  The bacterial counts in the vehicle-treated mice 
remained the same for 2, as well as 6 days post-infection, however, the bacterial counts 
decreased markedly by 30-fold in the E2-treated mice as the infection progressed from 2 
to 6 days following UTI induction (Figure 7C), but this difference was not found to be 
statistically significant. 
 
        The incidence of kidney infection among the E2-treated OVX mice was 73% lower 
compared to the incidence of kidney infection in the vehicle-treated OVX mice at day 6 
post-infection, however the reduction was not statistically significant (Figure 7E).  At 21 
day post- infection, significant reduction (by 60%) in Dr+ E. coli colonization was 
observed in the kidneys of E2-treated OVX mice compared to that in the kidneys of 
vehicle-treated OVX mice ( Figure 1).  Among the OVX mice, colonization in the 
kidneys at 6, and 21 days post-infection, was higher compared to the colonization at 2 
days post-infection, suggesting increase in Dr+ E. coli infection with time (Figure 7F).  In 
contrast, the E2-treated OVX mice showed reduced kidney colonization at 6 and 21 days 
post-infection compared to the colonization at 2 days post-infection, suggesting a gradual 
clearance of Dr+ E. coli infection from the kidneys of E2 treated OVX mice (Figure 7F).  
Although, the infection in the kidneys of E2-and vehicle-treated OVX mice persisted 
until 21 days post-infection, the colonization in the kidney of E2-treated mice remained 
significantly lower compared to that in the kidney of vehicle-treated mice (Figure 7F). 
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Figure 7:  Bacterial counts in the bladders and kidneys of E2-treated OVX C3H/HeJ mice.  
OVX mice were treated with vehicle (Veh) or E2 at a physiological dose prior to experimental 
UTI induction with Dr+ E. coli.  Bacterial CFU per gram bladder (A and B) and kidney (D and 
E) tissues in mice following 2 and 6 days post-UTI induction are presented in each graph.  
Bacterial counts from vehicle-treated mice are depicted by closed circles and those from E2-
treated-mice are indicated by closed squares. Each symbol in the graph represents values from a 
single mouse. Tissues with no detectable CFU recovered from the homogenate culture were 
counted as if 1 CFU was found.  The horizontal black bars denote the mean CFU ± SEM from 
each study group and the error bars represent data from 4-6 mice in each study group.  C) 
Bacterial counts in the bladders of vehicle-treated OVX mice remained similar, while those in the 
bladders of E2-treated OVX mice decreased during the course of infection.  F) Bacterial counts in 
the kidneys of vehicle-treated OVX mice increased while those in the kidneys of E2-treated OVX 
mice decreased during the course of infection.  Data were analyzed by Student’s t-test where 
P<0.05 was considered significant (*). 
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4.3.3:  ER-antagonist pretreatment increases Dr+ E. coli colonization in the 
bladders and kidneys of C3H/HeJ mice 
      To investigate the role of ERs in estrogen-mediated protective action against Dr+ E. 
coli colonization, age matched ER-antagonist ICI 182, 780- and vehicle-treated Non-
OVX C3H/HeJ mice were infected with Dr+ E. coli following which bacterial 
colonization in the bladder and kidney tissues of infected mice was determined at 3 and 7 
days post-infection. 
 
      At 3 days (Figure 8A), as well as 7days (Figure 8B) post-UTI induction, increased 
bacterial colonization was found in the bladders of ICI 182,789-treated mice compared to 
the colonization in the bladders of vehicle-treated mice, however the differences were not 
statistically significant.  The bacterial colonization in the bladders of the vehicle-treated 
mice decreased markedly at day 7 post-infection suggesting bacterial clearance; however, 
the bacterial colonization in ICI 182,780-treated mice increased at 7 days post-infection, 
suggesting bacterial replication and persistence in absence of active ER (Figures 8A and 
8B). 
 
      At both 3 and 7 days post-infection, bacterial colonization in the kidneys of ICI 
182,780-treated mice was comparatively higher than the colonization in the kidneys of 
vehicle-treated mice (Figure 8C and 8D). 
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Figure 8:  Bacterial counts in the bladder and kidneys of ICI 182, 780 treated-Non-OVX 
C3H/HeJ mice.  Non-OVX mice were treated with ER-antagonist ICI 182, 780 prior to UTI 
induction.  Bacterial CFU per gram bladder (A-B) and kidney (C-D) tissue from vehicle-and ICI 
182, 780-treated Non-OVX mice, at 3 and 7 days post-UTI induction are represented in each 
graph.  Bacterial CFU counts from vehicle-treated mice are depicted by closed circles and those 
from ICI 182 780 treated mice are indicated by open triangles.  Each symbol in the graphs 
represents a value from a single mouse.  The horizontal black bars denote the mean CFU ± SEM 
from each study group and the error bars represent data from at least 5 mice.  Data were analyzed 
by Student’s t-test for Figure 8A- 8D where P<0.05 was considered significant. 
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4.3.4:  Dr+ E. coli colonization in the bladders and kidneys of ERα-/- mice is higher 
compared to the colonization in the ERα+/+ mice 
       The mRNA levels of ERα were found to be significantly higher than those of ERβ in 
both the bladders and the kidneys of ERα+/+ B6.129 female mice (Figure 9A).  We 
investigated the specific role of ERα in determining the protective effects of estrogen 
against Dr+ E. coli colonization using ERα-/- and ERα+/+ female B6.129 mice.   
 
      Bacterial colonization were determined in the bladders and kidneys of ERα-/- and 
ERα+/+ mice following 3 and 7 days post-UTI induction.  We could not culture any 
bacteria from the bladder tissue homogenates of 3 day infected mice.  The bladder tissue 
sections that were used for culture were very small (1/3rd of the bladder).  It is thus 
possible that we were not able to detect any infection due to the small size of the tissue 
section.  Assuming that 1/3rd section of bladder is too small for bacterial culture; we used 
one half of bladder for determining the bacterial counts in the bladder tissues from the 
mice infected with Dr+ E. coli for 7 days. 
 
      The bacterial colonization in the bladders and kidneys of ERα-/- and ERα+/+ mice 
are represented in the Figures 9B-9D.  At 7 days post-infection, the bladders of ERα-/- 
mice had significantly increased bacterial colonization, showing 28-fold higher 
colonization compared to that in the bladders of ERα+/+ mice (Figure 9B).  At both 3 
(Figure 9C), and 7 days (Figure 9D) post-infection the bacterial colonization in the 
kidneys of ERα-/- mice were also found to be higher compared to that in the kidneys of 
ERα+/+ mice 
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Figure 9:  A) ERα and ERβ mRNA levels in the bladders and kidneys of ERα+/+ mice.  ER 
subtype mRNA levels were analyzed by SYBR green quantitative real-time RT-PCR using ∆CT 
method with gene specific primers.  Target gene expression was normalized relative to PPIA 
exprssion in each animal.  Expression values are presented as mean relative expression ± SEM 
from 2 mice.  ERα mRNA were found to be predominant in bladders, as well as kidneys (##, 
P<0.005).  No significant difference was observed in the ERα and ERβ mRNA levels between 
bladders and kidneys.  Data were analyzed by Two-way ANOVA, followed by Bonferroni post 
hoc test for multiple comparisons where P <0.05 was considered significant. 
B-D) Bacterial counts in the bladders and kidneys of ERα-/- and ERα+/+ mice.  Bacterial 
CFU per gram bladder (B) and kidney (C and D) tissues in ERα-/- and ERα+/+ mice following 3 
and 7 days post-UTI induction are represented.  The Bacterial counts from ERα+/+ mice are 
depicted by open circles and those from E2-treated mice are indicated by open squares.  Tissues 
with no detectable CFU recovered were counted as if 1 CFU was obtained.  Each symbol in the 
graphs represents a value from a single mouse.  The horizontal black bars denote the mean CFU ± 
SEM from each study group and the error bars represent data from 2-7 mice in each study group.  
Data were analyzed by Student’s t-test where P<0.05 was considered significant (*). 
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4.4 Discussion 
         Estrogen exerts multiple actions on the female urinary tract; however, there is 
limited information regarding the effects that estrogen has on bacterial colonization in the 
host urinary tract.  In the present study, we demonstrate that estrogen deficiency induced 
by ovariectomy resulted in marked increase in the colonization of Dr+ E. coli in the 
bladders, as well as kidneys of OVX mice, compared to that in the estrogen-sufficient 
Non-OVX mice.  Subcutaneous administration of E2 at a physiological dose in the OVX 
mice induced a definite reduction in the levels of bacterial colonization in the bladders 
and kidneys, suggesting a protective action of the physiological dose of estrogen against 
Dr+ E. coli colonization.  From these results it is evident that following UTI induction, 
the mice with circulating physiological estrogen levels start clearing the Dr+ E. coli 
infection from bladders as well as kidneys.  In contrast, mice with estrogen deficiency 
cannot clear the infection during initial stages following UTI induction, and so are unable 
to control bacterial replication, therefore infection increases and persist in these mice.  
Thus, it appears that under the conditions in which these experiments were performed, 
estrogen deficiency increases, while physiological estrogen levels protect against Dr+ E. 
coli colonization in the the mice urinary tractss.  Our result is consistent with the study by 
Ruiz et al that also reported decrease in levels of UPEC colonization in the urinary tracts 
of mice treated with E2 (de Ruiz et al, 2001).  Furthermore, using a rat uterus model, it 
has been previously shown that E. coli adhered to the epithelium of OVX rats, causing 
purulent endometritis, but the OVX mice treated with physiological E2 levels did not 
show E. coli adherence to the epithelium (Nishikawa, 1985).  Additionally, several 
clinical studies have suggested that decreased estrogen levels in postmenopausal females 
103 
 
may be an important contributing factor leading to increased UTI susceptibility, and that  
estrogen replacement ( local and /or systemic) therapy provides protective effects against 
UTIs in these women (Hextall, 2000, Oliveria et al, 1998, Perrotta et al, 2008). 
 
     Interestingly, a similar study reported an increase in the rate of Dr+ E. coli and other 
UPEC infections, in the kidneys of OVX C3H/HeJ mice following treatment with a 
pharmacological dose of E2 (Curran et al, 2007).  The contrasting results from Curran et 
al and our study may be due to differences in the doses of E2 administered to the 
experimental animals.  The dose of E2 used in our study is comparable to the 
physiological estrogen range found in the host (6µg/kg/day administered for 5 days 
results in serum estrogen levels of 35 pg/ml), whereas, the total dose of E2 used in the 
study by Curran et al was very high (21 day release 0.25mg E2 pellets were implanted 
that resulted in serum estrogen levels of 800 pg/ml).  Pregnancy, during which estrogen 
levels are elevated, is also associated with higher incidence of UTIs.  Moreover, 
epidemiological studies have indicated that over 30% of pregnant women with 
pyelonephritis are colonized by UPEC expressing the Dr adhesins (Servin, 2005).  
Notably, a group studying the effects of estrogen therapy in older females reported that 
the postmenopausal females receiving long term estrogen therapy have 2-fold higher risk 
for acquiring UTIs than do the control patients (Orlander et al, 1992).  The effects of E2 
on bacterial colonization in the urinary tract appear to be complex and may be dose-
dependent.  Based on our results and the information available in the literature, it appears 
that estrogen at physiological doses have beneficial effects in the hosts against UTIs; 
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while, pharmacological E2 doses and long-term estrogen therapy may contribute to 
increased susceptibility to UTIs. 
 
      Estrogen acts through ERs that are expressed throughout the urinary tract.  In this 
study, we have demonstrated that antagonizing ER activation with anti-estrogen ICI 
182,780 in Non-OVX C3H/HeJ mice leads to abolition of the estrogen-protective effects 
resulting in increased Dr+ E. coli colonization in the bladders and kidneys of the infected 
mice.  Thus, it is evident that the estrogenic protection in the the mouse urinary tract 
against Dr+ E. coli colonization is mediated through ER-activation.  Furthermore, we 
found increased susceptibility of ERα-/- mice to Dr+ E. coli colonization compared to 
that in the ERα+/+ mice, indicating a functional role of ERα in providing estrogenic 
protection against Dr+ E. coli colonization in the urinary tracts of the female mice.  
Protective effects of estrogen via ERα activation against infection have also been 
reported by other studies.  For example, estrogen via ERα activation is found to be 
protective against Listeria monocytogen infection in female mice (Yeretssian et al, 2009).  
Interestingly, treatment of female mice with higher doses of E2 was found to increase 
Listeria monocytogen infection (Pung et al, 1984).  In addition, ERα gene polymorphisms 
have been found to be associated with HBV infection in the Chinese population (Deng et 
al, 2004,).  To date, there are no direct studies reporting the specific role of ERα or ERβ 
in estrogen action on the susceptibility to UTIs.  Our study provides the first in vivo 
evidence for ERα mediated estrogenic protection against Dr+ E. coli infection in the 
mouse kidney.  Furthermore, our results indicate that female populations carrying 
mutations or polymorphisms in ERα gene may be more prone to UTIs.   
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      The female genitourinary tract is known to be sensitive to the effects of estrogen 
(Robinson & Cardozo, 2004), however the precise mechanisms by which estrogen affects 
susceptibility to UTIs remain to be fully characterized.  Moreover, from the view of 
numerous reports that have studied the effects of estrogen on UTI susceptibility in 
females, it appears that these effects may be multi factorial (Ahmed et al, 2008, Hextall, 
2000, Hooton, 2000, Jelinsky et al, 2008).  While several clinical studies have 
documented that estrogen replacement therapy (local topical application/ oral 
administration) lowers the risk of UTIs in the postmenopausal women, some studies 
either did not find any therapeutic benefits of estrogen replacement, or reported it to 
increase the rate of UTIs in females receiving the therapy (Hextall, 2000, Molander, 
1993, Oliveria et al, 1998, Orlander et al, 1992, Perrotta et al, 2008, Stern et al, 2004, Xu 
et al, 2001).  The conflicting evidences regarding the effectiveness of estrogen for 
prophylaxis against recurrent UTIs in the postmenopausal women exist because the 
optimum doses of therapy, route of delivery, and duration of therapy are yet to be 
determined.  Moreover, precise molecular mechanisms associated with estrogenic effects 
on female genitourinary tract are not completely understood. 
 
      In premenopausal women, the circulating estrogens promote lactobacilli colonization 
in the vagina by regulating glycogen metabolism, resulting in low vaginal pH that inhibits 
the growth of potential uropathogens.  In the postmenopausal females, estrogen 
deficiency causes reduced glycogen and disappearance of lactobacilli from the vaginal 
flora, resulting in increased vaginal pH.  This promotes vaginal colonization by members 
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of Enterobacteriaceae, predominantly E. coli and increases the risk of UTIs in the 
postmenopausal women.  Furthermore, low estrogen levels in the postmenopausal women 
also contribute to local mucosal atrophy and reduction in mucin secretion resulting in 
increased risk for UTIs.  Estrogen replacement therapy in postmenopausal women at low 
doses have been shown to restore the vaginal flora and pH and greatly reduce the risk of 
vaginal atrophy, thus providing protection against recurrent UTI (Cotreau et al, 2007, 
Hextall, 2000, Raz, 2001b, Rozenberg et al, 2004).   
 
      Our results show that estrogen and ERα activity play a definite role in Dr+ E. coli 
colonization in the bladder and kidney of the female mouse.  Estrogen may induce 
multiple effects on reducing the risk of UTIs, and the possible mechanisms may include 
modulation of colonization receptor expression, regulation of bacterial internalization and 
induction of inflammatory responses during infection.  Elucidating the cellular and 
molecular mechanisms behind ERα-mediated enhanced estrogenic protection against Dr+ 
E. coli induced UTI will have broad clinical and experimental implications.  Results of 
the present study illustrate the potential effects of estrogen deficiency and physiological 
E2 levels as well as role of ERα in modulation of Dr+ E. coli colonization in the urinary 
tract during the course of experimentally induced UTI.  We next investigated the effects 
of estrogen on bacterial internalization in vitro in mIMCD3 cells.
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CHAPTER V 
 
 
ESTROGEN MODULATES Dr+ ESCHERICHIA COLI INVASION IN THE 
MOUSE INNER MEDULLARY COLLECTING DUCT (mIMCD3) CELLS 
VIA ESTROGEN RECEPTOR ACTIVATION 
 
5.1 Introduction 
          UTIs have typically been considered extracellular infections of the urinary tract.  
However, recent reports from animal as well as clinical studies, have demonstrated 
invasion of nonphagocytic uroepithelial cells by UPEC (Bower et al, 2005, Mulvey, 
2002, Rosen et al, 2007).  Following attachment, invasion of UPEC into host cells is 
recognized as a crucial event during UTI pathogenesis.  Invasion allows the UPEC to 
colonize, multiply, disseminate, and persist within the host for a long period of time.  In 
addition, invasion into the host epithelium facilitates UPEC evasion from the innate 
immune defense mechanisms, neutrophil clearance, and microbicidal effects of 
antimicrobial peptides and antibiotics in the host’s urinary tract (Blango & Mulvey, 2010, 
Dhakal et al, 2008, Kerrn et al, 2005, Mulvey et al, 2000, Mulvey et al, 2001).  Scanning 
and electron micrographs of infected tissues have shown the presence of internalized 
UPEC either in the endocytic vesicle or free within the cytoplasm of infected cells 
(Goluszko et al, 1997, Kerrn et al, 2005,  Mulvey et al, 2000). 
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Following invasion, the bacteria are able to reside and multiply in an endocytic vesicle 
within the cells forming the quiescent reservoirs of UPEC called intracellular bacterial 
communities.  They are then effluxed, only to adhere and invade the adjacent host’s cells, 
thus maintaining the infectious cycle within the host urinary tract (Mulvey et al, 2000, 
Mulvey, 2002, Rosen et al, 2007).  
 
      Dr+ E. coli, a pyelonephritic UPEC and has been shown to be internalized by several 
epithelial cell lines following its attachment to its receptor DAF which is expressed on 
the apical surface of the cells (Das et al, 2005, Fang et al, 2004, Goluszko et al, 1997, 
Goluszko et al, 2001, Guignot et al, 2000, Guignot et al, 2001, Kerneis et al, 1994, 
Zalewska-Piatek et al, 2009).  Invasion of Dr+ E. coli in mIMCD3 cells has not been 
previously reported.  Although some studies have been conducted to elucidate the role of 
estrogen on bacterial adhesion onto the uroepithelium, no direct or indirect role of 
estrogen and ERs on regulating bacterial invasion in urpoepithelial cells has been 
previously described. 
 
      Results from our in vivo experimental UTI mouse model indicate that E2 treatment at 
physiological levels decreases Dr+ E. coli colonization in the mouse kidney and this 
estrogen-mediated protection is ERα-dependent.  Dr+ E. coli has been shown to adhere to 
human kidney collecting duct cells (Virkola et al, 1988).  Our preliminary in vitro 
experiments have demonstrated that E2 treatment at physiological levels decreased Dr+ 
E. coli invasion in human hepatocytes and Huh7 cells a liver cell line.  The present study 
was conducted to elucidate the Dr+ E. coli invasion in the mouse kidney collecting duct 
109 
 
mIMCD3 cells to determine and verify our previous observations on protective effects of 
E2 treatment against Dr+ E. coli invasion in vitro.  In this study, we have also 
characterized the functional roles of ER subtypes, ERα and ERβ, in mediating E2 effects 
during Dr+ E. coli invasion in mIMCD3 cells.  This was achieved by determining Dr+ E. 
coli internalization in mIMCD3 cells treated with ERα and ERβ selective ligands.  The 
compound PPT displays 410-fold more selectivity for ERα over ERβ and is used as ERα 
selective agonist, and DPN exhibits a 70-fold higher binding affinity for ERβ than ERα; 
therefore, it is used as ERβ selective agonist (Meyers et al, 2001, Stauffer et al, 2000).  
We antagonized the ERs with ICI 182, 780 and ER subtypes with specific antagonists 
MPP and R, R-THC to further confirm the role of ERα and ERβ respectively.  We report 
here that E2 at physiological doses reduces Dr+ E. coli invasion in mIMCD3 cells while 
E2 deficiency and a pharmacological E2 dose increases bacterial invasion.  Our study 
indicates that ERα plays a predominant role in estrogen-mediated protection against Dr+ 
E. coli invasion.  
 
 
5.2 Statement of Hypothesis 
            Estrogen via ERα activation regulates invasion of Dr+ E. coli in the kidney 
tubular cells and thus determine the host susceptibility to Dr+ E. coli induced ascending 
UTI. 
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5.3 Results 
5.3.1:  E2 treatment differentially modulates Dr+ E. coli invasion in mIMCD3 cells 
in a dose-dependent manner 
      We analyzed the expression of DAF in the mIMCD3 cells at the mRNA, and protein 
levels, to determine the susceptibility of mIMCD3 cells for Dr+ E. coli colonization and 
internalization (Figure 10 A and 10B).  We also examined the cells for ER subtype 
expression at the mRNA and protein levels (Figure 11A-C).  DAF, ERα, and as ERβ 
were found to be expressed in mIMCD3 cells.  Similar to the ER subtype expression 
pattern in the mouse kidney, we found more ERα mRNA than ERβ  in mIMCD3 cells. 
 
      To elucidate the effect of E2 on Dr+ E. coli infection, mIMCD3 cells were either left 
untreated or were pretreated with E2 at different non-toxic doses (1, 10, 50 and 100 nM) 
for 24hrs prior to infection.  Drug toxicity for E2 treatment in the cells was determined by 
MTT assay (appendix supplementary Figure 2A).  E2-treated, as well as untreated control 
cells were incubated with Dr+ E. coli for 2 hrs, following which the amount of bacterial 
infection (determined as bacteria adhered and bacteria invaded) in the cells was 
enumerated (details in chapter 3 sections 3.3.2 and 3.3.3).  Amount of Dr+ E. coli 
invasion in the cells was determined by gentamicin protection assay following 2 hrs of 
infection.  Percentage CFU infection and invasion in the E2-treated cells relative to 
untreated control cells were calculated.  
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Figure 10:  DAF expression in the mIMCD3 cells.  A) The DAF mRNA levels were 
determined by quantitative SYBR green real-time RT-PCR.  Amplification plot shows DAF and 
PPIA expression in mIMCD3 cells.  DAF mRNA levels were normalized relative to PPIA mRNA 
levels in each sample. Expression values are mean relative expression ± SEM from 4 different 
passages (p 15-p18) of mIMCD3 cells.  B)  Protein expression of DAF in mIMCD3 cells detected 
using western blot.  Total mIMCD3 cell lysate from four different passages were blotted using rat 
anti-mouse DAF mAb (2C6) and β-actin was blotted as a loading control.  C) Surface expression 
of DAF protein on mIMCD3 cells determined by flow cytometry.  The area marked by the red 
boundary represents unstained control cells and the area marked by the black boundary represents 
cell population stained with PE labeled, hamster anti-mouse DAF mAb (RIKO 5); the same gate 
was applied for analyzing control and the RIKO 5 stained cell population. 
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Figure 11:  ERα and ERβ expression in the mIMCD3 cells.   
A) ERα and ERβ mRNA levels in the mIMCD3 cells.  ERα and ERβ mRNA levels were 
determined by quantitative SYBR green real-time RT-PCR using gene specific primers.  
Amplification plot shows the expression of ER subtypes and PPIA in mIMCD3 cells.  ERα and 
ERβ mRNA levels were normalized relative to PPIA mRNA levels in each sample. Expression 
values are mean relative expression ± SEM and error bars represents data from 4 different 
passages (p 15-p18) of mIMCD3 cells.  Data were analyzed by Student’s t test where P< 0.05 was 
considered significant (*). 
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Figure 11:  ERα and ERβ expression in the mIMCD3 cells.   
B) and C) Protein expression of ERα and ERβ in the mIMCD3 cells.  The ERα and ERβ 
proteins were detected using western blot and immunocytochemistry with ERα and ERβ specific 
antibodies.  B)  Total mIMCD3 cell lysate from four different passages were blotted using ERα 
(MC-20) or ERβ (H-150) specific antibodies, β-actin was blotted as a loading control. C)  Cells 
grown in chamber slides were stained with ERα (MC-20) or ERβ (PPG5/10) specific antibodies.  
Negative control images represent hematoxyline-eosine staining of the cells done in absence of 
the target specific antibodies.  In the Figure C black arrows are pointing to cells showing ER 
staining in cytoplasm, as well as in nucleus and blue arrows are pointing to the cells with only 
cytoplasmic staining.  Scale bar of 20µm applies to all the images in Figure C. 
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      Pretreatment of mIMCD3 cells with physiological doses of E2 (1-10 nM) 
significantly reduced Dr+ E. coli infection (Figure 12A), as well as cellular invasion 
(Figure 12B).  Maximum reduction in bacterial infection, as well as invasion, was 
observed at a 10 nM E2 treatment.  Overall, 40-60 % reduction in Dr+ E. coli infection as 
well as invasion was observed in mIMCD3 cells treated with 10 nM E2 in different 
experiments.  The similarity observed in the amount of bacterial infection and bacterial 
invasion in mIMCD3 cells implies that bacterial invasion is proportional to bacterial 
adherence.  A significant increase in bacterial invasion was observed in cells treated with 
pharmacological E2 dose (100 nM), compared to the cells treated with E2 at 
physiological (1-10 nM E2) doses (Figure 12A and 12B).   
 
      We also determined the effect of E2 on Dr+ E. coli internalization in hIMCD cells.  
We confirmed the mRNA expression of DAF by SYBR green real-time RT PCR and ER 
subtypes by TaqMan real-time RT-PCR; the protein levels of DAF were detected using 
western blot (data not shown).  Dr+ E. coli invasion in hIMCD cells treated with different 
doses of E2 (0, 1, 10, and 50 nM) was determined post 2 hrs of infection.  MTT test was 
performed to determine the E2 toxicity in hIMCD cells (appendix supplementary Figure 
2B).  Similar to the observations in mIMCD3 cells, Dr+ E. coli internalization in hIMCD 
cells was found to be significantly reduced in cells treated with E2 at physiological doses 
(Figure 12C).  
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Figure 12:  Relative infection and invasion of Dr+ E. coli in E2-treated cells.  A) Relative 
bacterial infection in E2-treated mIMCD3 cells following 2 hrs of incubation with Dr+ E. coli.  
Total infection represents bacteria adhered and internalized into the cells.  Infection values are 
mean bacterial CFU ± SEM expressed as % infection in E2-treated cells relative to untreated cells 
(considered as 100%).  The error bars represent data from at least 2 experiments performed in 
triplicate.  B) Relative bacterial invasion in E2-treated mIMCD3 cells following 2 hrs of Dr+ E. 
coli infection determined by gentamicin protection assay in mIMCD3 cells.  C)  Relative 
bacterial invasion in E2-treated mIMCD3 and hIMCD cells following 2 hrs of Dr+ E. coli 
infection.  Invasion values are mean bacterial CFU ± SEM expressed as % invasion in treated 
cells relative to untreated cells (considered as 100%).  The error bars represents data from 6 
experiments for Figure B and at least 3 experiments for Figure C, each performed in triplicate. 
Data were analyzed by One-Way ANOVA followed by Tukey’s post hoc test for multiple 
comparison where P<0.05 was considered significant.  The character, * indicates significant 
differences among the treatment groups,  # indicates significant difference relative to control 
treatment in mIMCD3 cells, x indicates significant difference relative to control treatment in 
hIMCD cells,  $ indicates significant difference relative to 100 nM E2 treatment in Figure B. 
(Physiological E2 dose:1-10 nM). 
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5.3.2:  ER-antagonist treatment reverses E2-mediated protection against Dr+ E. coli 
invasion in mIMCD3 cells 
      The role of ERs in E2 action against bacterial invasion was tested by blocking ER 
activation with ICI 182, 780. We co-treated mIMCD3 cells with 10 nM E2 (protective 
physiological dose) and various doses of ICI 182, 780 (0, 0.1, 1 and 10 µM) for 24 hrs 
prior to infection with Dr+ E. coli.  The cells were also treated with ICI 182, 780 alone at 
the above defined doses.  The MTT assays were performed to determine the toxicity of 
ICI 182, 780 at these doses in mIMCD3 cells (appendix supplementary Figure 2C).  Cells 
were infected and bacterial invasion was determined. 
 
        A significant increase in bacterial invasion in a dose dependent manner was 
observed in ICI 182, 780 and E2 co-treated cells compared to cells treated with E2 alone.  
Treatment with ICI 182, 780 significantly reversed the protective effect of E2 against Dr+ 
E. coli invasion in the cells.  Maximal reversal of E2 meditated protection by ICI 182,780 
was observed at a dose of 10 µM (Figure 13 A).  Bacterial invasion in cells treated with 
only ICI 182, 780 was comparable to that in control untreated cells and was significantly 
higher than in cells treated with 10 nM E2 (Figure 13B). 
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Figure 13:  Relative invasion of Dr+ E. coli in ICI 182, 780-treated cells. Relative bacterial 
invasion following 2 hrs of Dr+ E. coli infection in A) ICI+E2 co-treated and B) ICI alone treated 
mIMCD3 cells compared to control untreated cells, as determined by gentamicin protection 
assay.  Invasion values are mean bacterial CFU ± SEM expressed as % invasion in treated cells 
relative to untreated cells (considered as 100%).  The error bars represent data from 6 
independent experiments performed in triplicate.  Data were analyzed by One-Way ANOVA 
followed by Tukey’s test for multiple comparisons where P<0.05 was considered significant.  The 
character, * indicates significant differences among the treatment groups, # indicates significant 
difference relative to control treatment,  $ indicates significant difference relative to E2+ICI co-
treatment and x indicates significant difference relative to ICI alone treatment. (Physiological E2 
dose1-10 nM)  
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5.3.3:  E2 mediates protection against Dr+ E. coli invasion in mIMCD3 cells 
primarily via ERα activation pathway 
      To investigate the specific role of each ER subtype in estrogen-mediated protection 
against during Dr+ E. coli invasion, we determined the effect of ERα- and ERβ-specific 
agonists and antagonists treatment on bacterial internalization in mIMCD3 cells.  Cells 
were treated with non-toxic doses of ERα- and ERβ-selective agonist and antagonist for 
24 hrs prior to infection.  The antagonist treatments were given either alone or were co-
administered with 10 nM E2 (protective physiological dose).   The MTT tests were 
performed to determine the cell toxicity of the ERα- and ER-β selective agonist and 
antagonist at all the doses used for treatment (appendix supplementary Figures 2F-2I). 
 
        ERα selective activation by PPT treatment at various doses (0.01 and 0.1 µM) 
significantly reduced Dr+ E. coli invasion in mIMCD3 cells compared to untreated 
control cells.  Maximum protection (32%) against bacterial invasion was observed with 
0.1 µM PPT treatment (Figure 14 A).  Similar to the treatment with 100 nM E2, increased 
bacterial invasion was observed in cells treated with a higher dose of PPT (1 µM) 
compared to invasion in the cells treated with 10 nM E2 and lower doses of PPT.  
Invasion of Dr+ E. coli at 1 µM PPT treatment was not significantly different than that in 
the untreated control cells.  Co-treatment of mIMCD3 cells with ERα-selective antagonist 
MPP (at doses 0.01, 0.1, and 1 µM) and 10 nM E2 led to significant attenuation of the 
protective effect of E2 against bacterial invasion in a dose dependent manner (Figure 14 
B).  Dr+ E. coli infected mIMCD3 cells treated with MPP alone at all  
119 
 
 
 
Figure 14:  Relative invasion of Dr+ E. coli in PPT- and MPP-treated cells.  Relative bacterial 
invasion following 2 hrs of Dr+ E. coli infection in A) an ERα-selective agonist, PPT-treated, B) 
E2 and an ERα antagonist MPP-co-treated, and C) MPP-alone treated mIMCD3 cells, as 
determined by gentamicin protection assay. Invasion values are mean bacterial CFU ± SEM 
expressed as % invasion in treated cells relative to untreated cells (considered as 100 %).  The 
error bars represent data from 4 independent experiments performed in triplicate.  Data were 
analyzed by One-Way ANOVA followed by Tukey’s post hoc test for multiple comparisons 
where P<0.05 was considered significant.  The character * indicates significant differences 
among the treatment groups, # indicates significant difference relative to control treatment, x 
indicates significant difference relative to MPP alone treatment.  (Physiological E2 dose1-10 nM)  
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of the above defined doses showed invasion comparable to the invasion in the untreated 
control cells, and significantly higher invasion than  invasion in the cells treated with 10 
nM E2 (Figure 14 C). 
 
      In contrast to the ERα- selective agonist PPT, pretreatment of cells with the ERβ 
selective agonist DPN at various doses (0.01, 0.1 and 1 µM) did not cause significant 
change in Dr+ E. coli invasion compared to the untreated control cells (Figure 15A).  The 
bacterial invasion in DPN treated cells was comparable to that in the untreated controls 
and was significantly higher than invasion in the 10 nM E2-treated cells (Figure 15A).  
Furthermore, no reversal of E2-protection against bacterial invasion was observed when 
the cells were co-treated with 10 nM E2 and the ERβ-selective antagonist R, R-THC at 
doses 0.1 and 1 µM.  Interestingly, a significant increase in the bacterial invasion was 
observed in the cells co-treated with 10 nM E2 and 10 µM R, R THC (Figure 15B).  
Treatment with R, R-THC alone at doses of 0.01 and 0.1 µM did not cause significant 
change in the bacterial invasion when compared to that in the untreated cells; but when 
cells were treated with at a very high dose of R, R-THC (10 µM), a significant increase in 
the bacterial invasion was observed (Figure 15C).  Notably, there was relatively less 
bacterial invasion in the cells co-treated with 10 µM R, R-THC and 10 nM E2 compared 
to the invasion in the cells treated with only 10 µM R, R-THC.  This observation suggests 
that R, R-THC at 10 µM increases bacterial internalization in the cells that appears to be 
partly reversed by 10 nM E2 treatment (Figure 15 B and C). 
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Figure 15:  Relative invasion of Dr+ E. coli in DPN- and R, R THC-treated cells.  Relative 
bacterial invasion following 2 hrs of Dr+ E. coli infection in A) an ERβ-selective agonist, DPN 
treated, B) E2 and an ERβ-antagonist R, R THC co-treated, and C) R, R THC-alone treated 
mIMCD3 cells, as determined by gentamicin protection assay.  Invasion values are mean 
bacterial CFU ± SEM expressed as % invasion in treated cells relative to untreated cells 
(considered as 100%).  The error bars represent data from 4 independent experiments performed 
in triplicate.  Data were analyzed by One-Way ANOVA followed by Tukey’s post hoc test for 
multiple comparisons where P<0.05 was considered significant.  The character * indicates 
significant differences among the treatment groups, # indicates significant difference relative to 
control treatment, and x indicates significant difference relative to R, R THC treatment.  
(Physiological E2 dose10 nM)  
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Discussion 
         To our knowledge, invasion of Dr+ E. coli in mIMCD3 cells and hIMCD cells has 
not been previously reported.  In this study, we have demonstrated for the first time the 
invasion of pyelonephritic Dr+ E. coli strain in vitro in mIMCD3 and hIMCD cells.  Our 
study also provides the first in vitro evidence for E2/ERα-mediated modulation of Dr+ E. 
coli infection and invasion in mIMCD3 cells.  In the present study, E2 treatment at 
different doses resulted in a significant modulation of Dr+ E. coli invasion in mIMCD3 
cells in a dose-dependent manner.  Kaul et al have previously reported significant 
differences in binding of the Dr adhesins on clinical endometrial samples from different 
stages of the menstrual cycle (Kaul et al, 1996).  Furthermore, the ability of vaginal 
mucus to bind to E. coli expressing type1pili has been reported to vary through the 
menstrual cycle (Venegas et al, 1995) .We have observed a dichotomy in effects of 
estrogen on  the Dr+ E. coli invasion in mIMCD3 cells at lower- and higher-E2 doses.  
E2 at physiological doses (1-10 nM) provided marked protection to mIMCD3 and 
hIMCD cells against Dr+ E. coli mediated invasion in vitro compared to untreated control 
cells.  In contrast, a pharmacological E2 (100 nM) dose contributed to a significant 
increase in bacterial invasion in mIMCD3 cells compared to cells treated with a 
physiological dose of E2.  We have also observed E2-mediated protective effects against 
Dr+ E. coli invasion at physiological doses in Huh7 and human hepatocytes.  This 
suggests that the protective effect of E2 at physiological doses against Dr+ E.coli 
invasion is not limited to IMCD3 cells and that various cell types may employ the same 
molecular mechanisms of Dr+ E. coli internalization. 
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      Our in vitro results are consistent with our in vivo observations of E2-mediated 
modulation of Dr+ E. coli infection in the the mouse urinary tract (results discussed in 
chapter IV).  We have demonstrated significant reductions in colonization of Dr+ E. coli 
in the kidneys of Non-OVX mice, as well as in OVX mice treated with a physiological 
dose of E2, whereas the estrogen deficient mice showed a marked increase in bacterial 
colonization.  Furthermore, Curran et al in their study have demonstrated increased Dr+ 
E. coli colonization in the kidney of OVX mice treated with a pharmacological dose of 
E2 (Curran et al, 2007).  Nonetheless, Kaul et al have also shown increased susceptibility 
to Dr+ E. coli infection and associated pre-term labor in pregnant C3H/HeJ mice (Kaul et 
al, 1999).  Taken together from these observations, it is clearly evident that estrogen at 
physiological doses provide protection against Dr+ E. coli colonization as well as 
invasion, in contrast, both estrogen deficiency and a pharmacological estrogen dose 
contribute to increased Dr+ E. coli colonization in the mouse urinary tract. 
 
      We further report that E2-mediated protection against Dr+ E. coli invasion in 
mIMCD3 cells following infection involves classical activation of ERs.  Results from our 
invasion experiments using ER subtype-specific agonist indicate that ERα plays the 
predominant role in inducing the protective effect of E2 against Dr+ E. coli invasion in 
mIMCD3 cells.  Similar to the effects of E2 administration, treatment with the ERα 
selective agonist PPT resulted in a significant reduction in Dr+ E. coli invasion, whereas 
treatment with the ERβ selective agonist, DPN did not provide any protection.  Similarly, 
as observed with 100 nM E2 treatment, ERα-selective agonist PPT treatment at a higher 
dose resulted in relatively elevated bacterial invasion in the cells.  Furthermore, ERα 
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selective antagonist MPP reversed the protective effects of E2; however treatment with 
ERβ antagonist R, R- THC had no such effects.  Our results clearly imply that E2-
mediated modulation of Dr+ E. coli invasion in mIMCD3 cells is dependent on ERα-
activation. 
 
      Expression of both, ERα and ERβ were detected in mIMCD3 cells and in the kidneys 
of C3H/HeJ and B6.129 mice, however only ERα was observed to be functional in 
determining the E2-mediated protection against Dr+ E. coli infection in vitro.   Our in 
vivo results also demonstrate a functional role of ERα in mediating the protective effects 
of estrogen against Dr+ E. coli colonization in the mouse kidney.  We have not 
investigated the Dr+ E. coli colonization in the urinary tracts of ERβ gene knock-out 
mice in this sudy; however, our in vitro results clearly demonstrate that ERβ may not be 
involved in the protective effects of estrogen against Dr+ E. coli infection in the renal 
cells.  Moreover, ERβ mRNA levels were found to be markedly lower than the levels of 
ERα mRNA in the mouse kidney, as well as in mIMCD3 cells. This may explain the 
specific role of ERα in mediating E2-effects in vivo, as well as in vitro.  Nonetheless, 
several studies have reported ERα to be the functional subtype in the mouse kidney 
(Carley et al, 2003, Esqueda et al, 2007, Jelinsky et al, 2003, Rogers et al, 2007). 
 
      Binding of UPEC adhesins to the receptors expressed on the host cellular surfaces 
enables UPEC to colonize and invade the uroepithelium within the urinary tract (Mulvey, 
2002).  Dr+ E. coli adhere to the host uroepithelium by binding to GPI- DAF through its 
Dr adhesins thus allowing its internalization into the host’s uroepithelial cells.  
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Internalization is regulated via intracellular cytoskeleton rearrangements induced by 
tyrosine kinase-activated PI3K/Akt signaling (Goluszko et al, 1997, Goluszko et al, 
1999, Goluszko et al, 2001, Guignot et al, 2001, Korotkova et al, 2008, Selvarangan et 
al, 2000).  One mechanism by which estrogen modulates Dr+ E. coli colonization and 
invasion in renal cells may involve dose-dependent modification of DAF expression on 
the renal tubular epithelium.  Differential effects of E2 on Dr+ E. coli infection and 
invasion in mIMCD3 cells, as observed in our in vitro study, indicate that estrogen via 
ERα may differentially regulate the expression of colonization receptor DAF in mIMCD3 
cells, thereby modulating Dr+ E. coli infection and invasion in these cells.  Hormonal 
regulation of DAF expression has been indicated by several studies and regulatory 
regions of DAF do contain ERE (Kaul et al, 1995, Kaul et al, 1996, Mirkin et al, 2005, 
Song et al, 1996).  A second possibility related to the estrogenic modulation of Dr+ E. 
coli cellular invasion may be related to non-genomic mechanisms for estrogen action.  
Estrogen via ERα may regulate the tyrosine kinase cellular signaling pathway to 
influence the process of Dr+ E. coli internalization in the renal cells.  Estrogen through 
ERs has been reported to regulate PI3K/Akt signaling under different experimental and 
clinical settings (Gu et al, 2009, Simoncini, 2009, Titolo et al, 2008).  A third potential 
reason for  reduced bacterial colonization and internalization of Dr+ E. coli at 
physiological E2 levels as opposed to increased colonization and internalization at higher 
estrogen dose and estrogen deficiency could be related to estrogen-mediated modulation 
of inflammatory responses following infection.  Estrogen has the potential to 
differentially influence the outcome of immune responses following infection.  Low 
physiological levels of estrogen enhance pro-inflammatory cytokines (TNFα, IL6) 
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production, while higher levels of estrogen stimulate anti-inflammatory cytokines (IL-10) 
production (Straub, 2007).  Such a dichotomy in the effects of different doses of estrogen 
may modulate the host immune responses,influence the bacterial clearance, as well as 
colonization following infection.  
 
      Based on our in vitro and in vivo experimental results it seems that estrogen, 
particularly via ERα, modulates host susceptibility to UPEC colonization and invasion 
following UTI induction.  Targeted disruption of the processes of adhesion and invasion 
may provide a novel means to prevent and treat recurrent, relapsing and chronic 
infections within the urinary tract.  Furthermore, our results indicate that ERα agonists 
may play an important role in determining susceptibility to UTIs and can be developed as 
possible therapeutic drug target to reduce UPEC adhesion and entry during Dr+ E. coli 
induced UTI pathogenesis.  We therefore, investigated the possible molecular 
mechanisms involved in bringing the modulatory effects of estrogen on Dr+ E. coli 
infection in vitro and in vivo.  We next investigated the role of estrogen and ERα on the 
expression of colonization receptors DAF, in vivo, in the mouse kidney and in vitro, in 
mIMCD3 cells following infection with Dr+ E. coli. 
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CHAPTER VI 
 
 
ESTROGEN REGULATES Dr+ ESCHERICHIA COLI COLONIZATION 
RECEPTORS EXPRESSION IN THE MOUSE KIDNEY AND MOUSE INNER 
MEDULLARY COLLECTING DUCT (mIMCD3) CELLS VIA ESTROGEN 
RECEPTOR ACTIVATION 
 
6.1 Introduction 
            Adherence to specific colonization receptors on the host uroepithelium is the most 
crucial event for UPEC to successfully colonize and establish infection in the harsh 
environment of the host urinary tract (Mulvey, 2002, Sauer et al, 2000, Servin, 2005).  
Adherence also stimulates UPEC entry into the host epithelial cells (Bower et al, 2005).  
Within the urinary tract, DAF expressed at the apical surfaces of the urpoepithelial cells 
and type IV collagen present in the epithelial basement membrane serve as the 
colonization receptors for Dr+ E. coli (Nowicki et al, 1987, Nowicki et al, 2001, 
Vaisanen-Rhen, 1984, Westerlund et al, 1989).  Epithelial surfaces of the urethra, 
bladder, ureter and renal pelvis are rich in DAF expression, and there is abundance of 
type IV collagen in the renal tubular basement membrane as well as in the renal 
glomerular Bowman’s capsule (Nowicki et al, 1988).  Binding of Dr adhesin to DAF and 
type IV collagen is crucial for establishment of Dr+ E. coli infection in the urinary tract.
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Attachment of Dr+ adhesins to DAF allows binding, colonization, and invasion of Dr+ E. 
coli on the uroepithelium and its adherence to type IV collagen enables the uropathogen 
to colonize the renal interstitium causing persistent infection and pyelonephritis (Nowicki 
et al, 2001, Selvarangan et al, 2000, Selvarangan et al, 2004). 
 
      Our in vivo results discussed in chapter IV, indicate that estrogen at a physiological 
dose provides protection against Dr+ E. coli colonization in the mouse urinary tract via 
the ERα activation pathway, whereas estrogen deficiency and absence of functional ERα 
increases the colonization of Dr+ E. coli.  Moreover, increased Dr+ E. coli colonization 
has been observed in the kidneys of OVX mice treated with a high dose of estrogen 
(Curran et al, 2007).  This dichotomy of estrogen effects was also observed in our in vitro 
invasion studies using mIMCD3 cells.  As discussed in chapter V, significantly lower 
Dr+ E. coli internalization is observed in cells treated with physiological doses of E2 
compared to the untreated cells.  In contrast, treatment with a pharmacological dose of E2 
markedly increases the Dr+ E. coli internalization.  Furthermore, we found that protective 
effects of physiological doses of E2 against Dr+ E. coli internalization in mIMCD3 cells 
are mediated primarily by ERα activation. 
 
      Adherence of the UPEC in the urinary tract and thus susceptibility to UTIs is 
primarily determined by the expression pattern of UPEC colonization receptors in the 
host (Mulvey, 2002).  Dr+ E. coli adherence to its receptors DAF and type IV collagen 
has been suggested to be hormonally regulated, and hormonal regulation of DAF and 
collagen expression has also been reported (Kaul et al, 1995, Kaul et al, 1996, Lekgabe et 
129 
 
al, 2006, Song et al, 1996).  Based on our in vivo, as well as in vitro studies, we propose 
that estrogen, via ERα activation, regulates the expression of DAF and type IV collagen 
and thereby modulates Dr+ E. coli colonization and internalization in the the mouse 
urinary tract, and in mIMCD3 cells.  The present study was conducted to determine the 
effects of estrogen and ERα on the expression of DAF and type IV collagen in vivo as 
well as in vitro.  We analyzed the expression of DAF and type IV collagen in the kidneys 
of vehicle- and E2-treated OVX, as well as vehicle- and ICI 182 780-treated Non-OVX, 
C3H/HeJ mice.   
 
      We report here that estrogen deficiency and ER inactivation increase DAF and type 
IV collagen expression in the kidneys of uninfected as well as Dr+ E. coli infected 
C3H/HeJ mice; whereas E2 replacement at physiological level in OVX mice significantly 
decreased the expression of these receptors.  Furthermore, compared to ERα+/+ mice, 
ERα-/- mice express higher DAF in the kidneys following infection.  Consistent with the 
in vivo results, physiological levels of E2 via ERα, significantly reduced the DAF and 
type IV collagen expression in mIMCD3 cells; in contrast E2 at a pharmacological dose 
increased the DAF expression. 
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6.2 Statement of Hypothesis 
            Estrogen via ERα activation regulates the expression of Dr+ E. coli colonization 
receptors, DAF and type IV collagen, in the host and thus modulates the host’s 
susceptibility to Dr+ E. coli induced UTIs. 
 
 
6.3 Results 
A) In vivo results 
6.3.1:  Estrogen deficiency increases the expression of DAF and type IV collagen in 
the kidneys of OVX C3H/HeJ mice 
      We analyzed the mRNA levels of DAF and type IV collagen in the kidneys of 
uninfected, estrogen-deficient OVX, and estrogen–sufficient Non-OVX mice to 
determine their susceptibility to Dr+ E. coli infection.  We next investigated the effect of 
estrogen deficiency on the expression of DAF and type IV collagen in the kidneys of age 
matched OVX mice at 2, 6 and 21 days post-UTI-induction.  Non-OVX mice were used 
as estrogen-sufficient controls at each of the time points.  
 
      Prior to the induction of UTI, the kidneys of estrogen-deficient OVX mice showed 
significantly higher levels of DAF mRNA compared to the DAF mRNA levels  in the 
kidneys of Non-OVX mice (Figure 16A).  At 2 and 6 days post-infection, DAF mRNA 
levels in kidneys of both, the OVX and the Non-OVX mice were found to be profoundly  
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Figure 16:  DAF and type IV collagen subtype A1 (Col4A1) mRNA levels in the kidneys of 
C3H/HeJ mice.  A) The DAF mRNA levels and B) the Col4a1 mRNA levels in the kidneys of 
OVX and Non-OVX mice prior to UTI-induction  C) DAF mRNA levels and D) Col4A1 mRNA 
levels in the kidneys of OVX and Non-OVX mice at 2, 6 and 21 days post-Dr+ E. coli mediated 
UTI induction.  The DAF and Col4a1 mRNA levels were determined by quantitative SYBR 
green real-time RT-PCR using gene specific primers.  Target mRNA levels were normalized 
relative to PPIA mRNA levels in each sample.  Expression values are mean relative expression ± 
SEM and the error bars represent data from 5-8 animals in each study group.  Data were analyzed 
by Student’s t- test for Figure 16A and 16B and by Two-Way ANOVA for Figure 16C and 16D 
where P< 0.05 was considered significant.  The character, * indicate significant differences 
among the treatment groups and the character # indicate significant difference in between OVX 
and Non-OVX mice at 21 day post infection in Figures 16C and 16D 
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increased compared to DAF mRNA levels in the kidneys of their respective uninfected 
control mice.  However, at 21 days post-infection, DAF mRNA levels declined in the 
kidneys of OVX as well as Non-OVX mice (Figure 16C). 
 
        Among the infected group of mice at 2 days post-infection, DAF mRNA levels in 
the OVX mice kidneys were lower compared to the levels in the Non-OVX mice kidneys.  
However, at 6 days post-infection DAF mRNA levels in the OVX mice were higher than 
those in the Non-OVX mice.  These differences were not fornd to be statistically 
significant.  At 21 days post-infection, DAF mRNA levels in the OVX mice kidneys were 
found to be significantly increased compared to that in the Non-OVX mice kidneys 
(Figure 16 C).  Notably, DAF mRNA levels in the Non-OVX mice at 21 days post-UTI 
induction were found to be significantly reduced compared to their levels in the 
uninfected mice and in the mice infected for 2 and 6 days.  
 
       Similar to DAF mRNA, levels of type IV collagen mRNA in the kidneys prior to 
infection were significantly higher in the OVX mice compared to those in the Non-OVX 
mice (Figure 16B).  At 2 and 6 days post-UTI induction, no significant change in type IV 
collagen mRNA levels was observed in the OVX or the Non-OVX mice compared to 
those in the uninfected mice.  However, at 21 days post-UTI induction, expression of 
type IV collagen increased significantly in the OVX mice, whereas its expression was 
markedly reduced in the Non-OVX mice (Figure 16D). 
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      Unlike DAF, at 2 days following infection, the mRNA levels of type IV collagen in 
the OVX and the Non-OVX mice were not significantly different.  However, similar to 
the observation for DAF, at 6 days post-infection, the mRNA levels of type IV collagen 
in the OVX mice were found to be higher compared to their levels in the Non-OVX mice.  
However the differences were not statistically significant.  At 21 days post-infection, type 
IV collagen mRNA levels in the OVX mice was found to be significantly higher 
compared to those in the Non-OVX mice (Figure 16 D). 
 
 
6.3.2:  Estrogen pretreatment decreases expression of DAF and type IV collagen in 
the kidneys of OVX C3H/HeJ mice post-infection 
      We analyzed the mRNA levels for DAF and type IV collagen in the kidneys of 
vehicle- and E2-treated OVX mice, at 21 days post-UTI induction (Figure 17).  We also 
determined the expression of DAF and type IV collagen proteins in the kidneys of these 
mice (appendix supplementary Figure 3A and 3B). 
  
      DAF mRNA levels in the E2-treated mice was significantly lower than in the vehicle-
treated mice (Figure 17A).  DAF expression was also found to be lower in the E2-treated 
mice compared to the vehicle-treated mice at the protein level (appendix supplementary 
Figure 3).  Similar to DAF, expression of type IV collagen was also found to be 
significantly reduced at mRNA (Figure 17B) and protein levels (appendix supplementary 
Figure 3) in the E2-treated mice compared to the vehicle-treated mice.  
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Figure 17:  DAF and Col4A1mRNA levels in the kidneys of E2-treated OVX and ICI 182, 
780-treated Non-OVX C3H/HeJ mice.  OVX mice were treated with a physiological dose of E2 
and Non-OVX mice were treated with ER complete antagonist ICI 182, 780, prior to induction of 
infection.  A) DAF mRNA levels and B) Col4a1 mRNA levels in the kidneys of vehicle- and E2-
treated OVX and Non-OVX mice at 21 days post-UTI induction.  C) DAF mRNA levels and D) 
Col4A1 mRNA levels in the kidneys of vehicle- and ICI 182,780-treated Non-OVX mice at 21 
days post-UTI induction.  The DAF and Col4a1 mRNA levels were determined by quantitative 
SYBR green real-time RT-PCR using gene specific primers.  Target mRNA levels were 
normalized relative to PPIA mRNA levels in each sample. Expression values mean relative 
expression ± SEM and the error bars represent data from 5-8 animals in each study group.  Data 
were analyzed by Student’s t-test where P<0.05 was considered significant (*). 
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6.3.3:  ER antagonist pretreatment increases DAF and type IV collagen expression 
in the kidneys of C3H/HeJ mice post-infection 
      To determine the ER involvement in estrogen-mediated regulation of DAF and type 
IV collagen expression, we blocked the ERs in the Non-OVX mice with a pure ER-
antagonist ICI, 182,780, prior to the induction of experimental UTI.  DAF and type IV 
collagen mRNA levels of in the kidneys of vehicle- and ICI 182, 780-treated mice were 
determined at 21 days post-UTI induction.  Treatment with ER-antagonist resulted in 
significant increase in DAF and type IV collagen mRNA levels in the kidneys of Non-
OVX mice compared to those in the vehicle-treated control mice (Figure 17C and 17D). 
 
 
6.3.4:  ERα-/- mice show increased DAF expression in the kidneys compared to the 
DAF expression in ERα+/+ mice post-infection 
      To discern the specific role of ERα in transcriptional regulation of DAF and type IV 
collagen during Dr+ E. coli infection, we employed the ERα-/- and ERα+/+ B6.129 
female mice.  DAF and type IV collagen mRNA levels were measured in the kidneys at 3 
and 7 days post-UTI induction. 
 
      Figure 18A and 18B represent mRNA levels of DAF and type IV collagen in the 
kidneys of ERα-/- and ERα+/+ mice.  At 3 days post-UTI induction, DAF mRNA levels 
in ERα-/- and ERα+/+ mice were not significantly different.  However, at 7 days post-  
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Figure 18:  DAF and Col4A1 mRNA levels in the kidneys of ERα-/- and ERα+/+ mice.  A) 
DAF mRNA levels and B) Col4a1 mRNA levels in the kidneys of ERα-/- and ERα+/+ mice at 3 
and 7 days post-infection.  The DAF and Col4a1 mRNA levels were determined by quantitative 
SYBR green real-time RT-PCR using gene specific primers.  Target mRNA levels were 
normalized relative to PPIA mRNA levels in each sample.  Each graph represents expression 
values from 1 experiment for 3 day infection and 2 experiments for 7 days infection.  Expression 
values are mean relative expression ± SEM and the error bar represents data from 4-7 animals in 
each study group.  Data from 3 day infected ERα-/- mice are from 2 animals.  Data were analyzed 
by Student’s t- test and Two-way ANOVA followed by Bonferroni post hoc test for multiple 
comparisons.  P<0.05 was considered significant.  The character * indicate significant difference 
among the treatment groups, and # indicate significant difference between ERα-/- and ERα+/+ 
mice. 
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infection the kidneys of ERα-/- mice had markedly elevated levels of DAF mRNA 
compared to those of ERα+/+ mice (Figure 18A).  At 3 days post-infection type IV 
collagen mRNA levels in ERα-/- mice kidneys were lower compared to those in ERα+/+ 
mice.  However, at 7 days post-infection, we found increase in type IV collagen mRNA 
levels in the ERα-/- mice kidney compared to those in the ERα+/+ mice, but the 
differences were not found to be statistically significant (Figure 18B).   
 
 
B) In vitro results 
6.3.5:  E2 regulates expression of DAF and type IV collagen in mIMCD3 cells in a 
dose-dependent manner 
      To test if E2-mediated dose-dependent modulation of Dr+ E. coli invasion in 
mIMCD3 cells involves differential regulation of DAF expression, we determined DAF 
mRNA levels at different doses of E2 in Dr+ E. coli infected as well as uninfected 
mIMCD3 cells.  We also analyzed the effect of different E2 doses on type IV collagen 
expression in mIMCD3 cells.  The cells were treated with 0, 1, 10, 50 or 100 nM E2 for 
24 hrs (details in chapter III, section 3.3.2) and then were either left uninfected or were 
infected with Dr+ E. coli for 2 hrs.  Following infection, cellular levels of DAF and type 
IV collagen mRNA were determined (details in chapter III section 3.4). 
 
      Figure 19A represents the mRNA levels of DAF in mIMCD3 cells treated with 
various E2 doses.  In both uninfected and infected cells, DAF mRNA levels remained  
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Figure 19:  DAF mRNA levels in the mIMCD3 cells treated with E2, ICI 182, 780 (ICI) or 
PPT.  DAF mRNA levels relative to PPIA were analyzed by quantitative SYBR green real-time 
RT-PCR in Dr+ E. coli infected and uninfected mIMCD3 cells treated either with A) E2 at 
different doses or B) 10 nM E2, 10 nM E2+10 µM ICI,or 0.1 µM PPT.  Untreated cells served as 
controls.  Expression values are mean relative expression ± SEM and the error bars represent data 
from at least 4 experiments, performed in triplicate.  Data were analyzed by Two-way ANOVA 
followed by Bonferroni post hoc test where P<0.05 was considered significant.  The character * 
indicate significant differences among treatment groups, x indicate significant difference relative 
to control in infected cells, $ indicate significant differences relative to 100 nM E2 treatment in 
uninfected cells, and # indicate significant differences in between infected and uninfected cells. 
C) DAF mRNA expression and Dr+ E. coli relative invasion in mIMCD3 cells treated with 
different doses of E2.  Invasion values are mean bacterial CFU ± SEM expressed as relative % 
invasion in E2-treated cells relative to untreated cells (invasion in untreated cells is considered to 
be 100%). 
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significantly reduced in the cells treated with physiological E2 doses (1-10 nM), 
compared to those in the untreated cells (Figure 19A).  The cells treated with 10 nM E2 
expressed significantly lower DAF compared to the cells treated with a higher (100 nM) 
dose of E2 (Figure 19A).  Infection with Dr+ E. coli resulted in up-regulation of DAF 
expression in control as well as E2-treated cells at all E2 doses, except at 100 nM (Figure 
19 A).  Notably, among the E2-treated cells, the relative increase in DAF expression in 
the infected cells compared to uninfected cells remained low (Figure 19 A).   
However, in the control untreated group of mIMCD3 cells, DAF mRNA levels in 
infected cells are significantly higher compared to those in the uninfected cells (Figure 
19A). 
 
      Figure 19C represents the bacterial invasion and DAF mRNA levels in E2-treated 
mIMCD3 cells.  The bacterial invasion at physiological doses of E2 (1-10 nM) was lower 
compared to the bacterial invasion in the untreated control cells and also to the cells 
treated with a higher dose of E2 (100 nM).  Notably, bacterial invasion in cells correlated 
with the DAF mRNA levels at different E2 doses, where higher DAF mRNA corresponds 
with increased bacterial invasion and lower DAF mRNA corresponds with reduced 
bacterial invasion. 
 
      Type IV collagen mRNA levels in both infected and uninfected cells were found to be 
markedly reduced in E2-treated cells at all the doses compared to that in untreated cells 
(Figure 20A).  Infection with Dr+ E. coli increased type IV collagen expression in all the 
treatment groups compared to that in uninfected cells (Figure 20A).  Similar to the 
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observations for DAF expression, the relative increase in type IV collagen mRNA levels 
following infection in the E2-treated cells remained lower compared to the relative 
increase in untreated cells (Figure 20A). 
 
 
6.3.6:  E2 regulates expression of DAF and type IV collagen in mIMCD3 cells via 
ERα activation pathway 
      To test the involvement of ERs in E2-mediated regulation of DAF and type IV 
collagen expression in mIMCD3 cells, we co-treated the cells with E2 (10 nM) and the 
ER complete antagonist ICI 182,780 (10 µM).  DAF and type IV collagen mRNA levels 
were analyzed in both Dr+ E. coli infected and uninfected cells following treatment with 
ICI, 182 780. 
 
      ER antagonist treatment led to an increase in DAF mRNA levels compared to E2-
treated cells, following infection (Figure 19B).  Blocking of ERs with ICI 182, 780 
resulted in a significant increase in type IV collagen mRNA levels in infected as well as 
uninfected cells compared to those in the E2-treated cells.  
 
      To further determine the role of ERα on estrogen-mediated regulation of DAF and 
type IV collagen expression, mIMCD3 cells were pretreated with an ERα specific agonist 
0.1 µM PPT (at the dose that provided protection against Dr+ E. coli invasion in 
mIMCD3 cells, chapter V section 5.3.3).  DAF and type IV collagen mRNA levels were 
measured in PPT treated Dr+ E.coli infected as well as uninfected cells.  
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Figure 20:  Col4A1 mRNA levels in the mIMCD3 cells treated with E2, ICI 182, 780 (ICI) 
or PPT.  Col4A1 mRNA levels relative to PPIA were analyzed by quantitative SYBR green real-
time RT-PCR in Dr+ E. coli infected and uninfected mIMCD3 cells treated either with A) E2 at 
different doses or B) 10 nM E2, 10 nM E2+10 µM ICI, 0.1 µM PPT.  Untreated cells served as 
controls.  Expression values are mean relative expression ± SEM and the error bars represent data 
from at least 4 experiments performed in triplicate.  Data were analyzed by Two-way ANOVA 
followed by Bonferroni post hoc test where P<0.05 was considered significant.  The character * 
indicates significant differences among treatment groups, x indicates significant differences 
relative to control in infected cells, $ indicates significant differences relative to control in 
uninfected cells, ^ indicates significant differences relative to E2+ ICI treatment in infected cells, 
& indicates significant differences relative to E2+ ICI treatment in uninfected cells, and # 
indicates significant differences between infected and uninfected cells for each treatment 
group.treated cells were comparable to their expression in cells treated with E2 at a physiological 
dose (10 nM).  
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      In both uninfected and infected cells, PPT treatment led to significant decrease in 
DAF (Figure 19B), as well as type IV collagen (Figure 20B) mRNA levels, compared to 
the levels in untreated cells.  The expression of DAF and type IV collagen in 0.1 µM PPT 
treated cells were comparable to their expression in the cells treated with E2 at a 
physiological dose (10nM). 
 
 
6.4 Discussion 
           An influence of estrogen on the adherence of UPEC to female urogenital tract has 
been suggested by several studies (Schaeffer et al, 1979, Sharma et al, 1987, Sobel & 
Kaye, 1986).  However, the precise molecular mechanism associated with the estrogenic 
effect on UPEC adhesion has not been previously described.  In this study, we 
demonstrate for the first time that estrogen, via ERα, regulates colonization and 
internalization of Dr+ E. coli by regulating the expression of its colonization receptors, 
DAF and type IV collagen, in vivo in the mouse kidney and in vitro, in mIMCD3 cells.  
Our study also provides the first direct in vitro evidence for estrogen-mediated dose-
dependent regulation of DAF and type IV collagen expression in mIMCD3 cells during 
Dr+ E. coli infection. 
 
            Prior to infection, estrogen deficient menopausal OVX C3H/HeJ mice expressed 
significantly higher levels of DAF and type IV collagen in the kidneys compared to those 
in estrogen-sufficient Non-OVX mice, suggesting increased susceptibility of OVX mice 
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to Dr+ E. coli colonization.  Following infection, the OVX mice showed higher DAF as 
well as type IV collagen expression compared to the Non-OVX and E2-treated OVX 
mice.  Consistent with these observations we have found increased Dr+ E. coli 
colonization in OVX mice compared to that in Non-OVX and OVX mice treated with 
physiological doses of E2 (Discussed in chapter IV).  Binding of Dr+ E. coli to DAF and 
type IV collagen is essential for bacterial colonization and initiation of infection in the 
renal tissues (Nowicki et al, 2001, Selvarangan et al, 2000, Selvarangan et al, 2004).  
Estrogen-mediated reduction in DAF expression may attenuate the adherence of Dr+ E. 
coli to the host uroepithelium.  Similarly, reduction in type IV collagen expression will 
lower type IV collagen deposition in the epithelial basement membrane and thus reduce 
susceptibility to Dr+ E. coli colonization in the renal interstitium.  This will result in 
reduced susceptibility to Dr+ E. coli colonization and inflammation-induced kidney 
fibrosis in the host following infection.  Taken together, results from this study support 
our hypothesis and provide evidence for a possible molecular mechanism associated with 
the protective effect of host physiological estrogen levels against Dr+ E. coli induced UTI 
and increased susceptibility to Dr+ E. coli infection in estrogen deficient conditions. 
 
       Furthermore, our in vitro studies utilizing mIMCD3 cells show dose-dependent 
regulation of DAF expression by E2 that correlates with the dose-dependent modulation 
of Dr+ E. coli invasion in the cells (Figure 19C and results discussed in chapter V).  
Treatment of cells with physiological doses of E2 resulted in attenuated DAF expression 
and a 40-60% reduction in Dr+ E. coli invasion compared to that in untreated cells.  
Thus, it is clear that physiological E2 levels reduce DAF expression resulting in reduction 
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of bacterial attachment and invasion; whereas expression of DAF is increased in cells 
growing under E2 deficient conditions, resulting in higher bacterial invasion.   
 
      Significant increases in DAF expression and Dr+ E. coli internalization were also 
observed in mIMCD3 cells treated with a pharmacological dose of E2.  High estrogen 
levels during pregnancy have been implicated in increased risk for cystitis and 
pyelonephritis which in turn may contribute to premature delivery and congenital 
anomalies (Kaul et al, 1999, Mittal & Wing, 2005, Santos et al, 2002, Schnarr & Smaill, 
2008).  Furthermore, Kaul et al have reported differential adherence of Dr adhesins to 
endometrial samples from females with normal menstrual cycle, showing luminal up-
regulation of DAF expression during the secretory phase (Kaul et al, 1995, Kaul et al, 
1996).  Interestingly, Curran et al have also reported increased Dr+ E. coli colonization in 
the kidneys of OVX C3H/HeJ, as well as in the C3H/HeN (LPS responder) mice treated 
with a higer level of E2 (Curran et al, 2007).  Importantly, treatment with a higher E2 
level in these mice was not found to alter the colonization of Dr adhesin mutant E. coli 
(Dr- E. coli) that has lost the capacity to adhere to DAF and invade the host cells (Curran 
et al, 2007).  Based on our result, it can be inferred that in the study by Curran et al, 
higher estrogen levels may possibly have led to up-regulation of adhesion receptor DAF 
expression thus resulting in increased infection by Dr+ E. coli but not by Dr- E. coli.   
 
      Studies investigating estrogen-mediated gene regulation have revealed that there is 
significant diversity among estrogen response networks found in different cells and at 
different doses.  Variation in expression networks can occur due to the occupancy of 
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different ERα/ ERβ binding sites in the genome, and may also be determined by the co-
factor compositions of a particular cell type (McDonnell et al, 1995, Nilsson et al, 2001, 
Nilsson & Gustafsson, 2002).  From our results, it is now evident that host’s endogenous 
estrogen levels play an important role in determining host susceptibility to Dr+ E. coli 
induced UTI by regulating DAF and type IV collagen expression in the renal tissue and 
cells.  Kaul et al have also shown regulation of DAF expression by progesterone.  
However in this study, we have not investigated the effects of progesterone on DAF or 
type IV collagen expression (Kaul et al, 1995).   
 
      Utilizing ERα-/-mouse model and ERα specific agonist PPT treatment in mIMCD3 
cells, we demonstrate for the first time that estrogen-mediated regulation of DAF and 
type IV collagen in the mouse kidney and mIMCD3 cells is ERα dependent.  Expression 
of DAF and type IV collagen has been previously reported to be regulated by estrogen 
(Potier et al, 2001, Potier et al, 2002, Song et al, 1996).  Estrogen-mediated regulation of 
DAF expression has earlier been reported in the mouse uterus (Song et al, 1996).  
Regulatory regions of the DAF gene do contain ERE and induction of mouse DAF by 
estrogen has been found to be tissue specific (Mirkin et al, 2005, Song et al, 1996).  
Besides ERE, DAF gene regulatory regions also contain Sp1, Ap1and NFκB 
transcription factor binding sites and regulation of its expression has been reported to 
include ER mediated transcriptional and cellular signaling activation pathways, MAPK 
and NFκB (Ahmad et al, 2003, Cauvi et al, 2006, Mirkin et al, 2005, O'Brien et al, 2008, 
Thomas & Lublin, 1993).  E2 is known to regulate activation of MAPK pathway and 
there seems to exist a cross-talk between MAPK and ER subtype activation (Altiok et al, 
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2007, Endoh et al, 1997, Frigo et al, 2006, Lee & Bai, 2002, Lee & Eghbali-Webb, 1998, 
Migliaccio et al, 1996, Ruzycky, 1996, Seval et al, 2006, Wade & Dorsa, 2003). 
Estrogen-mediated regulation of collagen type IV expression has been found to be 
renoprotective because estrogen-mediated down regulation of type IV collagen 
expression following injury or infection attenuates renal fibrosis (Neugarten et al, 2000, 
Potier et al, 2002).  The promoter of type IV collagen has not yet been reported to contain 
ERE, and E2-mediated transcriptional regulation of type IV collagen occurs via cellular 
signaling pathway activated Sp1 transcription factor (Burbelo et al, 1988, Zdunek et al, 
2001).  In the kidney, E2 is reported to suppress collagen type IV expression by 
downregulating TGFβ and TGFβ receptors (Dixon & Maric, 2007, Milanini-Mongiat et 
al, 2002, Potier et al, 2002).  MAPK has been reported to regulate DAF and collagen type 
IV expression (Ahmad et al, 2003, Dixon & Maric, 2007, Milanini-Mongiat et al, 2002, 
O'Brien et al, 2008, Potier et al, 2002).  Using Huh-7 cells, we have previously shown 
that E2-mediated protection against Dr+ E. coli invasion involves MAPK activation 
(Kaul et al, 2007), however we have not yet investigated the interaction of ERs and 
MAPK in the regulation of DAF and type IV collagen expression in mIMCD3 cells or in 
vivo.   
  
      In our study, we found that infection increased DAF as well as type IV collagen 
expression, both in vivo and in vitro.  Notably, in the in vitro study we found that the 
relative increases in DAF and type IV collagen expression following infection in E2-
treated cells were lower than the relative increase observed in the untreated control cells.  
Consistent with this, our in vivo results also indicate that following infection the relative 
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increase in DAF and type IV collagen expression is higher in the estrogen-deficient OVX 
mice compared to the estrogen-sufficient Non-OVX and to the  E2-treated OVX mice.  
These observations suggest the existence of additional regulatory mechanisms for DAF 
and type IV collagen expression following infection that may be associated with 
influence of estrogen on infection induced inflammatory responses.  Both DAF and type 
IV collagen expression have been found to be up-regulated following activation of 
inflammatory pathways.  Pro-inflammatory cytokines including TNFα and chemokines 
including IL8 have been reported to up-regulate DAF as well as type IV collagen 
expression following injury and infection, in vivo, as well as in vitro(Betis et al, 2003b, 
Fang et al, 2004, Mankhey et al, 2007, Meldrum et al, 2007, Nowicki et al, 2009, Potier 
et al, 2002).  Moreover, estrogen is known to have immunomodulatory effects on the 
inflammatory responses showing pro-as well as anti-inflammatory effects (Cutolo et al, 
2004, Straub, 2007).  Thus, the estrogen-mediated regulation of DAF and type IV 
collagen may involve direct estrogen/ER-mediated regulation of their expression as well 
as indirect regulation via modulation of inflammatory responses.  We test the regulatory 
effect of estrogen on inflammation following Dr+ E. coli infection later in the study 
(discussed in chapter VIII). 
 
      Based on our observations from this study, we conclude that adherence of 
uropathogens to uroepithelium is a dynamic process and is differentially influenced by 
estrogen levels.  Physiological levels were found to be protective, whereas, both higher 
and reduced doses of estrogen contribute to increased UTI susceptibility.  Furthermore, 
our study provides the first in vitro, as well as in vivo evidences, for ERα mediated 
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modulation of Dr+ E. coli colonization and internalization in the host via regulation of its 
colonization receptors DAF, and type IV collagen expression.  Furthermore, we propose 
that ERα selective ligands may serve as possible therapeutic targets against Dr+ E. coli 
mediated UTI in estrogen deficient and in postmenopausal females. 
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CHAPTER VII 
 
 
ESTROGEN MODULATES Dr+ ESCHERICHIA COLI INVASION IN THE 
MOUSE INNER MEDULLARY COLLECTING DUCT (mIMCD3) CELLS 
VIA REGULATING TYROSINE KINASE ACTIVATION PATHWAY 
 
7.1 Introduction 
            UPEC employs diverse mechanisms to invade the host uroepithelium including 
manipulation of cellular signaling, hijacking of host complement receptors via 
opsonization, binding to adhesin receptors, and activating cytoskeletal rearrangement 
(Bower et al, 2005, Dhakal & Mulvey, 2009, Li et al, 2006, Mulvey, 2002, Palmer et al, 
1997, Springall et al, 2001).  Uptake of uropathogenic bacteria by renal epithelial cells 
(Donnenberg et al, 1994, Palmer et al, 1997, Straube et al, 1992, Warren et al, 1988) has 
been found to be associated with tyrosine phosphorylation of specific host proteins 
(Palmer et al, 1997).  Adherence of pyelonephritic Dr+ E. coli to its colonization receptor 
DAF causes recruitment of α5β1integrins and additional DAF at the sites of bacterial 
attachment on the epithelial cell followed by bacterial internalization (Das et al, 2005, 
Goluszko et al, 1999, Guignot et al, 2001, Kansau et al, 2004, Plancon et al, 2003, 
Selvarangan et al, 2000).  Engagement of DAF with members of Afa/Dr adhesin bearing 
E. coli has been shown to induce tyrosine kinase mediated PI3K/Akt signaling activation
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(Cane et al, 2007, Peiffer et al, 1998) that triggers bacterial internalization by the host 
cells (Brumell & Grinstein, 2003, Goluszko et al, 1997, Goluszko et al, 1999, Goluszko 
et al, 2008, Wymann & Pirola, 1998).  Using our in vitro experimental UTI model we 
have demonstrated for the first time that Dr+ E. coli is internalized by mIMCD3 cells 
(results from chapter V).  However, involvement of tyrosine kinase activation during Dr+ 
E. coli invasion in mIMCD3 cells has not been previously investigated.  In the present 
study we tested the role of tyrosine kinase in Dr+ E. coli internalization in mIMCD3 
cells. 
 
      Our in vitro studies indicate that E2 modulates Dr+ E. coli invasion in mIMCD3 cells 
via regulating DAF expression (chapter VI).  Both in vitro and in vivo studies have 
reported that estrogen has regulatory effects on the tyrosine kinase activated PI3K/Akt 
signaling pathway in different cell types and under various physiological conditions in 
vitro as well as in vivo (Boonyaratanakornkit & Edwards, 2007, Cato et al, 2002, 
Edwards & Boonyaratanakornkit, 2003, Hammes & Levin, 2007).  For example, E2 
treatment in MCF-7 cells and in endometrial cancer cells has been shown to increase 
tyrosine kinase activity and promptly activate the PI3K/Akt signal pathway.  In contrast, 
positive effects of E2 treatment on post ovariectomy osteoporosis have been associated 
with inhibition of tyrosine kinase activity in osteoclast cells (Guo et al, 2006, Li & Yu, 
2003, Liu & Howard, 1991, Migliaccio et al, 1996, Pascoe & Oursler, 2001, Yoneda et 
al, 1993).  In addition, genistein, a compound that has structural similarity to E2 and 
binds to ERs is a known tyrosine kinase inhibitor; it has been observed to mimic 
beneficial biological effects of E2 on bone tissue by inhibiting osteoclast activity (Gao & 
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Yamaguchi, 1999, Gao & Yamaguchi, 2000, Li & Yu, 2003).  Based on these 
observations, we propose that E2-mediated modulation of Dr+ E. coli invasion in 
mIMCD3 cells may also include regulation of tyrosine kinase signaling.  Thus, the 
present study was conducted to investigate the role of tyrosine kinase and PI3K/Akt 
signaling in Dr+ E. coli invasion in mIMCD3 cells and to further test if estrogen 
modulates tyrosine kinase and PI3K/Akt signaling activation to influence Dr+ E. coli 
invasion in these cells.   
 
       In the present study, we found that inhibition of tyrosine kinase in mIMCD3 cells 
caused significant reductions in Dr+ E. coli invasion.  We also found that E2 at a 
physiological dose and at a higher dose differentially regulates PI3K and Akt signal 
activation resulting in different outcomes on Dr+ E. coli invasion in mIMCD3 cells.  
 
 
7.2 Statement of Hypothesis 
            Dr+ E. coli invasion in mIMCD3 cells require tyrosine kinase activation.  
Furthermore, estrogen regulates tyrosine kinase activation to modulate Dr+ E. coli 
invasion in mIMCD3 cells. 
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7.3 Results 
7.3.1:  Tyrosine kinase activation induces Dr+ E. coli invasion in mIMCD3 cells 
          To determine the role of the tyrosine kinase signaling pathway during Dr+ E. coli 
invasion in mIMCD3 cells, we treated these cells with known tyrosine kinase inhibitors 
prior to infection.  Genistein, a phytoestrogen is an ER agonist with known tyrosine 
kinase inhibitor activity and LY294002 is a potent PI3K inhibitor.  The cells were 
pretreated with non-toxic doses of genistein (0.01, 0.1, 1 and 10 µM) or LY294002 (10, 
50 and 100 µM) or left untreated.  Genistein treatment was given for 24 hrs and 
LY294002 treatment was given for 15 min prior to infection.  Following treatment, the 
cells were either left uninfected or were infected with Dr+ E. coli for 2 hrs and bacterial 
internalization was determined by the gentamicin protection assay.  Total infection 
(adhered and internalized bacteria) in mIMCD3 cells was determined as described in the 
methods section (chapter III).  Drug toxicity for genistein and LY294002 treatment in 
mIMCD3 cells was tested by MTT assay (appendix supplementary Figures 2D and 2E).  
The phosphorylated PI3K and Akt (pPI3K and pAkt) protein levels were detected by 
western blot to evaluate the activation status of tyrosine kinase in genistein and 
LY294002 treated, Dr+ E. coli infected and uninfected mIMCD3 cells. 
 
          Pretreatment of the mIMCD3 cells with genistein significantly reduced Dr+ E. coli 
internalization in mIMCD3 cells (Figure 21 A).  Importantly, genistein blocked uptake of 
Dr+ E. coli in a dose-dependent manner resulting in more than 60% inhibition at a 10µM 
dose (Figure 21A).  To further address the role of tyrosine kinase-activated PI3K 
signaling in Dr+ E. coli invasion, we inhibited the PI3K signaling pathway in mIMCD3  
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Figure 21:   Relative invasion of Dr+ E. coliin the mIMCD3 cells treated with tyrosine 
kinase inhibitors.  Relative bacterial invasion following 2 hrs of Dr+ E. coli infection in 
mIMCD3 cells treated with A) tyrosine kinase inhibitor genistein (0.1, 1 or 10 µM) and B) PI3K 
inhibitor LY294002, as determined by gentamicin protection assay.  Invasion values are mean 
bacterial CFU ± SEM expressed as % invasion in treated cells relative to untreated cells 
(considered as 100%). The error bars represent data from at least 4 independent experiments 
performed in triplicate.  Data were analyzed by One-Way ANOVA followed by Tukey’s post hoc 
test for multiple comparisons where P< 0.05 was considered significant.  The character * indicate 
significant differences among the treatment groups, x indicate significant differences compared to 
control treatment in Figures 21A and 21B, and #  indicate significant differences compared to the 
100 µM LY294002 treatment in Figure 21B. 
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cells by LY294002.  Clearly, PI3K inhibition strongly impaired uptake of Dr+ E. coli in 
mIMCD3 cells in a dose-dependent manner resulting in up to 90% reduction in invasion 
compared to that in the untreated control cells (Figure 21B).  No significant differences 
were found in the levels of total bacterial infection (bacteria adhered plus internalized as 
determined by the total CFU counts) in genistein and LY294002 treated mIMCD3 cells 
(Figure 22A-22B).  The amount of bacteria internalized was significantly reduced in 
genistein and LY294002 treated cells (Figures 22 C and 22D) and there was marked 
reduction in the rate of bacterial internalization (% of bacteria internalized/ bacteria 
infected) in a dose dependent manner (Figure 22D-F). 
 
      To confirm the inhibition of tyrosine kinase activity, we analyzed the protein levels of 
pPI3K and pAkt in both genistein-(10 µM) and LY294002-(10, 50 and 100 µM) treated 
uninfected and Dr+ E. coli infected mIMCD3 cells (Figure 23 and 24).  These inhibitors 
decreased tyrosine kinase activation, resulting in blocking of cellular bacterial invasion in 
a dose dependent manner.  Notably, LY294002 treated cells showed significant dose 
dependent decreases in pPI3K and pAkt levels, with maximum reduction at a 100 µM 
dose.  Marked reductions in pPI3K and pAkt levels were found in genistein treated cells 
compared to the untreated control cells.   
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Figure 22 
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Figure 22:  Dr+ E. coli infection and invasion in the mIMCD3 cells treated with tyrosine 
kinase inhibitors. Total bacterial infection (A and B) and invasion (C and D) were determined 
following 2 hrs of Dr+ E. coli infection in mIMCD3 cells treated with tyrosine kinase inhibitor A 
and C) genistein  and B and D) PI3K inhibitor LY294002.  Relative levels of bacterial invasion 
in mIMCD3 cells treated with genistein (E) and LY294002 (F) were expressed as a ratio of 
bacterial invasion and total bacterial infection (bacteria adhered plus bacteria internalized) in each 
treatment group.  Data for total bacterial infection and invasion are presented as mean CFU± 
SEM.  Relative invasion in each treatment group is expressed as % invasion and represented as % 
CFU internalized ± SEM for each treatment group.  The error bars represent data from up to 4 
experiments performed in triplicate.  Data were analyzed by One-Way ANOVA followed by 
Tukey’s post hoc test for multiple comparisons where P<0.05 was considered significant.  The 
character * indicates significant differences among the treatments, # indicates significant 
differences compared to the control untreated cells, and x indicates significant differences 
compared to 100µM LY294002 treatment. 
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7.3.2:  E2 at a physiological and a pharmacological dose differentially regulates 
tyrosine kinase activation in mIMCD3 cells 
        To determine if E2-mediated differential effects on bacterial invasion involves 
regulation of tyrosine kinase, we analyzed the activation status of PI3K and of Akt in E2-
treated mIMCD3 cells before and after Dr+ E. coli infection.  The mIMCD3 cells were 
either treated with a physiological or a pharmacological dose of E2 prior to the infection 
and then protein levels of pPI3K and pAkt were determined in both infected as well as 
uninfected cells.  
 
      Treatment with a physiological dose of E2 (10 nM) led to a non-significant reduction 
in pPI3K and pAkt levels in both uninfected and infected mIMCD3 cells (Figures 23 and 
24).  Treatment with a pharmacological dose of E2 (100 nM) caused significant 
reductions in pPI3K and pAkt levels in uninfected cells (Figure 23A and 24A).  In 
contrast among the infected cells, 100 nM E2 treatment induced significant increase in 
pPI3K and pAkt levels.  Furthermore, increase in pPI3K and pAkt following infection 
with Dr+ E. coli were observed in control untreated and E2-treated mIMCD3 cells.  
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Figure 23 
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Figure 23:  Cellular levels of pPI3K in the mIMCD3 cells. Cells were treated with E2, 
genistein or LY294002 and were either left uninfected (A) or were infected (B) with Dr+ E. coli 
for 2 hrs followed by cellular level detection of pPI3K using western blots.  Untreated cells were 
considered as the control (C).  Protein levels of pPI3K and total PI3K in drug-treated uninfected 
and infected cells were determined by staining the total cell lysate with anti-pPI3-K 5(T458) Ab 
and anti-total PI3-K Ab, respectively.  Staining for β-actin was used as a loading control.  Data 
represent mean relative pPI3K levels ± SEM.  Error bars represent data from two independent 
experiments performed in triplicate.  The replicates from each experiment were pooled for 
analysis.  Data were analyzed by One-Way ANOVA followed by Dunnett’s post hoc test for 
multiple comparisons where P<0.05 was considered significant.  The character * indicates 
significant differences among the treatments and # indicates significant differences compared to 
control untreated cells. 
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Figure 24 
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Figure 24:  Cellular levels of pAkt in the mIMCD3 cells.  The mIMCD3 cells were treated with 
E2, or genistein, or LY294002 and were either left uninfected (A) or were infected (B) with Dr+ 
E. coli for 2 hrs followed by cellular level detection of pAkt using western blot.  Untreated cells 
were considered as control (C).  Protein levels of pAkt and total Akt in drug-treated uninfected 
and infected cells were determined by staining the total cell lysate with anti-pAkt (S473) Ab and 
anti-total Akt Ab respectively.  Staining for β-actin was performed as a loading control.  Data 
represents mean relative pAkt levels ± SEM.  Error bars represents data from two independent 
experiments performed in triplicate.  The replicates from each experiment were pooled for 
analysis.  Data were analyzed by One-Way ANOVA followed by Dunnett’s post hoc test for 
multiple comparisons where P<0.05 was considered significant.  The character * indicates 
significant differences among the treatments and # indicates significant differences compared to 
the control untreated cells. 
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8.4 Discussion 
            The results of the present study indicate that Dr+ E. coli infection in mIMCD3 
cells induces activation of tyrosine kinase leading to phosphorylation and activation of 
the PI3K and Akt signaling pathways and this activation is essential for invasion of Dr+ 
E. coli into the cells.  Bacterial internalization by non-phagocytic host cells involves 
triggering of host signal transduction mechanisms to induce rearrangements of the host 
cytoskeleton, thereby facilitating bacterial internalization (Martinez et al, 2000, Martinez 
& Hultgren, 2002, Munter et al, 2006, Yam & Theriot, 2004).  Activation of tyrosine 
kinase involving phosphorylation and activation of the PI3K and Akt pathway appears to 
be a common feature leading to bacterial internalization into a variety of host cells by 
several invasive pathogens including UPEC (Hu et al, 2006, Korotkova et al, 2008, 
Martinez et al, 2000, Monteiro da Silva et al, 2007, Sandros et al, 1996, Uliczka et al, 
2009).  Using Huh7 hepatoma cells, we previously have demonstrated that tyrosine 
kinase inactivation by genistein inhibits Dr+ E. coli internalization (unpublished data), 
suggesting that a requirement for tyrosine kinase activation during Dr+ E. coli 
internalization is not limited to mIMCD3 cells.  Internalization of UPEC by non-
phagocytic epithelial cells requires binding of UPEC to the host cellular surface 
receptors.  However, our results confirm that attachment to host receptors alone is 
insufficient to induce internalization and it is also dependent on tyrosine kinase 
activation.  The fact that inhibition of tyrosine kinase markedly attenuated the 
internalization process, suggests that internalization of Dr+ E. coli is an active process 
mediated by epithelial cells. 
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      Our results are consistent with the several other cellular signaling models of infection 
showing uptake of intracellular pathogenic bacteria by epithelial cells (Hu et al, 2006, 
Korotkova et al, 2008, Martinez et al, 2000, Martinez & Hultgren, 2002, Monteiro da 
Silva et al, 2007, Munter et al, 2006, Sandros et al, 1996, Uliczka et al, 2009, Yam & 
Theriot, 2004).  Numerous studies have reported increase in tyrosine kinase activation 
following infection which is associated with bacterial uptake by the epithelial cells.  
Moreover, several host cellular proteins are known to participate in bacterial 
internalization via interacting with different host signal transduction systems.  For 
example, activation of mitogen-activated protein kinase (MAPK) and TGF-beta signaling 
pathways were shown to promote invasion of Steptococcus pneumoniae and 
Haemophilus influenzae in nasal epithelial cells in vitro following infection  
(Beisswenger et al, 2007).  Campylobacter jejuni 81-176 has been shown to interact with 
G protein-coupled receptor at host cell surface membrane caveolae, which triggers G-
proteins and kinases to activate host proteins including PI3K and MAPK, that appear to 
be intimately involved in C. jejuni 81-176 internalization (Hu et al, 2006).  
Staphylococcus aureus adherence and invasion in normal human and mouse osteoblasts 
was found to increase the phosphorylation of the extracellular signal-regulated protein 
kinases (ERK 1 and 2) that correlated with MAPK activation (Ellington et al, 2001).  
Tyrosine kinases and JNK signalling were found to be crucial in Neisseria meningitidis 
invasion in human brain microvascular endothelial cells (Sokolova et al, 2004).  Thus, we 
propose that the uptake of Dr+ E. coli by mIMCD3 cells may involve similar 
mechanisms that have been shown previously for internalization of Afa/Dr adhesion 
bearing E. coli and other intracellular pathogenic bacteria by non-phagocytic epithelial 
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cells involving host PI3K/Akt cell signal transduction activation induced engulfment of 
the bacterium (Donnenberg et al, 1994, Korotkova et al, 2008, Martinez et al, 2000, Yam 
& Theriot, 2004). 
 
      We further demonstrate that physiological and pharmacological E2 doses 
differentially regulate tyrosine kinase activation in infected and uninfected cells.  Our 
results suggest that higher E2 dose activates tyrosine kinase signaling and this may 
promote increased Dr+ E. coli internalization in mIMCD3 cells.  Physiological E2 doses 
attenuate tyrosine kinase activation and this may contribute to reduced bacterial 
internalization in mIMCD3 cells.  Taken together, our results show that physiological E2 
levels protect against Dr+ E. coli invasion by attenuating both DAF expression and 
tyrosine kinase activation; whereas, pharmacological E2 dose increases bacterial 
internalization by elevating DAF expression and tyrosine kinase activation.  Activation of 
the PI3K/Akt pathway in vitro at 1 µM and higher E2 doses has been previously reported 
in endometrial cancer cells (Guo et al, 2006).  Since bacterial internalization is an 
important feature of UTI pathogenesis, increased activation of tyrosine kinase signaling 
at higher E2 doses may be an important contributing factor for increased susceptibility to 
Dr+ E. coli and other UPEC induced UTIs during pregnancy.  The association between 
increased hormonal levels during pregnancy and susceptibility to UTIs may be attributed 
to increased colonization receptor expression (Kaul et al, 1999) and tyrosine kinase-
activated bacterial internalization (Wroblewska-Seniuk et al, 2005) induced by elevated 
estrogen levels.  Blockade or attenuation of PI3K/Akt signaling cascade may be 
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considered as potential therapeutic approaches for effective control of bacterial 
internalization during UTI pathogenesis in hosts.  
 
      To our knowledge, no other studies to date have shown estrogen-mediated regulation 
of tyrosine kinase activation during bacterial internalization.  Our study indicates ERα to 
be the functional ER subtype regulating DAF expression and Dr+ E. coli internalization 
in mIMCD3 cells.  We have not investigated the ER subtype involved in regulating E2-
mediated tyrosine kinase activation during Dr+ E. coli internalization in mIMCD3 cells.  
Since ERα is the predominant subtype expressed in mIMCD3 cells, it is expected that 
tyrosine kinase activation by E2 in these cells may be regulated by ERα, however, studies 
will be conducted in future to discern the ER subtype involved in this estrogen-induced 
response.  Nonetheless, ERα-mediated estrogenic regulation of PI3K/Akt signaling 
activation has been previously indicated (Castoria et al, 2001).   
 
      Non-genomic signaling by estrogen involves rapid activation of cellular signaling 
kinases via activated ERs resulting in transcriptional regulation of target genes (Cato et 
al, 2002, Edwards & Boonyaratanakornkit, 2003, Hammes & Levin, 2007, Mannella & 
Brinton, 2006).  For instance, in MCF7 cells E2-mediated regulation of PI3K signaling 
has been shown to regulate gene transcription via MAPK activation (Migliaccio et al, 
1996).  Moreover, we have previously shown that estrogen-mediated protection against 
Dr+ E. coli internalization in Huh-7 hepatoma cells and primary human hepatocytes 
involves regulation of MAPK activation (Kaul et al, 2007) and DAF expression 
(unpublished data).  However, we have not yet investigated the effects of PI3K/Akt 
167 
 
signaling or PI3K/Akt and MAPK interaction on DAF expression.  Our previous 
observations and results from this study indicate that E2-mediated transcriptional 
regulation of DAF in mIMCD3 cells may possibly include regulation by classical ER 
dependent genomic pathways as well as signaling activation of MAPK or other related 
pathways via PI3K/Akt activation, and this will be further investigated. 
 
      We, conclude that binding of Dr+ E. coli to DAF on mIMCD3 surfaces entails 
activation of PI3K and Akt via tyrosine kinase signaling pathway and the uptake of Dr+ 
E. coli in mIMCD3 cells during infection is dependent on tyrosine kinase activation.  A 
dichotomy in the effects of E2 on tyrosine kinase activation at physiological as well as 
pharmacological doses is observed.  This may influence the differential modulation of the 
process of bacterial internalization at varying E2 doses.  The detailed mechanism for 
estrogen-mediated regulation of cellular signaling needs to be explored to delineate the 
signaling pathways involved in bacterial colonization and internalization in host 
epithelium.  The information obtained can be further exploited to find therapeutic 
applications against UTIs. 
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CHAPTER VIII  
 
 
ESTROGEN IS REQUIRED FOR PROPER INFLAMMATORY RESPONSE 
AGAINST INFECTION IN THE KIDNEY 
 
8.1 Introduction 
            Inflammation is a multicomponent response to infection and tissue injury that 
functions to defend the host against infection and provides tissue remodeling and repair.  
The most distal renal tubule segments, the medullary collecting ducts are the first to come 
in contact with the ascending UPEC.  Thus, IMCD are the primary site for bacterial 
adherence and early inflammatory responses against UPEC.  UPEC activate TLRs 
expressed on the renal tubular epithelial cells and induce adequate immune responses in 
the host.  TLR activation up-regulate secretion of pro-inflammatory cytokines (TNFα. 
IL6, IL-1β) and chemokines ( MIP-2, RANTES, MCP-1), contributing to UPEC 
clearance (Chassin et al, 2006, Patole et al, 2005, Samuelsson et al, 2004, Schilling et al, 
2001b, Tsuboi et al, 2002, Wolfs et al, 2002, Wullt et al, 2001).  In the renal tubules, 
TLR4 are considered to be the key inflammation inducer against the gram negative 
UPEC.  Additionally, activation of other TLRs including TLR2, TLR5, TLR 6 and 
TLR11 has also been shown to induce inflammatory response against UPEC (Chassin et 
al, 2006, Vandewalle, 2008).  Furthermore, expression of TLR2 and TLR4 has been
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 observed to be up-regulated in the distal nephrons of the inflammed kidneys following 
injury and during UTIs (El-Achkar & Dagher, 2006, Gluba et al, 2010, Wolfs et al, 
2002). 
 
      Recent studies have shown that pro-inflammatory responses are crucial for providing 
the first line of defense against invading pathogen in the urinary tract.  Nonetheless, 
overwhelming activation of TLR signaling and excessive inflammatory responses are 
deleterious.  Heightened inflammation can induce cellular damage in the kidney, causing 
the development of chronic pyelonephritis and tubulointerstitial nephritis.  This may 
further lead to impaired kidney function and ultimately kidney fibrosis and kidney 
failure.  Activation of TLRs under normal physiological condition appears to be tightly 
regulated and at present various mechanisms employed in regulation of TLR triggered 
inflammatory immune responses are under study (O'Neill, 2008, Wang et al, 2009).  
 
      The kidneys of estrogen-deficient OVX mice had more colonization with Dr+ E. coli 
compared to the kidneys of OVX mice that were pretreated with E2 at a physiological 
dose.  The kidneys of ERα-/- mice also showed increased Dr+ E. coli colonization 
compared to the kidneys of  the ERα+/+ mice.  These results indicate E2/ERα mediated 
protection against UTIs.  Furthermore, OVX mice pretreated with E2 at a physiological 
dose have reduced kidney inflammation compared to kidney inflammation observed in 
the vehicle treated OVX mice post 21 days of Dr+ E. coli infection (preliminary data, 
Figure 2), suggesting induction of chronic inflammation in estrogen deficient mice post-
infection.  It appears that E2/ERα play an important role in the immunoregulation of 
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inflammatory responses against UTIs in the host.  The present study was conducted to 
determine the effects of E2/ERα on the immune responses post UTI-induction in vivo and 
in vitro.  We measured the mRNA levels of TLR 2 and TLR 4 and pro-inflammatory 
cytokines (TNFα and IL6) and chemokine (MIP2) in the kidneys of OVX C3H/HeJ and 
the ERα-/- B6.129 mice post-UTI induction.  The mRNA levels of these genes were also 
determined in mIMCD3 cells, following infection with Dr+ E. coli  
 
      Estrogen-deficient OVX C3H/HeJ and ERα-/- mice show depressed immune 
responses during the onset of infection and show heightened inflammatory responses at 
later time points post-infection.  In contrast, the respective control group of estrogen-
sufficient Non-OVX C3H/HeJ mice and ERα+/+  B6.129 mice  show rapid inflammatory 
responses at 2 days post-infection, immediately followed by a decline in inflammatory 
responses at a later time point post-infection.  Dr+ E. coli infection of mIMCD3 cells for 
2 hrs caused increased inflammatory responses in the mIMCD3 cells.  Estrogen treatment 
of cells resulted in reduction of inflammatory responses; however the reduction was not 
statistically significant.  
 
 
8.2 Statement of hypothesis 
            Estrogen, via ERα, regulates inflammatory response in the mouse kidney against 
Dr+ E. coli infection promoting rapid bacterial clearance and reducing inflammation 
mediated tissue damage. 
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8.3 Results 
A) In vivo results 
8.3.1:  Estrogen deficiency leads to delayed inflammatory responses in the kidneys of 
OVX C3H/HeJ mice post-infection  
       To understand the role of estrogen in regulating inflammation following UTI 
induction, we investigated the effect of estrogen-deficiency on the host’s inflammatory 
responses against Dr+ E. coli infection in OVX C3H/HeJ mice.  The mRNA levels of 
inflammation inducer, TLR2, pro inflammatory cytokines, TNFα and IL6, and 
chemokine, MIP2 were measured in the kidneys of uninfected and Dr+ E. coli infected 
OVX and Non-OVX mice.  C3H /HeJ mice are defective in TLR4 signaling therefore we 
analyzed the expression of only TLR2.   
 
      The kidneys of uninfected Non-OVX mice expressed higher levels of TLR2 mRNA 
compared to the the kidneys of OVX mice, but the difference was not statistically 
significant.  In the infected mice, at 2 and 6 days post-UTI induction TLR2 mRNA levels 
in the OVX and the Non-OVX mice were comparable to those in the uninfected mice.  
However, at 21 days post- infection TLR2 mRNA levels were found to be significantly 
increased in both, the OVX and Non-OVX C3H/HeJ mice compared to those in the 
uninfected controls (Figure 25A).  Among the infected group, TLR2 expression remained 
decreased in the OVX mice compared to that in the Non-OVX mice at both 2 and 6 days  
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Figure 25:  TLR2 and pro-inflammatory cytokines mRNA levels in the kidneys of OVX and 
Non-OVX C3H/HeJ mice.  Target gene mRNA levels were determined by quantitative SYBR 
green real-time RT-PCR using gene specific primers.  Target mRNA levels were normalized to 
PPIA mRNA levels in each sample and relative expression was calculated.  Expression values are 
mean relative expression ± SEM and the error bars represent data from at least 5 animals in each 
study group. 
A)  TLR2 mRNA levels in the kidneys of uninfected (Un) and Dr+ E. coli infected OVX and 
Non-OVX mice at 2, 6 and 21 days post-UTI induction.  Data were analyzed by Two-way 
ANOVA followed by Bonferroni post hoc test for multiple comparisons where P< 0.05 was 
considered significant.  The character * represents significant difference among the study groups, 
# represents significant difference between OVX and Non-OVX mice, $ represents significant 
difference from 21 day infected OVX mice and x represents significant difference from 21 day 
infected Non-OVX mice. 
B)  TLR2 mRNA levels in the kidneys of Dr+ E. coli infected E2 and vehicle treated OVX 
mice 21 days post-UTI induction.  Data were analyzed by Student’s T test where P< 0.05 was 
considered significant. 
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Figure 25:  C-E)  Levels of pro inflammatory cytokines TNFα (C), IL6 (D), and MIP2 (E) 
mRNA in the kidneys of uninfected (Un) and Dr+ E. coli infected OVX and Non-OVX mice 
at 2, and 6 days post- UTI induction.  Data were analyzed by Two-Way ANOVA followed by 
Bonferroni post hoc test for multiple comparisons where P< 0.05 was considered significant.  The 
character * represents significant difference among the study groups, # represents significant 
difference between OVX and Non-OVX mice, $ represents significant difference from 21 day 
infected OVX mice and x represents significant difference from 21 day infected Non-OVX mice. 
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post-infection.  However, at 21 days post- infection TLR2 mRNA expression was 
observed to be increased by 2-fold in the OVX mice compared to that in the Non-OVX 
mice.  The E2-treated OVX mice also showed 2-fold reduced expression of TLR2 
compared to that in the vehicle-treated mice (Figure 25B), however the differences were 
not found to be staitistically significant. 
      Infection increased cytokine mRNA in the kidneys of both the OVX and the Non-
OVX mice.  Among the infected group of mice, time specific serial increase of cytokine 
mRNA was found in OVX, as well as Non-OVX mice, at 3 versus 7 days post-UTI 
induction.  However, in the OVX mice significant increase in TNFα, IL6, or MIP2 
mRNA was observed only at 6 days post-infection.  In contrast, in the Non-OVX mice, 
expression of these cytokine mRNA were found to be markedly elevated at 2 days post 
infection and their levels increased significantly at 6 days post infection (Figure 25C).  
Notably, at both 3 and 7 days post-infection, the OVX mice expressed reduced cytokine 
mRNA levels compared to the Non- OVX mice.  However at 7 days post–infection the 
TNFα mRNA levels in the kidneys of OVX mice were found to be increased compared to 
those in the kidneys of Non-OVX mice (Figure 25C).   
 
 
8.3.2:  ERα-/- mice mount delayed inflammatory responses than do the ERα+/+ mice 
post-infection  
      To determine the specific role of ERα in regulating the kidney immune responses 
against Dr+ E. coli in the infected kidneys, we measure the mRNA levels of TLR4, 
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TLR2, TNFα, IL6, and MIP2 in the kidneys of ERα-/- and ERα+/+ mice at 3 and 7 days 
post-UTI induction. 
 
      The expression of TLR2, TLR4 and pro-inflammatory cytokines in the ERα-/- and 
ERα+/+ mice are represented in Figure 26.  Time specific serial increases in TLR2 and 
TLR4 mRNA levels at 3 verses 7 days post-infection were found in ERα-/- mice (Figure 
26 A-B).  In contras, ERα+/+ mice showed a serial decrease in the TLR2 mRNA levels 
from 3 to 7 days post–infection (Figure 26A).  TLR4 expression in the ERα+/+ mice 
remained similar at 3 and 7 days post-infection (Figure 26B).   
 
      At 3 vs 7 days post infection, we observed time specific serial increases in TNFα and 
IL6 mRNA in the ERα-/- mice.  In contrast, there was a serial decrease in the mRNA 
levels of these cytokines in the ERα+/+ mice from 3 to 7 days post-infection (Figures 
26C and 26E).  Importantly, the serum TNFα levels in the ERα-/- were also found to be 
significantly higher compared to that in the ERα+/+ mice at7 days post-infection (Figure 
26 D).  In comparison to the the ERα+/+ mice, the ERα-/- mice expressed higher levels of 
MIP2 mRNA at 3, as well as 7 days, post-UTI induction (Figure 26F). 
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Figure 26 
Figure 26:  TLR2, TLR4 and pro-inflammatory cytokines mRNA levels in the kidneys of 
ERα-/- and ERα+/+ mice.  Target gene mRNA levels were determined by quantitative SYBR 
green real-time RT-PCR using gene specific primers.  Target mRNA levels were normalized to 
PPIA mRNA levels in each sample and relative expression was calculated.  Expression values are 
mean relative expression ± SEM and the error bars represent data from at least 4- 5 animals in 
each study group.   
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Figure 26:  TLR2, TLR4 and pro-inflammatory cytokines mRNA levels in the kidneys of 
ERα-/- and ERα+/+ mice 
A-B) TLR2 and TLR4mRNA levels in the kidneys of ERα-/- and ERα+/+ mice at 3 and 7 
days post-UTI induction.  Data were analyzed by Two-Way ANOVA followed by Bonferroni 
post hoc test for multiple comparisons where P< 0.05 was considered significant.  The character * 
represents significant difference among the study groups, # represents significant difference 
between ERα-/- and ERα+/+ mice, and x represents significant difference between 3 and 7 day 
infected ERα+/+ mice.   
C-D) TNFα expression in kidneys of Dr+ E. coli infected ERα-/- and ERα+/+ mice post-UTI 
induction at mRNA (C) and protein (D) levels.  Data were analyzed by Two-Way ANOVA 
followed by Bonferroni post hoc test for multiple comparisons for Figure C and Student’s t test 
for Figure D where P< 0.05 was considered significant.  The character * represents significant 
difference among the study groups, # represents significant difference between ERα-/- and 
ERα+/+ mice. 
E-F) Levels of pro inflammatory cytokines, IL6 (D) and MIP2 (E) mRNA in the kidney of 
ERα-/- and ERα+/+ mice at 3 and 7 days post-UTI induction.  Data analyzed by Two-Way 
ANOVA followed by Bonferroni post hoc test for multiple comparisons where P< 0.05 was 
considered significant.  
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B) In vitro results 
8.3.3. Effects of E2 on inflammatory responses in vitro in mIMCD3 cells post-
infection. 
            We determined the effect of estrogen at different E2 doses on the mRNA levels of 
TLR2 and 4, pro-inflammatory cytokines (TNFα, IL6), and chemokines (MIP2) in the 
uninfected and Dr+ E. coli infected mIMCD3 cells following 2 hrs of infection.   
         Infection significantly increased the mRNA levels of TLR2, TLR4, TNFα, IL6, and 
MIP2 in both E2-treated, as well as untreated cells (Figure 27).  At 2 hrs post-infection no 
significant difference was observed in mRNA levels of these inflammatory markers in E2 
treated or untreated mIMCD3 cells. 
 
 
8.4 Discussion 
              To our knowledge we demonstrate for the first time, the modulatory effects of 
estrogen on pro-inflammatory responses in the kidneys of mice challenged with Dr+ E. 
coli.  We also show that the estrogen-mediated regulation of innate immune response in 
the kidney is mediated via action of ERα activation pathway.  Our time point data 
following Dr+ E. coli infection in the OVX mice showed delay in induction of innate 
immune responses in the kidneys.  In contrast, the Non-OVX mice exhibited induction of  
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Figure 27 
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Figure 27 TLR2, TLR4, and pro-inflammatory cytokines mRNA levels in E2-treated 
mIMCD3 cells following infections with Dr+ E. coli for 2 hrs.  Target gene mRNA levels were 
determined by quantitative SYBR green real-time RT-PCR using gene specific primers.  Target 
mRNA levels were normalized to PPIA mRNA levels in each sample and relative expression was 
calculated.  Expression values are mean relative expression ± SEM and error bars represent data 
from at least 4 experiments performed in triplicate.  Data analyzed by Two-Way ANOVA 
followed by Bonferroni post hoc test for multiple comparisons where P<0.05 was considered 
significant.  The character * represents significant difference among the study groups, and # 
represents significant difference between uninfected and infected cells. 
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robust inflammatory responses following the onset of infection.  We have earlier 
demonstrated that estrogen at a physiological dose provides protection against Dr+ E. coli 
colonization, whereas estrogen deficiency increases Dr+ E. coli colonization in the mice 
kidneys (results discussed in chapter IV).   Based on these results, it appears that 
differential inflammatory responses are generated in the kidneys in the presence or 
absence of estrogen as observed in these mice and may contribute to differential bacterial 
colonization.  Furthermore, following UTI induction in the ERα-/- mice, we found a 
similar depressed and delayed immune responses in the kidneys that may be responsible 
for increased bacterial colonization in these mice (discussed in chapter IV).  On the 
contrary, similar to Non-OVX mice ERα+/+ mice were able to generate rapid immune 
responses resulting in clearance of infection and regulation of the inflammatory responses 
earlier compared to the ERα-/- mice.  Thus, apart from proinflammatory cytokines, 
function of ERα is important for regulating infection and inflammation against Dr+ E. 
coli in the kidney. 
 
      Following infection, bacterial colonization in the urinary tract is controlled by TLR 
activation and pro-inflammatory cytokine up-regulation (Svanborg et al, 2001a, 
Svanborg et al, 2001b).  The bladder and kidney epithelial cells are reported to be the 
major sources of IL6 and IL 8 following infection with UPEC (Hedges et al, 1994, 
Hedges et al, 1996).  IL6 serves a variety of immunoregulatory functions including 
amplification of inflammatory signals involved in neutrophil recruitment and stimulation 
of IgA secretion by B cells (Hedges et al, 1991, Hedges et al, 1992).  In the human 
urinary tract IL8 attracts the neutrophils and a similar role is played by MIP2 in the 
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murine urinary tract (Hang et al, 1999).  TNFα initiates the inflammatory signaling 
cascade by TLR2 and TLR4 up-regulation, as well as induction, of IL6 and IL8/MIP2 
secretion from the uroepithelial cells (Billips et al, 2007, Wolfs et al, 2002).  In our 
study, the estrogen deficient OVX mice and the ERα-/- mice had reduced stimulation of 
these pro-inflammatory cytokines during the early stages of UPEC infection that 
correlated with increased bacterial colonization in their kidneys.  Also, the ERα-/- mice 
exhibited lack of regulation of proinflammatory responses and continued to have higher 
levels of cytokines at the later time point compared to the that in the ERα+/+mice. TNFα 
but not IL6 or MIP2 were found to be expressed more in the OVX mice kidneys than in 
the Non-OVX mice kidneys, at day 6 post-infection.  This indicates a differential 
regulation of TNFα by estrogen. 
 
        We found a delay in increase of TLR2 expression in the OVX, as well as the Non-
OVX C3H/HeJ mice post-infection, and an increase in TLR2 expression was found only 
at 21 days post-infection.  The delay in TLR2 activation at early time points may be 
responsible for the increased bacterial colonization and elevated inflammation in the 
OVX mice at a later time point compared to those in the Non-OVX and E2-treated OVX 
mice.  TLR2 expression is suggested to be dependent on inflammatory cytokines priming 
(Wolfs et al, 2002).  C3H/HeJ mice are defective in TLR4 signaling resulting in LPS 
unresponsiveness and reduced inflammatory signaling (Haraoka et al, 1999, Shahin et al, 
1987), which may explain the delay in up-regulation of TLR2 in these mice.  Despite the 
delayed immune resposes, the Non-OVX and E2-treated OVX C3H/HeJ mice were found 
to express increased levels of TLR2 compared to the OVX C3H/HeJ mice at earlier time 
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points following infection, suggesting estrogen mediated regulation of TLR2.  However, 
at 21 days post-infection, Non-OVX mice and E2-treated OVX mice expressed reduced 
TLR2 mRNA levels compared to that in the OVX mice.  Furthermore, in the E2-treated 
group of mice we found significantly reduced levels of serum TNFα, IL6, MIP 1α, and 
other pro-inflammatory cytokines at 21 days post-UTI induction (unpublished data).  
Supporting this data on E2 effects, at 21 days post-UTI induction the kidney tissues of 
E2-treated OVX mice were also found to have significantly reduced inflammation and 
lymphocyte infiltration compared to those observed in the kidneys of vehicle- treated 
OVX mice (preliminary data, Figure 2).  Thus, physiological levels of estrogen in mice 
seems to be necessary for initial rapid stimulation of TLR activation and pro-
inflammatory cytokine secretion resulting in bacterial clearance and further to limit the 
inflammatory response at the later stages of infection to prevent tissue damage associated 
with sustained inflammation.  It is possible that estrogen may also stimulate anti-
inflammatory effects as we have found down-regulation of TLR and pro-inflammatory 
cytokine secretion at later stages of infection in estrogen sufficient mice.  However in this 
study we have not assessed the expression of anti-inflammatory cytokines. 
 
      Modulatory effects of estrogen have been studied in several animal models of chronic 
inflammatory diseases and in kidney damage (Blush et al, 2004, Elliot et al, 2007, Satake 
et al, 2008, Silbiger & Neugarten, 2008, Straub, 2007).  Our results are in accordance 
with the study, where physiological dose of E2 via ERα was found to be necessary for 
rapid induction of TLR2, TNFα, and IL-12 following bacterial or viral infections in 
female mouse brain (Soucy et al, 2005).  In addition, estrogen at physiological levels was 
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found to enhance the antibacterial activity in secretions of polarized human uterine 
epithelial cells (ECC-1) in culture (Fahey et al, 2008).  Moreover, the proestrous state of 
estrous cycle in females is characterized by more vigorous immune responses compared 
to the diestrous stage and to the males (Angele et al, 2006).  Also, proestrous female mice 
have maintained splenocyte function and tolerate polymicrobial sepsis much better than 
do the male mice that exhibit depressed immune responses under those conditions, 
indicating a possible role of estrogen in enhanced immune responses in females 
(Zellweger et al, 1997).  Depressed release of pro-inflammatory cytokines is also 
observed in aged female mice following trauma haemorrhage and this observation is in 
accordance with the clinical finding demonstrating higher mortality rates in septic 
postmenopausal women (Angele et al, 2003, McLauchlan et al, 1995).  Furthermore, 
immune cells also express ERs (Straub, 2007), suggesting that estrogen may influence the 
immune cells within the tissue of the affected organ to modulate inflammatory responses.  
For example physiological E2 levels were found to directly modulate dendritic cell 
differentiation (Carreras et al, 2008, Carreras et al, 2010).  Estrogen deficiency has been 
associated with increased TNFα production by T cells leading to increased osteoclast 
formation and bone resorption, furthermore estrogen is suggested to prevent bone loss by 
regulating T cell function and immune cell bone interactions (Weitzmann & Pacifici, 
2006).  Additionally, estrogen deficiency has been shown to up-regulate TLR2 and TLR 
4 expression in osteoclast cells and epidermal keratinocytes; furthermore, presence of 
estrogen has also been shown to up-regulate TLR signaling (Kim et al, 2009, Koh et al, 
2009, Moeinpour et al, 2007).  Our findings support the results from these studies 
showing importance of estrogen in immune modulation and in maintenance of host 
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immune homeostasis following infection.  Thus far, there are limited studies reporting 
estrogen mediated regulation of TLR expression.  Our study provides the first in vivo 
evidence for estrogen/ERα-mediated regulation of TLR2 and TLR4 in the kidney during 
Dr+ E. coli induced UTI. 
 
       In mIMCD3 cells, following 2 hrs of infection we found increased expression of 
TLRs and pro-inflammatory cytokines.  For uninfected, as well as infected cells treated 
with physiological dose of E2 (10 nM), we found a slight decrease in expression of 
inflammatory markers except for TLR2 and MIP2, however the decrease was not 
statistically significant.  Lack of time course experiments for E2 treatment in this study 
are responsible for inconclusive data.  Infection and cytokine kinetics experiments will be 
performed in the future to better determine the effects of estrogen on expression of TLRs 
and pro-inflammatory cytokines using our in vitro mIMCD3 cells culture model.  
 
       Inflammation is also associated with increased expression of DAF and type IV 
collagen that are the receptors for Dr+ E. coli colonization.  The basal expression of DAF 
and type IV collagen expression in the uninfected mice are higher in OVX than in Non-
OVX mice, suggesting E2 mediated regulation of these receptors.  Our studies, as well as 
other in vivo and in vitro studies have shown inflammation induced elevated expression 
of DAF and collagen expression following infection (Betis et al, 2003b, Fang et al, 2004, 
Mankhey et al, 2007, Meldrum et al, 2007, Nowicki et al, 2009, Potier et al, 2002).  In 
the present study following 2 days of infection, the Non-OVX and the ERα+/+ mice 
expressed higher levels of cytokines that corresponded with relatively higher DAF and 
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type IV collagen mRNA expression (discussed in chapter VI).  Supporting our argument, 
we found higher Dr+ E. coli colonization initially in the Non-OVX mice and in the 
ERα+/+ at this time point.  However at a later time point the expression of pro-
inflammatory cytokines, DAF, and type IV collagen decreased in the estrogen sufficient 
mice.  These mice also showed reduced bacterial colonization compared to the OVX 
mice at later stages post-infection.  
 
      Pathogen recognition by mucosa and subsequent release of pro inflammatory 
cytokines are critical features of the innate host defense system against invading 
pathogens.  Our results support our hypothesis that physiological estrogen levels regulate 
bacterial colonization and the resulting innate inflammatory responses thus promoting 
rapid bacterial clearance and limiting inflammation induced tissue damage in Dr+ E. coli 
infected mouse kidney.  Furthermore, ERα action is involved in this protection.  
Additional studies are needed to be conducted to understand the effects of estrogen at 
different cellular levels in modulating inflammatory responses and to study its role in 
shifting the immune responses from innate to adaptive during pathogen elimination.   
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CHAPTER IX  
 
 
SUMMARY AND SIGNIFICANCE 
 
9.1 Summary and Conclusion 
          The pathogenesis of UTIs is complex and is influenced by various virulence factors 
of the UPEC as well as by several host factors.  Possible role of ovarian hormones, 
particularly estrogen has been implicated in the etiology of UTIs in females.  However, 
the precise mechanism associated with estrogen related etiology of UTIs is unclear.  
Limited in vivo and in vitro studies have been conducted in this area.  By utilizing our in 
vivo experimental UTI mouse model and in vitro mIMCD3 cell culture model, we 
investigated the possible effects of estrogen deficiency and physiological dose of 
estrogen on susceptibility to Dr+ E. coli uropathogenesis.  We also determined the role of  
ER subtype in mediating the possible effects of estrogen during Dr+ E.coli infection 
using our in vitro as well as in vivo experimental UTI models.  To our knowledge, this 
study provides the first in vitro and in vivo evidences for estrogen and ERα mediated 
modulation of Dr+ E. coli uropathogenesis.  The results and conclusions from our in vivo 
and in vitro studies are summarized below. 
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A) In vivo studies 
9.1.1:  Estrogen-deficiency in OVX C3H/HeJ mice increases Dr+ E. coli colonization 
in the urinary tracts, and estrogen supplementation at a physiological dose in these 
mice provides protection against Dr+ E. coli colonization in the urinary tracts. 
      The estrogen-deficient OVX mice showed increased susceptibility to Dr+ E. coli 
colonization in the bladder and kidneys compared to the colonization in the bladders and 
kidneys of the estrogen-sufficient Non-OVX mice.  Additionally, treatment of the OVX 
mice with a physiological dose of E2, prior to UTI induction, led to a reduced bacterial 
colonization in their bladder and kidneys.  These observations suggest that estrogen at a 
physiological dose serves as an important host factor in providing protection against Dr+ 
E. coli colonization in the urinary tract. 
 
 
9.1.2:  Protective effects of a physiological dose of E2 in mouse kidney include 
regulation of DAF and type IV expression, and modulation of infection induced 
inflammation.  
      The estrogen-deficient OVX mice expressed increased levels of Dr+ E. coli 
colonization receptors, DAF and type IV collagen, in the kidneys compared to the 
expression of these receptors in the Non-OVX mice,  suggesting increased susceptibility 
of OVX mice to Dr+ E. coli induced UTI.  Following infection, the OVX mice treated 
with a physiological dose of E2 and the estrogen sufficient Non-OVX mice expressed 
reduced levels of DAF and type IV collagen in the kidneys compared to the expression of 
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these receptors in the vehicle-treated OVX mice.  These observations led us to conclude 
that host endogenous estrogen at host physiological dose down-regulate DAF and type IV 
collagen expression in the kidney, thus allowing reducing Dr+ E. coli colonization. 
 
      The inflammatory responses in the estrogen-sufficient Non-OVX C3H/HeJ mice at 
the onset of infection were found to be elevated.  In contrast, inflammatory responses in 
the estrogen-deficient OVX mice were found to be depressed which correlated with 
increased bacterial colonization in the kidneys of these mice.  The inflammatory 
responses in the estrogen-sufficient Non-OVX mice and the E2-treated OVX mice 
declined at latter time point; however the inflammatory responses in the estrogen-
deficient OVX mice increased profoundly.  These observations suggest that a 
physiological level of estrogen is an important host factor for resolution of infection as it 
promotes rapid induction of optimum immune response.  In contrast, host estrogen 
deficiency leads to a delayed immune response allowing increased bacterial colonization 
resulting in persistent infection.  It is known that the sustained infection results in 
continued inflammation that may contribute to kidney fibrosis and renal failure in the 
host.  Thus, we conclude that physiological levels of estrogen are protective by 
promoting immediate robust immune responses leading to bacterial clearance and 
maintenance of the host immune homeostasis, following pathogen elimination. 
 
 
9.1.3:  Estrogen-mediated modulation of Dr+ E. coli uropathogenesis in mouse 
kidney is ER dependent and occurs via ERα activation. 
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      We show that the protective effects of estrogen against Dr+ E. coli uropathogenesis 
are ER dependent and specifically involve ERα activation.  Blocking of ERs with a pure 
ER-antagonist ICI 182, 780, in the estrogen-sufficient Non-OVX mice resulted in 
increased Dr+ E. coli colonization in their bladders and kidneys post-UTI induction.  This 
suggested that estrogen-mediated protection against Dr+ E. coli in mouse urinary tract is 
ER dependent.  Further, ICI 182,780 treatment in these mice reversed the estrogen-
mediated down regulation of DAF and type IV collagen expression, suggesting that 
estrogen regulates DAF and type IV collagen via the classical ER dependent pathway. 
 
      The kidneys of C3H/HeJ and B6.129 mice do express both ERα and ERβ, however 
ERα expression is predominant.  Thus, we proposed that ERα may be the functional 
receptor for estrogen mediated protective effects in the mouse kidney.  Consistent with 
our hypothesis, we did find increased kidney bacterial colonization corresponding with 
increased DAF as well as type IV collagen expression in the ERα-/- mice as compared to  
the ERα+/+ mice.  The ERα-/- mice also had increased bacterial colonization in their 
bladders as compared to the ERα+/+ mice.  Consistent with our findings in OVX mice, 
the ERα-/- mice showed delayed innate inflammatory responses at initial time points and 
were responsive only later during the course of infection.  In contrast, ERα+/+ mice 
showed a robust innate immune response soon after the onset of infection.  Based on 
these observations we concluded that the protective effects of estrogen against Dr+ E. 
coli uropathogenesis are mediated via ERα.  
B) In vitro studies 
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9.1.4:  Estrogen differentially modulates Dr+ E. coli invasion in mIMCD3 cells in a 
dose-dependent manner. 
      E2 pretreatment of mIMCD3 cells, at physiological doses (1-10 nM) significantly 
reduced Dr+ E. coli internalization compared to that in the untreated control cells.  
Treatment of cells with a pharmacological dose of E2 (100 nM) prior to infection resulted 
in marked increase in the bacterial invasion compared to the cells treated with 
physiological doses of E2.  These observations led us to conclude that estrogen at a 
physiological dose provides protection against bacterial internalization in mIMCD3 cells, 
whereas estrogen deficiency or a pharmacological estrogen dose induces increase in 
bacterial invasion in these cells. 
 
 
9.1.5:  Estrogen differentially regulates expression of DAF and induction of the 
tyrosine kinase activation pathway in a dose-dependent manner. 
      DAF expression was found to be significantly reduced in the cells treated with 
physiological doses of E2 compared to that in the untreated control cells and in the cells 
treated with a pharmacological dose of E2.  Also, dose-dependent E2 regulated changes 
in DAF expression resulted in differential invasion of the Dr+ E. coli in mIMCD3 cells.  
We conclude that physiological levels of estrogen down-regulates DAF expression in 
mIMCD3 cells thus lowering bacterial invasion, while estrogen-deficiency or higher 
estrogen levels increase DAF expression leading to an increased bacterial invasion in the 
cells. 
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       The tyrosine kinase induced PI3K/Akt signaling pathway was found to be activated 
during Dr+ E. coli internalization in mIMCD3 cells.  Thus, tyrosine kinase mediated 
PI3K/Akt signaling activation, may represent one of the host cell signal transduction 
pathway during Dr+ E. coli internalization in these cells.  Furthermore, treatment of cells 
with E2 at a physiological dose was found to reduce the induction of the PI3K/Akt 
signaling pathway, whereas treatment with a pharmacological dose of E2 significantly 
enhanced the PI3K/Akt pathway activation.  It appears that modulation of DAF as well as 
tyrosine kinase activity following bacterial adherence may represent an important 
requirement for Dr+ E. coli internalization in mIMCD3 cells.  
 
 
9.1.6:  E2-mediated protective effects against Dr+ E. coli invasion in mIMCD3 cells 
occurs primarily via ERα activation pathway. 
      We found that blocking of ER activity by pure ER-antagonist ICI, 182 780 treatment 
resulted in increased Dr+ E. coli invasion in mIMCD3 cells.  ICI, 182 780 significantly 
reversed the protective effects of 10 nM E2 in a dose dependent manner, when cells were 
co treated with E2 (10 nM) and various doses of ICI,182 780.  This suggested that 
protective effects of E2 are ER dependent.  Furthermore, we found significant reduction 
in bacterial invasion in the cells treated with the ERα specific agonist similar to E2 
action, while ERα specific antagonist reversed the E2-mediated protection.  We did not 
observe any effect of ERβ activation or inactivation on Dr+ E. coli invasion in mIMCD3.   
Thus, the ERα but not the ERβ pathway is involved in the E2-mediated protection against 
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Dr+ E. coli invasion in the mIMCD3 cells.  In addition, ERα is the predominant subtype 
expressed at mRNA levels in mIMCD3 cells, explaining the functional role of ERα over 
ERβ in these cells.  Blocking ER activity in the cells with ICI, 182,780 caused increase in 
Dr+ E. coli invasion and DAF expression compared to the cells treated with E2.  
Furthermore, ERα-specific activation with PPT in the infected cells induced significant 
reduction in DAF expression and bacterial colonization which was comparable to those in 
the cells treated with E2, but was significantly lower than those in the untreated control 
cells.  These observations suggest that E2 regulated DAF expression via ERα activation 
serves as one of the possible mechanisms involved in estrogenic protection against Dr+ 
E. coli invasion in mIMCD3 cells. 
 
      Finally, we conclude that host endogenous levels of estrogen and ER subtype 
expression may play an important role in determining the host’s susceptibility to UTI by 
Dr+ E. coli.  A Physiological level of estrogen via activation of ERα seems to provide 
protection against Dr+ E. coli colonization by regulating expression of colonization 
receptors and induction of tyrosine kinase cellular signaling pathway.  In addition, a 
physiological level of estrogen may also regulate infection in the host by generating 
robust early induction of innate inflammatory response in the urinary tract, allowing rapid 
clearance of bacteria and establishment of immune homeostasis following bacterial 
elimination. 
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9.2 Significance and Future directions 
       UTI remains a problem of clinical and medical significance due to the ever 
increasing rate of antibiotic resistance in UPEC and the unavailability of vaccines.  This 
project will be the basis future studies investigating various host factors that may be 
responsible for occurrence of recurrent UTIs.  Increased understanding of uropathogenic 
bacterial virulence and host susceptibility factors will allow individualization of diagnosis 
and therapy for UTI; this will help combat the present limitations associated with 
available treatment options for UTIs (Godaly & Svanborg, 2007).  Furthermore, 
understanding of molecular mechanisms involved in bacterial pathogenesis and 
inflammation at the cellular level is vital for the development of novel strategies for 
prevention and treatment of UTIs (Sivick & Mobley, 2010).   
 
            Our study provides the first in vivo and in vitro evidences for the protective 
effects of a physiological dose of estrogen against Dr+ E. coli colonization and invasion 
in the kidney.  Using ERα-/- mice, we report for the first time that estrogen protection 
against uropathogenesis is mediated via ERα.  In our study, we also show that estrogen 
via ERα regulates expression of adherence receptors, DAF and type IV collagen, thereby 
regulating the attachment of Dr+ E. coli to the host urinary tract.   Clinical studies in 
patients have also indicated that increase in density of UPEC epithelial receptors tend to 
increase their risk to have recurrent UTIs and pyelonephritis (Herrmann et al, 2002).  Our 
experimental results do support the observations made in clinical settings on hormonal 
regulation of UTI susceptibility in patients.  For instance, increase in UTI susceptibility is 
observed in pregnant women that exhibit high estrogen levels or in postmenopausal 
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women that exhibit low or deficient estrogen levels (Hu et al, 2004, Maloney, 2002, 
Mittal & Wing, 2005, Schnarr & Smaill, 2008). 
 
      Based on these observations and utilizing the available information in the literature, 
mechanisms for interrupting host receptor and bacterial ligand interactions can be 
developed as a therapeutic strategy for blocking the adherence of UPEC to host cells and 
thus disrupting the cycle of re-infection during uropathogenesis.  Studies investigating the 
molecular mechanisms of UPEC colonization and invasion at cellular levels using an in 
vitro model will guide the identification of additional pharmacological regulators acting 
similar to physiological estrogen in regulating colonization receptor expression or in 
boosting innate inflammatory response in the host infected with UPEC.  Based on our 
results, preclinical studies are needed to include prophylactic estrogen replacement 
therapy at physiological doses or treatment with specific ERα selective ligands.  In 
addition, research needs to be conducted towards development of mucosal vaccines for 
Dr+ E. coli to generate local antibody responses to block UPEC binding receptors.  Such 
vaccines will block binding to DAF and prevent Dr+ E. coli colonization and infection in 
the urinary tract of patients with recurrent infections.   
 
      In our study ERα-/- mice showed increased UTI susceptibility and this suggests that 
clinical studies should be conducted to look for possible reduced ERα expression or ERα 
polymorphism in patients with recurrent UTIs or pyelonephritis.  
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      Our future work will focus on identifying different signaling mechanisms associated 
with estrogen-mediated modulation of DAF and type IV collagen utilizing in vivo and in 
vitro experimental models.  We will also work towards studying estrogen mediated 
differential regulation of inflammatory responses against UPEC under different clinical 
settings involving patients with different estrogen levels.  RNAi strategies against ERs 
and colonization factors will be employed under in vitro and in vivo settings to 
investigate the functional role of ERs and colonization receptors during UTI 
pathogenesis.  Role of ERα and ERβ and possible ER gene polymorphism in UTI 
susceptible hosts will be studied.  The information obtained will further guide us in 
identification of novel biomarkers or therapeutic strategies for treatment of UTI. 
.
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Appendix Figure 1:  Bacterial counts in the right and left kidneys of OVX C3H/HeJ mice.  
Bacterial CFU per gram kidney tissue in vehicle (A and B) OVX and E2 (C and D) treated OVX 
mice at 2 and 6 days post-UTI induction with Dr+ E. coli.  Bacterial CFU counts from right 
kidney are depicted by open diamonds and those from left kidney are indicated by filled 
diamonds.  Each symbol in the graph represents values from the right or left kidney of a mouse.  
Data in each graph shows bacterial counts with mean CFU ± SEM and error bar represents data 
from 4-6 mice.  There was no significant difference in bacterial counts from right and left kidneys 
of mice from each study group.  Data were analyzed by Student’s t-test where P<0.05 was 
considered significant. 
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Appendix Figure 2: MTT assay for drug toxicity in the mIMCD3 cells.  Toxicity of the drugs 
in mIMCD3 cells (A, C-I) and hIMCD cells (B) was determined by MTT assay.  Cellular growth 
is represented as the function of absorbance at 570nm. Absorbance values are plotted as mean 
absorbance ± SEM.  Error bars represent data from at least three independent experiments 
performed in triplicate.  P < 0.05 was considered significant.  Only the non-toxic doses were used 
for the treatment during the invasion studies.  Also, the proliferative dose of MPP (10 µM) was 
not used in the present study.  The character * indicate significant difference from the untreated 
control cells. 
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Appendix Figure 3:  Protein expression of DAF and type IV collagen in the kidneys of 
C3H/HeJ mice.  A) The DAF (a, b and c) and type IV collagen (d, e and f) protein expression 
were determined in the paraffin embedded kidney tissue sections of vehicle and E2-treated OVX 
mice post 21 days of UTI induction with Dr+ E. coli by immunohistochemistry using specific 
antibodies.  Negative control images represents hematoxyline-eosine staining of the tissue 
sections done in absence of the specific antibodies.  Images a, b and c are at 20 X magnification 
and images d. e and F are at 40X magnification in Figure A.  B) Staining intensities were 
quantified and are represented as mean staining score ± SEM for DAF as well as type IV 
collagen.  Staining scores represent a scale of 0 to 4, where 0 represents no staining and 4 
represents maximum staining.  E2-treated OVX mice showed decreased expression of DAF as 
well as the type IV collagen in the kidney tubules compared to vehicle treated OVX mice. 
(Unpublished lab data).  The character * indicate significant difference between treatment groups. 
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ABSTRACT:  Urinary tract infection (UTI) is a disease of medical significance.  One of 
the important clinical effects of estrogen deficiency in postmenopausal women is their 
increased susceptibility to UTIs.  Estrogen replacement in these women is effective in 
prevention of bacteriuria.  However, the molecular mechanisms involved with estrogen 
treatment against UTIs are poorly understood.  Uropathogenic Dr+ E. coli can cause 
cystitis, recurrent UTI and pyelonephritis in humans, and induce chronic pyelonephritis 
in C3H/HeJ mice.  Dr+ E. coli colonize and invade the host uroepithelium by adhering to 
decay accelerating factor (DAF) and type IV collagen and these are known to be 
hormonally regulated.  In the present study, we investigated the role of estrogen and 
estrogen receptors (ER) in modulation of Dr+ E. coli uropathogenesis using an in vivo 
C3H/HeJ murine model and an in vitro model of mouse kidney inner medullary 
collecting duct (mIMCD3) cells.  Ovariectomy (OVX) induced menopausal mice showed 
increased bacterial colonization in the bladder and kidney tissues compared to the ovary 
intact mice after experimental induction of Dr+ E. coli infection.  Pretreatment of the 
OVX mice with β-estradiol (E2) at a physiological dose reduced bacterial colonization.  
ER antagonist ICI 182,780 pretreatment increased bacterial colonization in the ovary 
intact mice, suggesting ER involvement.  Furthermore, UTI induction in ERα-/- mice led 
to increased bacterial colonization in the bladder and kidney tissues compared to the 
ERα+/+ mice confirming ERα involvement.  Increased kidney infection corresponded 
with an increase in DAF and type IV collagen expression in OVX as well as ERα-/- mice.  
Delayed induction of TLR2 and pro-inflammatory cytokines in the OVX and ERα-/- 
mice at onset of infection resulted in increased bacterial colonization compared to the 
control mice.  Protective effects of estrogen against Dr+ E. coli invasion were also seen 
in mIMCD3 cells, where physiological levels of E2 led to a 40-50% reduction in bacterial 
invasion and down-regulation of DAF expression.  ERα selective agonist (PPT) provided 
significant protection against bacterial invasion, while ICI 182, 780 blocked the E2 
protection.  In contrast, a higher E2 dose increased bacterial invasion and DAF 
expression.  E2 treatment activated tyrosine kinase in a dose-dependent manner in these 
cells.  In summary, we report for the first time that a physiological dose of estrogen via 
ERα action provides protection against Dr+ E. coli colonization in the urogenital tract by 
modulating binding receptors and regulating activation of innate inflammatory responses. 
